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Abstract 
 
Autism is a neurodevelopmental disorder that affects around 700,000 in the UK 
(Baird G. et al., 2006; Burgha et al., 2011) and these numbers are constantly 
increasing. Nonetheless, our understanding of the cellular and molecular 
processes underlying autism is limited. This has hindered the development of 
effective treatments and created a need for human specific models. The potential 
of modeling autism through the use of human induced pluripotent stem cells 
(iPSCs) is an exciting advancement towards uncovering the mechanisms 
underlying a disorder that affects the lives of so many people. Recent studies 
report that mutations in the SHANK3 gene are a major cause of autism 
(Nemirovsky et al., 2015; Bentancur et al., 2013; Buccoto et.al, 2013). This 
project aimed to track and compare the development of neurons generated from 
iPSCs lines derived from SHANK3 patients and healthy individuals.  These lines 
were produced from hair root biopsies from three categories of individuals: three 
healthy control individuals, two autistic patients with a heterozygous deletion in 
the SHANK3 gene and one sporadic ASD individual. iPSCs were differentiated 
into hypothalamic neurons and their structural and functional development was 
tracked during the various stages of neuralisation. These studies revealed that 
during early neuronal development, SHANK3 iPSC derived neurons have a 
smaller cell soma, but more and longer primary neurites than control cells. These 
morphogenetic deficits were rescued by overexpressing SHANK3. Further, 
embryonic stem cell lines, with homozygous and heterozygous deletion of the 
SHANK3 gene, gave rise to neurons with similar morphogenetic deficits to those 
seen in the SHANK3 patient neurons. Both studies validate that the reduced 
expression of SHANK3 is the cause for these morphogenetic deficits.  
The discovery of these early morphological defects in human SHANK3 mutant 
neurons has provided new insight into the mechanisms underpinning autism. 
This research has also developed a robust cell-based platform that can, not only 
be used to test these potential mechanisms, but also as a screen for potential 
therapies. 
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1.1 Autism Spectrum disorder 
 
Kanner first characterized autism in 1943 “As a group of children with an unusual 
pattern of behavior present from birth or before 30 months” (Kanner 1943).  
Autism is now considered as a spectrum of neural developmental disorders 
defined by the following behavior- (1) restricted repetitive behavior, interests and 
activities, (2) deficits in social interaction and communication and (3) decreased 
cognitive abilities (Carbonetto 2014).  The worldwide prevalence of ASD is about 
1-2.6 percent and is about four times more common in males than in females 
(Lord 2011; Baird et al., 2006).  
 
There are no individual tests to confirm a diagnosis of ASD. Instead a diagnosis 
is usually based on the characteristics that the child displays. A series of 
interviews takes place and a detailed family history is taken, to track any genetic 
link that might exist. Assessments are mostly based on language and social 
behavior skills (Baird 2003).  
 
In this introduction, I will present an overview of ASD, with special emphasis on 
the gene SHANK3 as its cause.  
 
1.2 Genetics of ASD 
 
The etiology of autism is not fully understood; though recent data shows that 10-
20 percent of ASD patients reported have an underlying genetic alteration  
(Betancur, 2011). There is a strong genetic basis to ASDs, as emphasized by 
studies with monozygotic twins where the concordance rate is up to 90 percent, 
while in dizygotic twins it is up to 20 percent (Hallmayer et al., 2011). 
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A fundamental challenge with the genetics of ASD is the large heterogeneity in 
the types of genetic mutations that contribute to ASD. These mutations include a 
large number of rare mutations including monogenic disorders, large 
chromosomal aberrations and multiplicative effects of common gene variants 
(Carbonetto 2014; VanderWeele et al., 2004). Approximately 5 to 7 percent of 
chromosomal abnormalities reported are 15q11-q13 duplications or 2q37, 
22q11.2 and 22q13.3 deletions (Betancur 2011; Fishawy et al., 2014). 
Monogenetic causes of ASD are reported in approximately 2 percent of cases. 
Some examples of these are Fragile X syndrome caused due to mutation in the 
FMR1 gene (Fragile X Mental Retardation 1), Rett’s syndrome caused due to the 
mutation in MECP2 gene (Methyl CpG binding protein 2), Angelman syndrome 
caused due to the mutation in UBE3A (Ubiquitin Protein Ligase E3A) and 
Timothy syndrome caused due the mutation in CACNA1C gene (Calcium 
channel, voltage-dependent, L type, alpha 1C subunit) (Kleijer et al., 2014).   
 
Entire exome and genome analyses have converged on a particular 
chromosomal abnormality in autism. These are submicroscopic structural 
changes in the chromosomes called copy number variants (CNVs) (LaFlamme 
2015).  Recent evidence suggests that ASD can arise from de novo CNVs that 
result from deletions or duplications of relatively large regions of chromosome 
(Huguet et al., 2013). Thus, there is a huge emphasis on studying rare, highly 
penetrant CNVs in order to understand the underpinnings of brain connectivity in 
ASD. 
 
One such example is the current research on the gene SHANK3. More than 1000 
cases of SHANK3 22q.13 deletion have been reported. 75 percent of these have 
ASD and 95 percent display severe mental developmental delay (Jiang et al., 
2013).  Moreover, 2 percent of people who have autism carry a harmful deletion 
in the SHANK3 gene (Leblond CS et al., 2014; Durand et al., 2007).  Another 
example is of a cohort study carried out on 133 patients from USA and 83 
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patients from Italy that revealed five detrimental mutations in the SHANK3 gene 
with an occurrence rate of 2.3 percent (Buccoto et.al, 2013; Bayés À et.al 2010).   
 
Additionally, two recent studies have shown that SHANK3 is the most under 
diagnosed highly penetrant monogenic cause of ASD. The first study used whole 
genome sequencing to reveal a de novo SHANK3 mutation in familial autism 
spectrum disorder (Nemirovsky et al., 2015). The second evaluated 32 patients 
and 0.5 percent of these cases revealed SHANK3 haplo-insufficiency as the 
monogenic cause of ASD (Bentancur et al., 2013). Therefore, mutations in 
SHANK3 can be considered as one of the causes of ASD.  
 
Although, the main aim of this project is to describe the role of SHANK3 gene in 
ASD. I will first describe the current ideas on mechanism that underpin autism 
and how these relate back to the SHANK3 gene.  
 
1.3 Current Hypothesis for ASD 
 
A number of interesting hypotheses have been proposed for autism. In this 
section I describe the three major ones that pertain mainly to cellular and 
molecular mechanism underlying autism.  
 
1.3.1 First hypothesis for the underlying mechanism of autism-“Synaptic 
dysfunction” 
 
The first hypothesis is the “synaptic dysfunction” that is primarily based on data 
from various genomic studies. The exome-sequencing analysis of 3871 autism 
cases implicated many genes that encode proteins for voltage-gates ion 
channels or proteins that are involved in synapse formation, synaptic scaffolding, 
and synaptic cell adhesion proteins (Rubeis SD et al., 2014; Bourgeon 2009; 
Zoghbi 2003). This data strongly indicates that synaptic dysfunction contributes 
to the cellular cause of autism. 
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Mutations in synaptic cell adhesion molecules, scaffold proteins and receptors 
and transporters have been linked to autism (Table 1.0).  I give examples of 
some of the genes that are linked to first hypothesis below- 
 
1.3.1 (a) Examples for the first hypothesis “Synaptic dysfunction”- Cell 
adhesion molecules 
 
Several synaptic cell adhesion molecules have been linked to autism. These 
include Neurexins (NRXNs) and Neuroligins (NGLNs), NRXNs and NGLNs play 
an important role in the formation, maturation and maintenance of synapses 
(Kleijer et al., 2014) by acting as the glue between scaffolding protein and 
synaptic receptors. The loss of these protein results in synaptic transmission 
deficits. For example, Nlgn3 knockout (KO) studies in mice have shown a loss of 
mGLUR-dependent LTD in the cerebellum. Furthermore, knock in studies of the 
same gene showed increased mEPSCs, (miniature excitatory postsynaptic 
current) and enhanced LTP (Long term potentiation) in the hippocampus.  Also, 
nrxn1 knockout in mice showed electrophysiological phenotypes such as 
reduced mEPSC frequency in the hippocampus (Baudouin et al., 2012; Etherton 
et al., 2011; 2009).  
 
Another synaptic cell adhesion protein that has been associated with autism is 
Contactin-associated protein like 2 (CNTNAP2). The CNTNAP2 is known to bind 
with PSD95 (Post synaptic protein 95). PSD95 is a postsynaptic density protein 
and helps recruit various postsynaptic channels. CNTNAP2 connects with 
PSD95 and participates in the clustering of potassium channels at the 
postsynaptic density (Horresh et al., 2008).  A RNAi-mediated knockdown of 
Cntnap2 in rodent hippocampal neurons resulted in reduction of both excitatory 
and inhibitory synapses. This lead to asynchronous firing in cortical neurons 
(Geschwind et al., 2012). 
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1.3.1 (b) Examples for the first hypothesis “Synaptic dysfunction”- 
Scaffolding proteins  
 
The proline rich synapse associated SH3 domain and ankryrin repeat family of 
postsynaptic scaffold proteins comprises of three members: SHANK1, SHANK2 
and SHANK3.  All three have been implicated as a cause of autism (Kleijer et al., 
2013). 
 
Various studies on autism, report that SHANK1 mutations were detected more in 
males than in females (Sato et al., 2012). Studies by Hung et al., 2008 on 
Shank1 knockout mice show decreased levels of Homer 1 b/c and mGLURs 
(metabotropic glutamate receptors). These authors also reported that these mice 
have a deficiency in basal synaptic transmission. 
 
In mice hippocampal culture Shank2 was knocked down which resulted in a loss 
synaptic clustering, mainly AMPA receptors (Berkel et al., 2012). Moreover, 
Shank2 mutant mice with deletion in exon 6 and 7 of Shank2, displayed increase 
in NMDA (N-methyl-D-aspartate receptor) regulation (Schmeisser et al., 2012; 
Won et al., 2012). 
 
 
Table 1.0: Summary of genes involved in ASD that affect the synapse (Adapted from 
Kleijer et al., 2014). 
 
 
As mentioned above, multiple studies have identified deleterious SHANK3 
mutations in patients with ASD (Moessner et al., 2007; Hamdan et al., 2011; 
!"#$%&'#(( )*'$+,,( -./(0+#+,(
.1#23%&$(.%*"$%"*+(( !"##$%&'"()*+$$ NRXN1, NLGN3, NGLN4X, 
CNTNAP2, CNTN3, CNTN4, 
CNTN5, CNTN6, 
NRCAM, CDH9$




VIPR, SSTR5, MET, 
GRIN2A, SCN1A, CACNA1C, 
FMR1, MECP2 
$
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Denayer et al., 2012). Compared to SHANK1 and SHANK2, mutations in 
SHANK3 are highly penetrant and the vast majority of patients carrying a 
mutation in this gene develop severe cognitive deficits. There have been five 
Shank3 mutant mice reported and one iPSCs (induced pluripotent stem cells) 
study of Phelan Mcdermid Syndrome. I will discuss these in detail in sections 1.6 
and 1.9, as the emphasis of this thesis is to study the effects of SHANK3 in 
autism.  
 
Hence, in the section above we have described some of the synaptic genes that 
form the basis of autism. Nevertheless, there are many more genes that support 
the synaptic hypothesis of ASD; we have summarized some of these 
representative genes in Table 1.0. 
 
1.3.2 Second Hypothesis for the underlying mechanism of autism-
“Abnormal Neuronal growth” 
 
The second hypothesis of ASD proposes that autism is caused by neuronal 
miscommunication, which arises from “abnormal neuronal growth”. (Shepard 
2013; Bourgeon 2009).  Specifically, abnormal neuronal growth leads to irregular 
neuronal connections, which results in miscommunication between neurons. This 
hypothesis stems from the observation that 30 percent of ASD patients present 
with macrocephaly (Amaral David G et al., 2008). Moreover, a number of ASD 
studies account for abnormal neuronal structure.  
 
1.3.2 (a) Examples for the second hypothesis “Abnormal Neuronal growth” 
 
The first example for the second hypothesis is Fragile X syndrome (FXS) that is 
caused by a mutation in the FMR1 gene. This gene encodes for a protein called 
fragile X mental retardation protein (FMRP) (Doers et al., 2014). This protein 
plays a role in mRNA transport from the nucleus to the cytoplasm in the neuronal 
cell soma. It is also involved in dendritic localization of mRNA and has a 
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suggested role in synaptic plasticity via stimulation of mGluRs (metabotropic 
glutamate receptors) (Lozano et al., 2014; Antar LN et al., 2005). Also, FMRP 
acts as a protein translational repressor (Darnell and Klann 2013). Almost 30 
percent of FXS patients report symptoms of ASD (Doers et al., 2014).  
 
Rodent models of FXS display an abnormal neuronal morphology such as thin 
and elongated dendritic spines in pyramidal neurons, increased spine density, 
fewer and shorter neurites and smaller cell body volume (Comer et al., 1997; 
Castren et al., 2005). Post mortem studies of FXS patients revealed a similar 
morphology to that observed in the mouse models - longer slender dendritic 
spines, smaller cell bodies and neurons with shorter neurites (Irwin et al., 2001; 
Castren et al., 2005). This suggests that the FMR1 gene plays a role in structural 
development of a neuron. 
 
In addition to these morphological changes, electrophysiological changes were 
also reported in Fmr1 knockout mice. The most common one was an impaired 
mGLUR- dependent LTP (long term potentiation) but also a decrease in the 
frequency of spontaneous mEPSCs was also described (Bassell et al., 2008).   
Taken together, this suggests that the loss of Fmr1 gene leads to abnormal 
neuronal morphology that could result in synaptic dysfunction.  
 
Another evidence for abnormal neuronal growth that leads to autism is the loss of 
vertical and horizontal organization of the cortical layers. This occurs due to the 
loss of neuronal polarity resulting in migration deficits (Wegiel et al., 2010). 
Impaired migrations of cortical projection neurons have been reported in Cntnap2 
knockout mice, resulting in a great imbalance in electrical activity, leading to 
epileptic seizures (Penagarikano et al., 2011). An interesting point to note is that 
this gene is also involved in the first hypothesis of synaptic dysfunction as 
discussed in section 1.3.1 (a). 
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Additionally, co-morbid disorder associated with autism is Rett Syndrome. Rett’s 
syndrome is caused by the deletion of MeCP2 (methyl-CpG-binding protein 2).  
The MeCP2 protein acts as a transcriptional regulator and is associated with 
maturation of the central nervous system, particularly with the formation of 
synaptic contacts (Luikenhuis et al., 2004; Lombardi et al., 2015). Various rodent 
and human post mortem studies have found abnormal neuronal morphology 
associated with this disorder.  For instance, reduced neuronal size, dendritic 
arborization, spine density and cell size have been reported (Brennand et al., 
2012). Thus, providing support to the second hypothesis of abnormal neuronal 
growth.  
 
Table 1.1: Common Cellular and Behavioral phenotypes: phenotypes found in mice models 
and postmortem studies of selective synaptic genes that are implicated in ASD (Adapted from 
Kleijer et al., 2014; Brennand et al., 2012). 
Phenotypes	   CNTNAP2-­‐/-­‐	   NLGN3-­‐/-­‐	   MeCP2-­‐/-­‐	   SHANK1-­‐/-­‐	   SHANK2-­‐/-­‐	   FMR1-­‐/-­‐	  
Spine	  density	   No	  change	   -­‐	   Decrease	   Decrease	   Decrease	   Decrease	  
Dendritic	  Aborization	   Decrease	   Increase	   Decrease	   -­‐	   -­‐	   Decrease	  
Cell	  volume	   -­‐	   -­‐	   Decrease	   -­‐	   -­‐	   Decrease	  
mGLUR	  dependent	  




Decrease	   	   -­‐	   Decrease	   Decrease	  
Social	  interaction	   Decrease	   Decrease	   	   	   Decreases	   	  
Communication	   Decrease	   Decrease	   	   Decrease	   Decrease	   Decrease	  
Repetitive	  behavior	   Increase	   Increase	   	   	   Increase	   Increase	  
 
1.3.3 Third hypothesis for the underlying mechanism of autism-“Protein 
translation” 
 
The third hypothesis of autism suggests that excess protein synthesis at the 
synapse leads to chemical imbalance in the brain (Kelleher et al., 2008).  
Protein synthesis/translation is the process by which mRNA produced during 
transcription is converted into a specific amino acid chain.  A number of mouse 
models of autism have shown an increase in protein production especially at the 
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synapse (Kelleher et al., 2008). These are PTEN1 (Phosphatase and tensin 
homolog), TSC1/2 (Tuberous sclerosis complex) and UBE3A. 	  
 
Moreover, mice lacking 4E-BP2 (Eukaryotic translation initiation factor 4E-binding 
protein 2) show an increase in production of neuroligins. They also exhibit social 
interaction deficits and abnormal electrical activity, both of which are autism-like 
behaviors (Gkogkas CG et al., 2013; Kelleher et al., 2008). 
 
From the above examples and Table 1.1, we observe that many of the genes 
implicated in the synaptic dysfunction hypothesis of ASD are also involved in the 
abnormal neuronal growth hypothesis. For example, Cntnap2, Ngln3, Shank1, 
Shank2 and Fmr1 knockout mice all showed abnormal neuronal growth and 
synaptic dysfunction (Table 1.1).  This leads to impaired communication between 
neurons, which results in desynchronization in the brain network (Welsh JP et al., 
2005; He BJ et al., 2007; Zikopoulos et al., 2010). All together causing behavioral 
deficits, which is the key symptom of ASD. Therefore, we can imply that both the 
hypotheses, the synaptic dysfunction and abnormal cellular growth are 
intertwined. It is highly likely that the electrophysiological deficits that we have 
shown in the first section could be due to abnormal cell growth. 
 
Therefore, I propose the following underlying mechanism for autism. ASD 
candidate genes disrupt the morphological structure of the neuron leading to 
aberrant synapse formation. This in turn causes deficits in synaptic transmission, 
which results in autistic phenotypes and symptoms (Figure 1.0). 
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Figure 1.0: Pathogenic pathway of autism:  The figure describes the proposed underlying 
mechanism for ASD. The candidate genes for ASD cause abnormal neuronal growth, which 
leads synaptic dysfunction resulting autistic phenotypes.  
 
 
In next section of this thesis, I discuss the role of SHANK3 in autism, as 
discussed in section 1.2. More than thousand cases of SHANK3 22q.13 deletion 
have been reported. 75 percent of these have ASD and 95 percent display 
severe mental developmental delay (Jiang et al., 2013). Several studies have 
reported that SHANK3 has the highest pentrance rate in monogenic cause of 
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1.4 SHANK3 and autism  
 
Durand et al (2007) described three ASD patients with severe language delay 
carrying SHANK3 mutation. The first two mutations were inherited missense 
mutations, termed R12C and R300C, which disrupted the N terminal ankyrin 
repeats within the gene (Figure 1.1). The third mutation was a de novo truncating 
stop mutation resulting in the loss of the C terminal of the gene.  Subsequently, 
these human SHANK3 mutants were overexpressed in vitro in mice hippocampal 
culture by Durand et al (2012). These resulted in disruption of several 
morphological and physiological functions of the neuron. In particular, the stop 
mutation resulted in loss of spine density and impaired synaptic transmission.  
Thus, suggesting that the mutant SHANK3 protein causes disruption in neuron 
morphology and synaptic signaling.  An interesting point to note in this 
experiment is that SHANK3 mutant protein supersedes the function of wildtype 
protein. However, the cause for this is unknown.   
 
Similarly, Moessner et al (2007) screened a cohort of 400 patients with ASD and 
found two gene deletions and one de novo mutation in SHANK3 gene. The 
patients exhibited severe hyperactivity and absence of speech.  
 
Additionally, Buccoto et al (2013) and Gautheir et al (2009) both reported more 
than 2% of SHANK3 mutation in their study of ASD patients. All patients with 
SHANK3 mutations exhibited signs of extreme speech delay and repetitive 
behavior. Likewise, a Japanese population study looked at 128 ASD patients with 
SHANK3 mutations and all of them displayed a language development delay, 
hypotonia and mental retardation (Waga et al 2011).  
 
Taken together the above studies demonstrate that SHANK3 mutation could be 
considered as a cause of ASD. As it has been reported that SHANK3 haplo-
insufficiency is the highest cause of monogenic autism (Kolevzon A et al., 2011; 
Nemirovsky et al., 2015; Bentancur et al., 2013). Therefore, it is important to 
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understand how the loss of SHANK3 might impact neuronal function and 
synaptic development, leading to ASD. The next section describes the known 
function of SHANK3 from various biochemical and mouse studies. 
 
1.5 The structure and function of SHANK3 gene 
 
The SHANK3 gene consists of 22 exons and encodes a multidomain protein as 
in shown figure 1.1. These domains comprise of N terminal ankyrin repeats 
(ANK), PDZ domain, sterile alpha motif (SAM) domain, SRC Homology (SH3) 
domain and proline rich domain (pro) (Uchino et al., 2013). The function of each 
domain is explained in table 1.2.  
 













C Verpelli et al., 
2011; Uchino et 
al., 2013; Jiang 
et al., 2013 




Formation of the 
post synaptic 
structure 
Nasbitt et al., 
1999; Verpelli et 
al., 2011; 2012; 
Uchino et al., 




Densin 180  Quitsch et al., 
2005 






remodeling and  
Proepper C et 
al., 2007; 
Verpelli et al., 
2012; Uchino et 
al., 2013; Jiang 
et al., 2013 
A sterile Alpha 
domain (SAM) 
Zinc Regulation of 
Protein structure 
Verpelli et al., 
2012 and 2011 
 Table 1.2: SHANK3 domains and its function. 
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Figure 1.1:  SHANK3 structure and function at the synapse.  A. The structure of the human 
SHANK3 gene. Arrows represent the various intragenic promoters. B. SHANK3 and it various 
binding partners. C. Protein isoforms of SHANK3 deduced from mRNA expressed in the human 
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Various transcriptional studies have deduced the gene structure of SHANK3, for 
both mouse and human (Bonaglia MC et al., 2006;	  Wang et al., 2011; Boeckers 
TM et al., 1999). The generic SHANK3 structure shown in figure1.1 is the same 
for both. However, the mouse Shank3 gene structure has been characterized 
more extensively than the human SHANK3 (Wang et al., 2011;	  Mameza et al. 
2013; Bonaglia MC et al., 2006;	  Boeckers TM et al., 1999). Moreover, not the 
entire SHANK3 gene has been mapped out, as it is highly GC rich which creates 
a difficulty in any method of DNA/RNA characterization. Thus, due to general 
similarity between the mouse and the human SHANK3, the functions of the 
SHANK3 are thought to be similar in both cases.  
 
1.5 (a) Isoforms of SHANK3 
 
As of yet the exact number of protein isoforms encoded by the SHANK3 gene 
have not been determined. Nonetheless, various mRNA studies (Durand et al., 
2007; Wang et al., 2011; Maunakea et al., 2010) have deduced the existence of 
seven isoforms, as shown in figure 1.1C in both human and mouse.  As each 
domain of SHANK3 has a unique function (Summarized in Table 1.2) and each 
isoform has a different combination of SHANK3 domains, it is highly likely that 
each SHANK3 isoform has a different function. For example, SHANK3e and 
SHANK3f lack the PDZ domain, which binds to the NMDA receptors via PSD95, 
while SHANK3b lacks the proline rich and the SAM domain, which is the Homer 
binding site. Therefore, this suggests that the different SHANK3 isoforms may 
have different functions. As of yet there are no studies that have investigated the 
function of different SHANK3 isoforms.  
 
An interesting phenomenon is that different ASD patients have different 
mutations in SHANK3 gene, these could be isoform specific. For instance, a 
splicing mutation in intron 5 encoding the N terminal ANK repeats would only 
affect SHANK3 isoforms a and b (Figure 1.1C, Jiang et al., 2013).  Other 
deletions, in exons1-9, will affect different isoforms of SHANK3.  Thus, we could 
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propose that isoform specific disruption of SHANK3 could lead to different 
phenotypic effects. This could also explain clinical heterogeneity seen in 
SHANK3 deleted ASD patients. There is also the possibility that some isoforms 
could be expressed earlier in development while others are expressed later in 
development. Till date no studies have been performed to observe the differential 
isoform expression of SHANK3 during development. To test these hypotheses 
we would need to generate isoform specific antibodies as qPCR fails to work due 
to high GC content in SHANK3 gene. 
 
1.5 (b) SHANK3 at the postsynaptic density  
 
In humans the SHANK3 protein is abundantly expressed in the brain, heart and 
spleen (Lim Sangmi et al., 1999). In the brain of both mice and humans, 
SHANK3 is mainly expressed at the synapse and acts as a scaffolding protein for 
synaptic proteins (Jiang et al., 2013). Most studies have used mouse cDNA to 
characterize the binding partners of SHANK3. For example, it interacts with 
NMDAR via the PSD95 (Post synaptic density 95)/GKAP (guanylate kinase 
associated protein) complex that binds to its PDZ domain.  This complex also 
binds the GluR1 subunit of the AMPAR (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor). In addition, the proline rich domain of SHANK3 
binds to the mGluR (metabotropic glutamate receptor) via Homer1 (Homer 
Scaffolding Protein 1) (Nasbitt et al., 1999; Lim S et al., 1999; M Sheng et al., 
2000; Uchino et al., 2006; Uchino et al., 2013). This suggests that SHANK3 
recruits various synaptic receptors to post-synapse. The activation of these 
receptors causes synaptic transmission and many forms of synaptic plasticity 
such as LTP and LTD. 
 
1.5 (c) SHANK3 associations with the cytoskeleton 
 
The cytoskeleton is an intracellular matrix that maintains the cell’s shape and 
function. There is a dynamic interplay between SHANK3 and actin via proteins 
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that attach directly or indirectly to actin. For instance, Densin -180 binds to the 
SH3 domain and N terminal ANK domain of SHANK3 protein antagonizes 
dendritic branching. SHANK3 binds to C terminus of Densin-180 making the PDZ 
domain of Densin-180 inaccessible to δcatenin. δcantenin binds with Densin-180 
and is required for the formation of new branches (Quitsch et al., 2005). Thus, 
suggesting that SHANK3 plays a role in maintenance of dendritic morphology.  
 
 Alpha fodrin interacts with the ANK domain of SHANK3 and helps regulate F 
actin elements in the spines (Bocker et al., 2001). Actin binding protein 1 (Abp1) 
and cortactin-actin-binding protein (cortactin) both bind to the proline rich domain 
of SHANK3 and are involved in regulation of spine morphology and actin 
polymerization at spine heads. Abp1 regulates Apr2/3 complex (Actin-Related 
Proteins ARP2 and ARP3) via N-WASP (neuronal Wiskott–Aldrich Syndrome 
protein) interaction to polymerize F actin to regulate spine density. As 
overexpression of Abp1 increases spine density this increases the number of 
synapses. (Du et al., 1998; Qualmann et al., 2004; Haeckel et al., 2008; Hering 
et al., 2003; Verpelli et al., 2012).  
 
SHANK3 also binds with SPIN90 (SH3 protein interacting with Nck90), a known 
partner of the Arp2/3 complex and N-WASP (Kim et al., 2009). SPIN90 binds 
with both Arp2/3 complex and G actin leading to actin polymerization, which 
causes cell membrane ruffling to form lamellipodia. This helps the cell to move, 
leading to cell motility (Kim et al., 2006). Hence, suggesting that SHANK3 with 
the help of SPIN90 may play a role in cell migration. 
 
The signal transduction molecule βPIX interacts with the PDZ domain of 
SHANK3 contributing to cytoskeletal organization within dendritic spines with the 
help of (guanine exchange factor) GEF. The downstream effectors of GEF are 
the GTPases Rac1 (Ras-related C3 botulinum toxin substrate 1) and Cdc42 (Cell 
division control protein 42). Both are involved in a wide variety of cellular 
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functions such as cell shape, structure, cell polarity, cell cycle and locomotion 
(Park et al., 2003; Verpelli et al., 2012).  
 
It has also been reported that the Abelson interacting protein (Abi-1) binds to the 
proline rich area of SHANK3. This protein controls actin assembly via the 
WAVE1 complex (Wiskott-Aldrich syndrome protein family member 1) (Proepper 
C et al., 2007; Verpelli et al., 2012). Abi-1 acts as synapse to nuclear messenger. 
It is localised in the neurites and growth cones during early development. At later 
stages, the protein is found in post synaptic density in spines. As soon as 
NMDAR reached the PSD, the Abi-1 shuttles back to the nucleus to enhance E-
box regulatated gene transcription (Proepper C et al., 2007).  
 
In conclusion, the multiple binding domains of SHANK3 and its binding partners 
form the core element of the post synaptic density.  Not only does SHANK3 play 
a role in synaptic recruitment, but it also binds with actin cytoskeletal elements to 
modulate synapse assembly.  
 
1.6 Rodent studies of Shank3 
 
Most of the known function of SHANK3 has come from studying mice engineered 
to comprehend the role of SHANK3 in autism. Five lines of Shank3 mutant mice 
carrying different deletions in the Shank3 gene have been generated (Wang et 
al., 2011; Yang et al., 2012; Bozdagi et al., 2010; Peca et al., 2011; Schmeisser 
et al., 2012).   Three of these carry deletions in the N terminal ankyrin domain 
(ANK); the homozygous deletion of exon4-9-/- (Wang et al (2011); the 
heterzygous deletion of exon4-9+/- (Bozdagi et al., 2010) and a homozygous 
deletion in exon4-7-/- (Peca et al 2011). Peca et al (2011) also made a SHANK3 
mutant line with homozygous deletion in exon13-16-/-, which encodes for PDZ 
domain, while Schmeisser et al (2012) made mutant mice with a homozygous 
deletion in exon11-/- that encodes for SH3 domain. The cellular and molecular 
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phenotypes associated with these Shank3 mutant mice are summarized in Table 
1.3.  
 
1.6 (a) Synaptic Proteins altered in Shank3 mutant mice  
 
Alterations have consistently been reported in the postsynaptic density (PSD) 
protein in all five mutant mice. Homer1 and GKAP protein levels were reduced in 
exon4-9-/- mice in the PSD fraction of the both hippocampal culture and tissue 
(Wang et al., 2011). Similarly, Homer 1, GKAP and PSD93 protein levels were 
also reduced in the PSD fraction of the striatum tissue in exon13-16-/- mice (Peca 
et al., 2011). However, no changes were reported in exon11-/- mice in Homer1 or 
GKAP protein levels in the neocortex tissue of the PSD fraction. However, Peca 
et al (2011) did not examine PSD fractions from neocortex and hippocampus, 
while Wang et al (2011) did not examine the striatum or neocortex. Therefore, 
this suggests that the protein level changes in PSD of mutant Shank3 are tissue 
specific and/or could be mutant specific too.   
 
Moreover, Shank2 was found to be increased in this mutant model (Schmeisser 
et al., 2012). This could mean that there might be compensatory mechanisms if 
one SHANK family membrane protein destabilizes the other comes to rescue. It 
would be of interest to examine if this also occurs in the rest of the Shank3 
mutant mice models. 
 
Mutations in the Shank3 gene have caused a change in the levels of both AMPA 
and NMDA receptors (Jiang et al., 2013). For example, the GluA1 subunit of 
AMPA receptor was reduced in the hippocampus of exon4-9-/- and exon4-9+/- 
mice, and GluA2 was reduced in the striatum of exon13-16-/- mice (Wang et al., 
2011; Bozdagi et al., 2010; Peca et al., 2011).  There was a reported decrease in 
NMDA receptor subunits, namely GluN2A and GluN2B in the striatum of exon13-
16-/- (Peca et al., 2011).  In contrast, GluN2B was increased in the hippocampus 
of exon11-/- mutant mice (Schmeisser et al., 2012; Jiang et al., 2013).  This 
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suggests that the loss of Shank3 in these mutants alters postsynaptic protein. 
Also, the loss of these receptor molecules would impact synaptic transmission, 
which is known to affect behavior. 
 
In conclusion, the pattern of synaptic protein alteration is different in each mutant 
mouse; this could be due to Shank3 isoform specific effect of each mutation. For 
example, Peca et al 2011 Shank3 mutant targets exon13-16-/-, the PDZ domain 
report reduction in GKAP levels while Schmeisser et al., (2012) SHANK3 mutant 
targets exon11-/- SH3 domain reports no reductions in GKAP. This phenotype 
could be purely due to the isoform specific loss of Shank3, as the PDZ domain 
binds GKAP and not the SH3 domain. Table 1.3 shows in green some of the 
similarities and differences between the Shank3 mutant models that could arise 
due to different isoforms being analyzed or the different brain tissues being 
examined by each Shank3 mutant mice model. 
 
Therefore, to fully understand the effects of Shank3 mutations on synaptic 
protein composition, a simultaneous comparison of each mutant line at matching 
ages and matched brain tissues would need to be carried out.  
 
1.6 (b) Morphological deficits in Shank3 mutant mice  
 
Since, Shank3 plays a major role in cytoskeleton modeling of the neuron, the 
neuronal structure was examined in these Shank3 mutant mice models. 
 
The neuronal structure of medium spiny neurons in the striatum brain slices was 
analyzed in exon13-16-/- mice and an increase in dendritic length and arborization 
was reported (Peca et al., 2011). Furthermore, they examined PSD thickness 
and length, which were both decreased, suggesting that Shank3 helps in the 
development of the PSD. Spine length was increased and spine density was 
decreased in the hippocampus of exon4-9-/- mice (Wang et al., 2011) and similar 
observations were observed in exon13-16-/- mice, where spine density was 
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decreased in the striatum (Peca et al., 2011). Neuron morphology has not been 
examined in any of the other mutant mice (Jiang et al., 2013). From the above 
studies we can reflect that Shank3 through its various cytoskeleton binding 
partners regulates neuronal and spine morphology (section 1.5 c). 
 
Another example of morphological changes to neurons was reported by Durand 
et al (2012), where they introduced two inherited deletion variants of SHANK3 
and two de novo mutations of SHANK3 were transfected into rat hippocampal 
neurons.  The inherited mutations (R12C and R300C) caused a decrease in 
spine density, while the two de novo mutations (truncating mutation STOP and 
ankyrin domain mutation Q321) decreased the development of dendritic spines 
and inhibited growth cone motility. They proposed that the mechanism by which 
SHANK3 regulated spine formation was through F actin polymerization (as 
discussed above section 1.4). They overexpressed wild type SHANK3 in rat 
hippocampal neurons and this lead to an increase in spine density and the same 
spines showed co-localization of SHANK3 with F actin. Hence, suggesting that 
SHANK3 binds to F actin to regulate spine formation. 
 
Thus, the morphological analysis of SHANK3 in mutant mice revealed that 
SHANK3 plays a complex role in synapse development particularly, its shape, 
size and structure. 
 
1.6 (c) Synaptic dysfunction in Shank3 mutant mice  
 
Synaptic transmission and plasticity were examined in all the Shank3 mutant 
mice. mEPSC frequency and amplitude, paired pulse ratio, input /output curves, 
synaptic transmission and LTP were reduced in hippocampal of exon4-9+/- mice ( 
Bozdagi et al., 2010). However, exon4-9-/- mice only showed a decrease in LTP 
(Wang et al., 2011).  Also, a decrease in frequency and amplitude of EPSCs 
were observed in the striatum of exon13-16-/- mice. EPSCs were also mildly 
affected in exon4-7-/- mutant mice (Peca et al., 2011). These variations between 
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studies could be due to mice genetic background, animal age and protocols 
used.  
 
Taken all together the data supports that synaptic transmission is perturbed in 
Shank3 mutant mice.  However, it is not very clear whether there is a common 
core synaptic dysfunction in the various mutants, as all Shank3 mutant mice 
show variation in synaptic phenotypes. This as mentioned before could be due to 
genetic heterogeneity between the Shank3 mutant mice. For instance, one 
Shank3 mice targets the PDZ domain (Peca et al., 2011) the other targets the 
SH3 domain (Schmeisser et al., 2012).  
 
Similarly, SHANK3 caused ASD patients to report various types of SHANK3 
deletion. For example, Moessner et al (2007) a missense mutation in exon 8 
while Bonaglia et al (2001) describes a mutation that disrupts exon 21 of the 
SHANK3 gene. The first patient in Messer’s study has a verbal repetitive 
behavior, understands complex instruction and has no motor disorder while 
Bonaglia’s study patient has severe language delay, mental retardation and 
hypotonia. Even though the patients have deletion in the same gene, there is 
clinical heterogeneity in symptoms. This could be due to the different SHANK3 
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Table 1.3: Cellular and molecular phenotypes associated with Shank3 mutant mice 
(References Wang et al., 2011; Yang et al., 2012; Bozdagi et al., 2010; Peca et al., 2011; 
Schmeisser et al., 2012). 
 
1.6 (d) Behavioral phenotypes associated with Shank3 mutant mice  
 
Extensive behavioral analysis has been performed on all five Shank3 mutant 
mice.  Reduced social interaction was the most consistent behavior noted in all 
five Shank3 mutant mice (Jiang et al., 2013). An increase in repetitive behavior 
such as behavior inflexibility and increased self-grooming were observed in 
exon4-9-/- and exon4-9+/- mice (Bodazagi et al., 2010; Wang et al., 2011).  
Exon13-16-/- mice showed a more marked increase in self-injurious and self-
grooming behavior, while no behavioral change was reported in exon4-7-/- mutant 
mice (Peca et al., 2011). In addition, exon11-/- mutant mice also reported an 
increase in self-grooming behavior (Schmeisser et al., 2012). 
 
Intellectual disability is commonly reported in patients with a SHANK3 mutation. 
In Shank3 mutant mice they tested this using learning and memory tasks such as 
the Morris water maze task. Only exon4-9-/- mice showed impairment in this area 
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Thus, we can conclude that most behavioral changes reported in these mice can 
be somewhat linked to behaviors observed in autistic patients in humans, but a 
difficulty arises from these studies since none of these Shank3 mice mutations 
have been found in human ASD. A better experiment would be to take human 
SHANK3 mutants and introduce those into mice, to see if it changes behavior. 
These have not been modeled in vivo because SHANK3 gene is very difficult to 
manipulate, as it is highly GC rich.  Durand et al., 2012 has done this in vitro in 
mice hippocampal culture but not in vivo to study the cellular effects of mutant 
SHANK3. 
 
1.7 Can we link Shank3 mutant mice studies to Human ASD? 
 
In humans, ASD is diagnosed through behavioral symptoms. Currently, there are 
no reliable biomarkers or anatomical and functional imaging studies that can be 
predictive of autism (Kleijer et al., 2014). Moreover, little is known about the 
etiology of autism although several brain region and circuits have been 
implicated in autism (Kleijer et al., 2014; Jiang et al., 2013).  Mice behavioral 
studies such as social, communication and intellectual ability studied by a range 
of learning and memory paradigms are not robustly translatable to humans 
(Silverman et al., 2010; Jiang et al., 2013).   In addition, there is a huge variability 
in the clinical presentation of these impairments in humans, which cannot be 
characterized in mice models.   
 
A burning issue is to understand the common pathophysiology that underlies 
autism, as this will help us develop better diagnostic tools and drugs to treat or 
prevent the disease. Studies on Shank3 mutant mice have provided somewhat 
overlapping but not identical phenotypes indicating, cellular disruption which 
leads synaptic dysfunction. However, this is still not robust enough because of 
the variability between mice models probably reflecting the heterogeneity of 
mutations studied. Thus, there is a need to study specific Shank3 mutations that 
correspond to the mutations that occur in humans and are known to cause ASD. 
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One way of doing this would be to study these SHANK3 mutations in human 
cellular models. These studies could help us understand the cellular pathway that 
forms the basis of autism.  
 
1.8 The need for human cellular models 
 
Much of our current knowledge of the molecular pathways that leads to human 
developmental disorders such as ASD have come from heterologous systems 
and genetic animal models, in particular, mouse models.  However, there are 
considerable differences that exist between the human and mouse genomes. 
Mouse models cannot fully represent the disease pathophysiology because of 
differences in brain development and signaling pathways. For example, Nitric 
oxide synthase-2 (NOS2) gene in the brain produces different levels of nitric 
oxide in humans than mice (Hoos et al., 2014).  There is no debate that mouse 
models of autism have provided some insight into the mechanism of the disease 
but these have not resulted into any translational benefits for patients. Human 
cellular models have the potential to address these issues as cellular phenotypes 
found in these model could be a reflection of the diseased state. Drugs can then 
be tested on the phenotypes found to cure or prevent the disease from 
happening. 
 
There are different types of human cellular models that could be considered. The 
first are immortalized human cell lines. These lines have been used to 
overexpress mutant proteins to understand disease pathophysiology (Eigenmann 
et al., 2012). Yet, these lines in prolonged culture acquire genetic abnormalities 
and massive overexpression of human proteins does not reflect human 
pathophysiology.  Thus, this approach has significant limitations. 
 
Another possibility could be the use of human embryonic stem cells (es). These 
cells are derived from embryos at the blastocyst stage and are pluripotent in 
nature and can self renew (Narinh Hazim et al., 2011). Nonetheless, the use of 
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human embryos for research purposes remains ethically controversial and 
logistically challenging because of the limited supply of human embryo donors 
(Narinh Hazim et al., 2011).  
 
The last and most recent approach to generating human cellular models is to 
reprogram adult somatic cells to generate pluripotent stem cells (Cocks et al., 
2014). The advantage of using induced pluripotent stem cells (iPSCs) is that we 
can generate patient-specific iPS cell lines to model complex disorders like 
autism. iPSCs retain the capacity to indefinitely renew and differentiate into cells 
from all three germ layers (Sterneckert et al., 2014). This makes iPSCs valuable 
for disease modeling, drug discovery and personalized medicine applications 
(Sterneckert et al., 2014).  
 
1.9 Modeling ASD in a dish using iPSC 
 
Takahashi and Yamanaka et al (2006) first reprogrammed mouse fibroblasts to 
generate pluripotent cell by overexpressing four transcription factors, Oct4, Klf4, 
Sox2 and c-Myc).  Later, Takahashi et al (2007) used human fibroblasts to 
reprogram into a pluripotent stage.  iPSCs have the capacity to self renew and to 
differentiate into various types of cells (Yamanaka 2012). Studies have shown 
that iPSCs retain the genetic memory of the parent cell (Shao et al., 
2013;Yamanaka 2012). Hence, the phenotype discovered from iPSC-derived 
cells would be indication of the parental genotype. 
 
Various human disorders have been successfully modeled using iPSC, including 
ASD (see section 1.9) and studies using iPSCs have resulted in the development 
of new drug treatment strategies.  For example, Parkinson Disease platelet 
deficiency, spinal cord injury and macular degeneration (Yamanaka 2012) have 
all been modeled through iPSCs. Thus, iPSCs have allowed the investigation of 
the complex mechanisms behind disease pathophysiology and explore potential 
new treatment.  
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1.9 (a) Rett Syndrome (RTT) 
 
To date three main iPSC studies have been reported for RTT syndrome. RTT is 
a neurodevelopmental autism spectrum disorder. It is caused by a mutation in 
the MECP2 gene.  Marchetto et al (2010) studied three female patients with 
missense mutations and one female patient with a frameshift mutation in this 
gene. They generated iPSCs lines from these patients. The neurons 
differentiated from patient lines reported fewer synapses, altered calcium 
signaling and a decrease in frequency and amplitude of spontaneous current. 
Morphological deficits were also evident, with neurons having a reduced cell 
soma size and reduced spine density. Additionally as mentioned above, post 
mortem and rodent studies of RTT syndrome have described morphological 
deficits in neurons such as reduced cell soma. Ananiev et al (2011) and Cheung 
et al (2011) both generated iPSC lines from RTT syndrome patients and showed 
that neurons generated from such lines had a decrease in cell soma area. The 
iPSCs studies of RTT corroborate the morphological phenotype as observed in 
post mortem studies of RTT. Thus, suggesting that iPSCs can be used as a 
model for neurodevelopmental disorders.  
 
1.9 (b) Fragile X syndrome FXS 
 
There have been a number of iPSC studies that have modeled FXS (Urbach et 
al., 2010; Sheridan et al., 2011; Jing Liu et al., 2012; Doers et al., 2014).  
FXS is a common form of mental retardation and is closely linked to autism. The 
genetic basis of FXS is an expansion of CGG repeats in the 5’ untranslated 
region of FMR1 gene (Fragile X mental retardation protein). The expansion of 
this nucleotide repeats leads to loss of function of FMR1 (Doers et al., 2014).  
 
Post morterm studies of FXS have described cortical neurons with smaller cell 
volume, neurons with shorter and fewer neurites. iPSCs models of FXS have 
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described similar phenotypes. For instance, Liu et al (2012) used FXS patients to 
generate iPSCs, which were then converted into cortical neurons. They 
described neuronal phenotypes associated with FXS, such as reduced neurite 
length, neurite number and synaptic puncta. Also, these neurons were 
functionally abnormal, with calcium transients that were increased in amplitude 
and frequency.  
 
Similarly, Sheridan et al (2011) studied iPSC-derived neurons from FXS patients. 
These also had fewer, shorter neurites and more compact cell soma.  Moreover, 
this was further confirmed by Doer et al (2014), they also studied neurite 
outgrowth and reported deficits in neurite initiation and extension. 
 
Taken together the iPSC studies validate the deficits in neurite morphology as 
they were also observed in post mortem studies. This also suggests that the 
iPSCs generated neurons can produce disease related phenotype.  
 
Recently, FXS iPS derived patient cells have been used as a high throughput 
screen to find compounds that could increase the expression of FMRP1 and 
reverse the phenotypes reported. Out of the 5000 compounds screened they 
found 6 compounds that modestly increased the expression of FMR1 (Kumari D 
et al., 2015), suggesting new compounds for developing therapeutics. These 
compounds have not been tested to see if they can reverse the disease 
phenotype as reported above. Hence, this indicates that patient derived iPSCs 
can be used for drug screening which could be useful in generating future 
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1.9 (c) Phelan McDermid Syndrome (PMDS) 
 
Phelan McDermid syndrome also known as 22q13 deletion syndrome is a 
neurodevelopmental disorder characterized by global developmental delay, 
speech delay, intellectual disability, poor motor coordination and ASD (Costales 
Jesse et al., 2015). Among the various genes deleted in this syndrome, SHANK3 
is considered the most likely candidate for causing the neurological abnormalities 
observed in patients (Scheglovitov et al., 2013). The cellular and molecular 
phenotypes associated with PMDS have been studied in iPSC lines generated 
from two patients. They found that iPSC-derived PMDS neurons have a reduced 
expression of SHANK3 and impaired excitatory synaptic transmission. Both 
amplitude and frequency of mEPSCs were significantly reduced and synaptic 
puncta staining revealed a decrease in both pre- and post-synaptic puncta, 
suggesting that there were fewer synapses in these neurons. Interestingly, these 
phenotypes could be rescued by treating the neurons with SHANK3 
overexpression.  
 
A few points to be noted in this study are first; that the study supports the first 
hypothesis that “synaptic dysfunction” causes autism (section 1.3). Second that 
the study focuses on synaptic phenotypes, which occur late in development. 
They did not look at morphological deficits in neurons. Third, the rescue 
experiment was performed using a rat Shank3 overexpression construct, which is 
similar to humans yet not completely the same. My study also looks at the role of 
SHANK3 not in PMDS but in ASD, therefore, the above points are my reflection 
on what are the potential gaps in the PMDS iPSC study that my study would fill in 
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1.10 Limitations of the iPS model and future  
 
There are a few issues regarding the modeling of diseases with iPSCs. They 
exist in the form variability between (1) neuron to neuron (intra-patient) (2) cell 
line to cell line from the same patient (intra patient) (3) patient to patient (inter 
patient) (Brennand et al.,2012).  
 
The variability between types of neurons generated exists due to the type of 
neutralization protocol used, all the iPSCs models described above use a mixed 
neuronal population. Currently, there are no studies that produce a specific 
neuronal subtype.   There are, however, protocols for different lineages, such as 
cortical, hypothalamic or motor neurons (Salimi et al., 2014). Also, all the iPSC 
studies mentioned above looked at cortical lineage. This would be important 
because there might be a disease those effects only specific subtype of neuron 
and the phenotype of disease might get diminished in the mixed population. For 
instance, Parkinson’s disease affects dopaminergic neurons.  To study specific 
neuronal subtypes one could separate the cells of interest by FACs 
(Fluorescence-activated cell sorting) or use immunocytochemistry to identify the 
neural subtypes present. 
 
It has been well established that there is variability in lines generated from the 
same patient (Brennand et al., 2012). Genetic variations can occur due to 
location and number of viral integration during the reprogramming process, iPSC 
generation and expansion (Brennand et al., 2012). However, these can be 
checked for by quality control testing for each iPS line generated. For example, 
our lab performs karyotyping analysis after each line generation and high 
passaged number lines are discarded (Cocks et al., 2014).  
 
Inter patient variability comes from the clinical heterogeneity of the patients 
(Brennand et al., 2012).  Most studies compare 2-3 patients’ iPSC lines and there 
is always a concern about whether such findings pertain to the whole patient 
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population. To overcome this we need to develop more robust methods that are 
less time consuming and permit the examination of thousands of patients 
simultaneously.  
  
1.11 Hypothalamus and ASD  
 
Most autism studies focus on neuronal defects within cortex, hippocampus and 
striatum. Nevertheless, there is another part of the brain that we can consider 
plays an important role in ASD – the hypothalamus. Recently, an MRI study was 
performed where 52 autistic children were compared to 52 matched controls 
(Kurth et al., 2012). This study looked at various brain regions and found 
diminished grey matter in the hypothalamus (Kurth et al., 2012).  These findings 
lead to our interest in understanding the role of the hypothalamus in autism. 
 
iPSCs can be converted into various neuronal lineages by using specific 
protocols (Salimi et al., 2014). A postdoctoral researcher in our lab, Dr. Graham 
Cocks, has generated a protocol to generate hypothalamic neurons. The 
hypothalamus controls for social behavior, growth, body temperature, appetite, 
sleep, energy storage and circadian rhythms (Brodal Per 2004). 
 
The hypothalamus is located above the pituitary gland and occupies about two 
percent of our brain. In terms of neuroanatomy, it is the most ventral part of the 
diencephalon (Lechan et al., 2013). The hypothalamus is a highly connected 
area of the brain forming connections with the limbic system including the 
amygdala and septum. It receives input from the brain stem, including the 
nucleus of the solitary tract, ventrolateral medulla and locus coeruleus (Lechan et 
al., 2013). The hypothalamus can be divided into three regions, the Anterior, 
Posterior and Tuberal region and these areas are further divided into nuclei, 
which releases different neurohormones that regulate different functions of the 
body (Table 1.4; Brodal Per 2004).  
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For example, the para ventricular nucleus of the anterior hypothalamus produces 
the hormone cortisol releasing hormone (CRH). This hormone stimulates the 
adrenocorticotropic hormone (ACTH), which helps regulates stress responses in 
the body (Brodal Per 2004). GnRH (Gonadotropic releasing hormone) released 
from the preoptic nucleus of the hypothalamus stimulates follicle stimulating 
hormone and luteinizing hormone, which play an important role in regulating sex 
hormones (Lechan et al., 2013).  
 
Children with autism have difficulty adapting to new environments (Spratt EG et 
al., 2012). When cortisol levels were compared in children with and without 
autism, higher peaks of cortisol with a prolonged duration were found in autistic 
children (Spratt EG et al., 2012). Cortisol is a downstream product of CRH, which 
is often regulated through the hypothalamic –pituitary-axis (HPA). The HPA axis 
regulates various body function such as stress responses, digestion, immune 
system and social behavior (Smith et al., 2006).  In primates elevated cortisol 
levels produce social withdrawal symptoms (Kerickson et al., 2005). Since, in 
autistic children the cortisol levels are higher due to the imbalance of HPA axis, I 
propose that this could lead to the social withdrawal symptoms often reported in 
ASD. 
 
A recent study reported that gestational hypothyroxinemia in rodents induced 
impaired cortical neuronal migration. Neuronal migration deficits have been 
reported in autistic children (Belmonte et al., 2005). TSH (Thyroid stimulating 
hormone) is produced by the hypothalamus and regulates thyroid hormone 
production (Roman GC et al., 2013).  Moreover, low levels of TSH during mid 
pregnancy have been shown to significantly increase the odds of a child being 
diagnosed with autism (Yau et al., 2015). 
 
Using mass spectrometry and liquid chromatography, the concentrations of four 
sex steroid hormones, progesterone, testosterone, 17α-hydroxy-progesterone 
androstenedione, have been studied in autistic children. All of these were found 
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elevated (Baron-Cohen et al., 2015). GnRH produced by the hypothalamus is a 
precursor to all of these hormones. All the above studies have clearly established 
a link between hypothalamus and autism. Therefore, in this study we focus on 
the role of hypothalamic neurons in autism (section 1.1). 
 
Table 1.4: Function of hypothalamus: The table describes the various hypothalamic nuclei and 
their respective function (Burbach et al., 2001; Ronald Lechan et al., 2013; Brodal Per 2004). 
!
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1.13 Neuralisation 
Neuralisation can be defined as the process of directing differentiation of stem 
cells (iPS or ES) into various neural lineages using small synthetic molecules.  
Over the years various protocols have been devised to make different neuronal 
types.  A few examples are described below: 
• Cortical neurons: The “dual smad inhibition” methodology has been 
shown as the most robust protocol to make cortical neurons (Shi, Yichen 
et al., 2012; Boissart et al., 2013). In this protocol iPS/ES cells are 
cultured as an adherent monolayer and is exposed to two smad inhibition 
molecules, SB431542 and Noggin. SB431542 blocks the phosphorylation 
of the ALK4, ALK5 and ALK7 (Anaplastic lymphoma kinase receptors), 
which leads to the inhibition of Lefty/Activin/TGFβ pathways 
(Transforming growth factor beta) . Noggin inactivates BMP4 (bone 
morphogenetic protein) . Both treatments together are required for the 
conversion of stem cells into neurons, specifically cortical (Chambers et 
al.,2009).  This protocol is now widely used to study various neurological 
disorders such as Autism, Schizophrenia, Alzheimer’s and Stroke. 
Recently, a study successfully transplanted hiPSC derived cortical neural 
progenitors into rats suffering from Stroke. These cortical progenitors not 
only differentiated into cortical neurons but also improved the neurological 
symptoms of the rats (Tornero et al., 2013). Now, research is moving 
towards generating three dimensional models of the cerebral cortex 
known as cerebral organoids using the same principles as small 
molecules inhibition (Lancaster et al., 2013).   
• Midbrain Dopaminergic neurons: Directing the differentiation of iPSC 
neurons into dopaminergic neurons is fundamental for realizing its 
potential as a treatment for Parkinson disease. Once the stem cells are 
exposed to smad inhibitors (Noggin and SB431542), which cause neural 
induction, additional factors such as SHH and FGF8 are added.  The 
signaling of these molecules causes the neurons to turn into 
midbrain/hindbrain fate (Perrier et al., 2004, Fasano et al., 2010). In 2011, 
Jaeger et al. reported a high efficient way of making dopaminergic 
neurons. They induced neural differentiation using dual smad inhibiton for 
3 days and then blocked FGF8 signaling using two small molecules 
namely PD0325901 and PD173074. This caused early neural induction 
and directed ventral midbrain neuronal characteristics. This treatment was 
followed by FGF8 and SHH treatment that promoted the generation of 
dopaminergic neurons and restricted alternative fates.  
• Striatal Projection neurons: The primary projection neurons of the 
striatum are the GABAergic medium-sized spiny neurons. These neurons 
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specifically degenerated in the early phases of Huntington’s disorder. 
Hence, neural differentiation protocols have been developed to make 
these striatal neurons. For example, a recent study uses Activin A to 
induce the formation of lateral ganglionic eminence (LGE) neural 
progenitors from human iPSCs and ES cells.  These LGE neural 
progenitors differentiate into DARPP32 positive striatal neurons (Charles 
Arber et al., 2015). 
• Other neuronal differentiation: There are many other neuralisation 
protocols that are still under development, such as the differentiation of 
stem cells into motor, hypothalamic and cerebellar neurons (Boulting et 
al., 2011; Wang et al.,2015, Erceg et al., 2012).  
Hence, through the above examples, we can infer that there are many 
neuralisation protocols that have not only allowed us to study various aspects of 
neuronal development but also to model neuron specific disorders such as 
Parkinson’s, Huntington’s, Autism and many more.  
 
1.14 Project Rationale 
 
In the above sections we have described various rodent and human cell-based 
models of autism. Also, SHANK3 has been reported as the highest monogenic 
cause of ASD. Hence, the next question that arises is what can we do to 
understand more about the role of SHANK3 in autism. This will help us 
understand the function of SHANK3 in humans and also provide us with tools to 
develop better therapeutics for ASD caused due to SHANK3.  
 
Recently, a postdoctoral researcher Dr. Walter Luchessi in our laboratory was 
studying SHANK3 expression at different stages of neuralisation. Neuralisation 
can be defined as the process of converting iPSCs into neurons. There are five 
main stages of neuralisation- the iPSC (day 0), the neural progenitor (day 12/13), 
the rosette (day18/19), the immature neurons (day 24 to 36) and mature neuron 
(day 70) stage (Figure 2.3A). He looked at the gene expression pattern of 
SHANK3 over the first four stages and compared four control lines taken from 
two healthy patients (Control P1 C1; Control P1 C2 and Control P2 C1; Control 
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P2 C2) to two SHANK3 patient lines taken from one SHANK3 ASD patient 
(SHANK3 P1 C1; SHANK3 P1 C2) 
 
He found that there is an early expression of SHANK3 from day 13 of 
neuralisation (Figure1.2A). This qPCR expression analysis was carried out using 
eight primer sets encompassing the various regions of the SHANK3 gene.  For 
the purpose of this discussion, Walter provided me with the results of two primer 
sets namely exon3-5 and exon16-18 (Figure 1.2 A and B). The position of these 
exons is shown in Figure1.2C, with a black line indicating exons 3-5 and a red 
line indicating exons16-18. Both graphs show SHANK3 expression starting from 
day 19 of neuralisation. To support this, the western blot in figure 1.2 D shows 
the SHANK3 protein expression starting from day 19 of neuralisation in a control 
line. It also depicts that SHANK3 protein is being expressed throughout 
neuralisation day 24 and 36. 
 
This data is also indicative of various SHANK3 isoform being expressed at 
different stages. For example, in SHANK3 exons3-5 are being expressed from 
day 13 onwards while SHANK3 exon16-18 expression only starts from day19 
(Figure 1.2 A).  This suggests that as cells go through the rosette stage (day19) 
and enter the immature neuronal stage (day24), expression of the SHANK3 
exon16-18 isoform goes up. Thus, taken together these results suggest that 
SHANK3 is being expressed early during neuralisation and there might be an 















Figure 1.2: SHANK3 expression pattern during early stages of neuralisation. Dr Walter 
Lucchesi performed these experiments. A. qPCR fold increase of control versus shank3 of exon3-
5. B. qPCR fold increase of control versus shank3 of exon16-18. C. Black line highlights the 
exon3-5 primer and red line highlights exon16-18 primer in the SHANK3 gene. D. Western blot 
showing the SHANK3 protein expression from day19 to day 36 from a control line. This study was 
performed in two controls versus one shank3 patient, with one clonal replicate of each (4 control 
vs. 2 SHANK3 lines, n=3). The antibody used in these experiments has an epitope against 
SHANK3 exon 21.  The gene expression (Fold increase) of SHANK3 is compared to day 0, the 
iPSC stage.  
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Figure 1.3: Project Rationale: The aim of this thesis is to discover the role of SHANK3 in early 
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As mentioned above most studies of SHANK3 in autism focus on the synaptic 
phenotype, which develops at later stages of neuronal development (Figure 1.3). 
Currently, there are no studies that show the effects of SHANK3 mutation on 
early neuronal development. Since, we have established that SHANK3 is 
expressed during early stages (Figure 1.2) this study aims to fill this gap in our 
knowledge by investigating the role that SHANK3 plays during early neuronal 
development and how disruption of this role may contribute to autism. Also, this 
builds on the hypothesis mentioned in figure1, which suggests that ASD 
candidate genes cause early neuronal abnormalities which leads to later synaptic 
dysfunction and combines the two main hypotheses for ASD - “the synaptic 
dysfunction hypothesis” and “the abnormal cellular growth hypothesis” - as the 
underlying mechanism for autism.  
 
The second potential gap in our knowledge lies in the type of neurons most 
studies have focused on. In rodent models, we have seen effects of Shank3 
mutation on the hippocampus, striatum and neocortex (section 1.6). The iPSCs 
studies of ASD have focused on generating cortical neuronal lineages. None of 
these studies have looked at hypothalamic neurons.  As mentioned in section 
1.11, the hypothalamus produces various neurohormones, which are important 
for social behavior. Social behavior is a key aspect of ASD, as one of the main 
symptoms is impaired social interaction.  Therefore, in this study we focus on the 
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1.15 Aims of our study 
 
Prof Jack Price’s lab has generated iPSC lines from root hair biopsies from three 
categories of individual:  autistic individuals carrying a deletion in the SHANK3 
gene, neurotypical controls and sporadic ASD patient line. The SHANK3 patient 
lines have been generated from two patients. The first patient is a four year old 
male diagnosed with autism, regression of motor skills, language and speech 
delay, who has a deletion from SHANK3 exon4 to the next gene ACR (Acrosin). 
Acrosin is a protease enzyme that is released from the acromsome of 
spermatozoa (Zheng et al.,2012).  The second SHANK3 patient line is from a 
five-year-old female diagnosed with autism, social communication disorder and 
speech delay. The patient has a deletion extending from SHANK3 exon4 to the 
next two genes ACR and RABL2 (Ras oncogene family like 2). I carried out this 
deletion mapping using a TaqMan assay as part of my master’s thesis project 
(Data shown in Supplementary table 1.0 and 2.0).  
 
As the etiology of autism is poorly understood, iPSCs provide us with a unique 
opportunity that allows us not only to study the cellular mechanism behind autism 
but also to follow the developmental trajectory. Thus, the aim of this project is to 
discover cellular and molecular phenotypes associated with autism.  
This study has three specific aims: 
1. To compare the morphology of control neurons to SHANK3 patient 
neurons at different stages of neuralisation. The structure of a neuron is 
critical for its function, as the size and shape of this cell defines its 
capacity to receive and send signals (Kulkarni et al., 2012). 
2. To rescue the morphogenetic phenotypes discovered by enhancing the 
expression of SHANK3. 
3. To assess via preliminary assays the underlying mechanisms behind the 
morphogenetic phenotypes discovered in Aim1. 
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These investigations will enable us to generate an in vitro system to help 
understand the cellular basis of ASD as well as provide a system that, in the 













































2.1 iPSC generation and characterization 
 
Hair root were harvested from three autistic patients and three neurotypical 
controls. Keratinocytes were derived from the hair root biopsies and converted 
into iPSCs using lenti-viral reprogramming (Cocks et al., 2014). Dr. Graham 
Cocks did this in Prof. Jack Price’s lab.  
 
The autism lines were generated from two individuals with a heterozygous 
deletion in the SHANK3 gene (see Table 2.1). The first patient was a 4-year-old 
male diagnosed with autism, regression of motor skills, language and speech 
delay. This individual carried a heterozygous deletion stretching from exon4 of 
the SHANK3 gene to the ACR gene (Acrosin).  The second patient was a 5-year-
old female diagnosed with autism, social communication disorder and speech 
delay. This individual had a heterozygous deletion stretching from exon 4 to the 
neighboring genes ACR and RABL2 (Rab-like protein 2A). The deletions were 
mapped out during my Master’s thesis using Taqman assay (Supplementary 
table 1.0 and 2.0). The third autism patient line was generated from a male 
patient diagnosed with sporadic autism. Two clonal lines were generated from 
each patient and control line. Please see table 2.1 for more details.  
 
Unlike the other cell lines used in this study, the control patient 2 clone 3 line was 
generated using sendai viral vector rather than lentiviral vectors (Table 2.1). The 
sendai virus contains single stranded negative anti-sense RNA, which replicates 
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  Cell Line Name  iPSC  Line Name  Patient Details  
Control Patient 1 Clone 1  
Control P1 C1 
Control Male 242  
CM242  
Healthy Control Male  
Control Patient 1 Clone 2 
Control P1 C2 
Control Male 205 
CM205 
Healthy Control Male  
Control Patient 2 Clone 1 
Control P2 C1 
Control Male 322 
CM322 
Healthy Control Male  
Control Patient 2 Clone 2 
Control P2 C2  
Control Male 315 
CM315 
Healthy Control Male  
Control Patient 2 Clone 3 
Control P2 C3 
Control Male m336s 
CM336s 
Healthy Control Male  
Control Patient 3  
Control P3 
 
Control Female  
CF102  
Healthy Control Female 
ASD Patient 1 
ASD P1  
 
ASD Male  
ASD M101 
Sporadic ASD Patient 
Male  
ASD Patient 1 Clone 2 
ASD P1 C2 
ASD Male 
ASD M108 
Sporadic ASD Patient 
Male  
SHANK3 Patient 1  
SHANK3 P1 C1 
SHANK3 Male 
SHANK3 M103 
SHANK3 deleted Male 
Patient 
SHANK3 Patient 2 
SHANK3 P1 C2 
SHANK3 Male  
SHANK3 M107 
SHANK3 deleted Male  
Patient 
SHANK3 Patient 2 
SHANK3 P2 C1 
SHANK3 Female  
SHANK3 F109 
SHANK3 deleted Female 
Patient  
SHANK3 Patient 2  
SHANK3 P2 C2   
SHANK3 Female  
SHANK3 F107 
SHANK3 deleted Female 
Patient  
SHANK3 Patient 2  
SHANK3 P2 C3  
SHANK3 Female  
SHANK3 F103 
SHANK3 deleted Female 
Patient  
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2.2: iPSC Cell Culture 
 
Vial of iPS cells, stored in liquid nitrogen, were thawed at 37°C and plated onto 
one Geltrex coated (Life Technologies, diluted in Dilbecco’s Modified Eagle’s 
Media F-12 (DMEM: F: 12); Sigma Aldrich and incubated for one hour at 37°C) 
well of a 6 well NunclonTM tissue culture dish (Thermo Scientific) in Essential 8TM 
medium (Life Technologies). Cultures were then placed in a Binder CB150 
incubator at 37°C, 5% O2, 5% CO2 and saturated humidity. The culture medium 
was then changed every 24 hours until the cells reached 50-80% confluence, 
when they were passaged at a dilution of 1:6 (1 well into 6 wells).  
 
For passaging, media was removed by aspiration and cells were washed with 
pre-warmed Hank’s Balanced Salt Solution HBSS without Ca2+ and Mg2+ (HBSS; 
Life technologies). The HBSS was removed by aspiration and then replaced with 
room temperature Versene (Life Technologies), which was left on for 4 minutes 
at 37°C. The Versene was then removed, the cells detached from the culture 
vessel using pre-warmed media (Essential 8TM medium) and transferred into a 
geltrex-coated 6 well tissue culture dish.  The volumes of the reagents used for 
passaging cells are detailed in Table 2.2. 
 
Table 2.2: Volumes: Tissue culture reagents volumes for different vessels. 
Vessel	   Media	   HBSS	   Accutase	  
96	  well	  plate	   200μl	   	   100μl	   50μl	  
6	  well	  plate	   2	  ml	   2ml	   1ml	  
12	  well	  plate	  	   1ml	   1ml	   500μl	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2.3 Neuralisation 
  
iPSCs were plated in 6 well plates (NunclonTM tissue culture) on to plates coated 
with Geltrex and treated with three inhibitors of SMAD (mothers against DPP 
homologs signaling) -1µM dorsomorphin + 10µM SB431542 + 5 µM XAV (SMAD 
inhibitors (SMADi) in N2:B27 (henceforth referred to as “neuralisation medium”). 
Plates were then incubated for 24 hours at 37°C (5% CO2; 20% O2).  Medium 
was replaced every 24 hours until day 7, or until formation of a uniform 
neuroepithelial sheet occurred (Figure 2.1). At day 7, wells were rinsed with 
HBSS and 1mL/well cold (4˚C) Accutase (1 ml) was added. The plates were then 
transferred to the incubator for 2-5 minutes (37°C; 5% CO2; 20% O2), until cells 
could be removed by gentle pipetting. The collected cells were transferred into 
DMEM (1 ml) and centrifuged at 900 RPM for 5 minutes. Once the supernatant 
was removed, DMEM (1 ml) was added to resuspend the pellet and the cell 
suspension was again centrifuged at 900 RPM for 5 minutes. After removing the 
supernatant, neuralisation medium + 10µM ROCKi was added to the tube to 
dissolve the pellet. The cells were plated on to fresh 6 well gletrex coated plate 
and then incubated for 24 hours (37°C; 5% CO2; 20% O2) Following this, the 
medium was removed and replaced with 2mL/well N2:B27 only (i.e. no SMADi) 
and the medium was replaced every 24 hours until day 12. The cells were then 
passaged using the protocol described above. Further passaging was carried out 
at day 15 and 18. On day 19/20, the cells were terminally plated on to Laminin for 
neural differentiation. See Table 2.3 for source of materials used. 
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Figure 2.1: Neuralisation protocol. A. The neuralisation protocol summary. B. iPSC colony 
(Scale=100µm) C. Rosette structure (Scale=50µm) D. Tuj1 positive neurons at day 26 
(Scale=50µm). D-1 (Day one, D0 (day 0)- iPSC stage, D7- (Day7) neural passage 1 (np1), D12-
Day 12 neural passage 2 (np2), D15- Day 15 neural passage 3 (np3), D18-Day18 neural passage 
4 (np4), D20-Day20 terminal plating of neural progenitors, D30-Day30 immature neurons and 
D70-Day70 mature neurons.  
 
 





















Culture	  media	  and	  reagents	   	  
Geltrex	  (Life	  Technologies;	  A1413302)	  
HBSS	  (Invitrogen;	  14170146)	  
Versene	  (Lonza;	  BE17-­‐711E)	  
E8	  Medium	  (Life	  Technologies;	  A1517001)	  
ROCKi	  (Sigma;	  Y0503)	  
Accutase	  (Invitrogen;	  a1110501)	  
N2	  Supplement	  (Life	  Technologies;	  17502-­‐048)	  
DMEM	  (Sigma;	  D6421)	  
B27	  Supplement	  (Life	  Technologies;	  17504-­‐044)	  
Neurobasal	  Medium	  (Life	  Technologies;	  21103-­‐049)	  
Glutamax	  (Life	  Technologies;	  35050-­‐038)	  
SB431542	  (Cambridge	  Bioscience;	  ZRD-­‐SB-­‐50)	  
Dorsomorphin	  (Sigma;	  P5499)	  
Laminin	  (Sigma;	  L2020)	  
DAPT	  (Abcam;	  ab120633)	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2.4 Plating and Quality check for Neurons: 
 
Plates were coated with poly-D-lysine (0.2mg/ml) in borate buffer (Thermo 
Scientific Pierce) and incubated (37°C; 5% CO2; 5% O2) overnight. The plates 
were rinsed with PBS and Laminin (Laminin from Engelbreth-Holm-Swarm 
murine sarcoma basement membrane Sigma L2020) was added at a 
concentration of 20µg/mL diluted in DMEM for plastic dishes (NunclonTM tissue 
culture) and 30µg/mL diluted in DMEM for glass dishes (Greiner Bio One) and 
incubated (37°C; 5% CO2; 5% O2) overnight.  Glass dishes were used for 
imaging studies while plastic dishes were used for protein studies.  
 
Day 20 neurons were removed from the culture dish using Accutase as 
described previously and the cells resuspended in B27 medium supplemented 
with 10µM ROCKi and 10 µM DAPT. ROCKi inhibitor helps single cell survival 
and DAPT anti Notch signal molecule, which induces the neural progenitors to 
differentiate into neurons. The cells were counted using a haemocytometer and 
at a density of 1500-2000 cells/well of a 96 well plate.   Following 24 hours of 
incubation, the medium was replaced with Neurobasal media (Life Technologies) 
and was supplemented with B27. B-27 was used because it is required for 
neuronal growth.  Medium was then replaced twice a week but after the first 
week, only half the medium was replaced in each well. On day 25, quality control 
was carried out on each neuronal culture and if 90% of cells were not positive for 
the Neuronal specific marker B-iii tubulin (Tuj1) the culture was discarded.  
 
2.5 Cryopreservation and Thawing of neural progenitors 
 
In order to generate independent iPSC samples to replicate experiments, neural 
progenitors were generated as described above and then cryopreserved at day 
19.  Three independent iPSC samples were generated for each line. 
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Neural progenitors that were supposed to be cryopreserved were collected using 
Accutase, as described above then following two washes in HBSS the cells were 
resuspended in freezing medium (10% DMSO in B27/N2) and transferred to pre-
labeled 1mL cryovials.  The cryovials were transferred into Mr. FrostyTM Freezing 
Container (Thermos Scientific) and kept in -80°C freezer for 24 hours before 
being stored in liquid nitrogen until required. 
 
The cryovials were thawed in a 37°C water bath. The vial contents was then 
transferred into a centrifuge tube (15 ml) and 5mL of 37°C B27/N2 medium + 
10µM ROCKi added in a dropwise fashion. This cell suspension was then 
centrifuged at 900 RPM for 5 minutes, the pellet was resuspended in B27 and 
10µM ROCKi (1 ml) and the cells were counted. Cells were plated on poly-d-
lysine and laminin coated 96 well plates at a concentration of 2000 to 3000 cells 
per well of 96 well plate. Following 24 hours of incubation, the medium in each 
well was replaced with 100µL of Neurobasal media with B-27 plus 10 µM DAPT 
and 10µM ROCKi. To maintain these cultures the medium was replaced twice a 
week but after the first week, DAPT was removed from the medium and only half 
media changes were carried out. On day 25, we analyzed the cultures to 
determine the percentage of neurons present, as described above.  
 
ROCKi is added on the day of passage and thawing. In the first 24 hours after 
passaging the cells are in single cell state, ROCKi helps this survival. After 24, 
we remove ROCKi from the medium as the cells need to clump and form a 
monolayer for neural induction to occur. Moreover, DAPT an anti notch signaling 
molecule is added for neuronal differentiation from neural progenitor. Only two 
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2.6 Immunocytochemistry for Confocal Microscopy 
 
In order to study the neuron morphology of control and SHANK3 neurons, GFP 
transfected neurons were analyzed at day 30 and 45 of neuralisation via confocal 
microscopy. Also to count the number of pre and post synaptic puncta, I used 
Immunocytochemistry and confocal imaging. This was done at day 70 of 
neuralisation. 
 
For immunofluorescence analysis, cultures were grown on 24 well glass bottom 
culture plates (Greiner Bio One) that were fixed with 100% methanol at -20°C for 
5 minutes on ice, and permeabilised with 0.1 % triton X 100 (Sigma) for 10 
minutes.  This was followed with three washes of phosphate buffered saline 
(PBS). Cultures were then incubated with the appropriate primary antibody 
(Table 2.4) diluted in normal donkey serum (NDS) at 4°C for 12 hours. Wherever 
the antibody classes permitted, cultures were incubated with various primary 
antibodies simultaneously.  The culture plate was then washed three times with 
PBS and incubated for 1 hour at room temperature with the appropriate 
secondary antibody (Table 2.5).  DAPI (4’-6 Diamindino-2-phenylindole) or 
Hoescht 2000 was added at a dilution of 1:2000 to stain the nucleus.  In all 
experiments, to ensure that the observed staining was specific, controls were 
included in which primary antibodies were omitted or incorrect secondary 
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Table 2.4: Antibody list 
 
Table 2.5: Secondary antibody list 
 
 
2.7 Immunocytochemistry for High Content Imaging 
 
To measure the morphology of the neurons for the whole cell population, I used 
high content imaging. Cryopreserved neural progenitors from day 19 of 
neuralisation were thawed for this analysis. Differentiated neurons were grown 
on 96 well NunclonTM tissue culture plates coated with PDL and laminin.  Then 
they were fixed with 4% para formaldehyde PFA for 20 minutes at room 
temperature, and permeabilised with 0.1 % triton X 100 (Sigma) for 10 minutes.  
This was followed with three washes of phosphate buffered saline (PBS). The 
cultures were incubated with the appropriate primary antibody (Table 2.4) in 
normal donkey serum (NDS) at 4°C for 12 hours.  Wherever the antibody classes 
permitted, cultures were incubated with various primary antibodies 
Antibody	  Used	   Species/	  Dilution	   Company	  
Tuj1	  (Neuronal	  specific	  Biii	  
tubulin)	  
Mouse/1	  in	  1000	   Covance	  
DCX	  (Double	  cortin)	   Rabbit/	  1in	  500	   AbCam	  
CRH	   Sheep/	  1	  in	  100	   Novus	  Biologicals	  
GnRh1	  	   Rabbit/	  1	  in	  500	   Atlas	  
TH	   Rabbit/1	  in	  1000	   AbCam	  
Phalloidin	  	   Cytopainter	  KIT	   AbCam	  
G	  actin	  staining	  (Bovine	  
pancreatic	  deoxyribonuclease	  
DnaseI)	  
-­‐	   Life	  Tech	  
Shank3	   Rabbit/	  1	  in	  100	   Atlas	  
Myc	   Mouse/	  1	  in	  5000	   Cell	  signaling	  	  
	  
Anti	  GFP	   Rabbit/	  1	  in	  500	   AbCam	   	  
Synaptophysin	  	   Mouse/	  1	  in	  300	   AbCam	  
Homer	   Rabbit	  /	  1	  in	  300	   Synaptic	  systems	  
Puromycin	   Mouse	  1/1000	   Kerafast	  
Secondary	  Antibodies	   Species/Dilution	   	  Company	  
Alexa	  488	   Mouse/	  1	  in	  500	   Invitrogen	  	  
Alex	  594	   Rabbit/	  1	  in	  500	   Invitrogen	  
Alexa	  594	   Mouse/	  1	  in	  500	   Invitrogen	  
Alex	  680	   Mouse/	  1	  in	  500	   Invitrogen	  
Oydessey	  800	   Rat/1	  in	  5000	   Oydessey	  
Alexa	  594	  	   Sheep/	  1	  in	  500	   Invitrogen	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simultaneously.  The plate was then washed three times with PBS and incubated 
for 1 hour at room temperature with the appropriate secondary antibody (Table 
2.5).  DAPI (4’-6 Diamindino-2-phenylindole) or Hoescht 2000 was added at 
dilution of 1:2000 to stain the nucleus.  In all experiments, to ensure that the 
observed staining was specific, controls were included in which primary 
antibodies were omitted or incorrect secondary antibodies were used.  
 
2.8 Actin staining 
 
To compare the cytoskeletal organization of control and SHANK3 patient 
neurons, the expression of F actin and G actin were investigated.  Ten days after 
terminal plating onto PDL coated laminin 96 well dish, cells were fixed using 4% 
paraformaldehyde (PFA) for 20 minutes at room temperature, and then 
permeabilised with 0.1% triton X 100 (Sigma) for 10 minutes. This was followed 
with three washes of phosphate buffered saline (PBS).   Phalloidin was used to 
visualize F actin filaments (Phalloidin CytoPainter F actin staining kit abcam 
1121125) and Bovine pancreatic deoxyribonuclease (DNase1, 31,000 daltons life 
technologies) was used to visualize G actin.  Both reagents were added for 30 
minutes and then removed to add Hoechst 2000 to stain the nucleus. The 
fluorescence intensity was measured using high content imaging. The measured 
fluorescence intensity was normalized to total the number of nucleus present in 
the well, as determined by nuclear Hoechst staining. The following cell lines were 
compared: In this assay, I used three control lines and two shank3 lines, these 
were the following: Control P3, Control P2 C2, Control P1 C2 were compared to 
SHANK3 P1 C2 and SHANK3 P2 C1. The experiment was repeated three times 
(each independent experiment started from the iPSC stage). In total I compared 
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2.9 Neuronal morphological assessment via GFP transfections 
 
The morphological properties of control and SHANK3 neurons were compared by 
analyzing the number of primary, secondary and tertiary neurites, the primary 
neurite length and cell soma diameter. Here, the term neurite is used as a 
collective term for dendrites and axons that are formed by the cultured neurons.  
 
To visualize neuronal morphology, iPSC derived neurons were transfected with 
an eGFP plasmid at two stages of neuralisation (Figure 2.1) at day 30 (immature 
neurons) and at day 45 (young neurons). To do this, Lipofectimine 2000 (life 
technologies) was mixed with the eGFP plasmid (2 µg) (Figure 2.2) and added to 
cells for 4 hours.  After 4 hours, the media was changed and the neurons were 
assayed 48 hours later.  
 
 
Figure 2.2: eGFP plasmid vector with a PGK (Phosphoglycerate kinase) mouse promoter. 
 
Images were taken of eGFP expressing cells using the 10x objective on a 
Confocal Laser Scanning Microscope Leica TCS SP8 coupled with LAS AF lite 
software. The 488 nm laser was used along with the appropriate excitation and 
emission filters. Acquired images were converted into 8 bit tiff files and analyzed 
with Neuron J software version 7.3.  Quantitative analysis was performed on 
images blinded for genotype from two control lines with one clonal replicate and 
two shank3 lines with one clonal replicate. The following cell lines were 
compared: Control P1 C1, Control P1 C2, and Control P2 C2 to SHANK3 P1 C2, 
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SHANK3 P1 C1 and SHANK3 P2 C2. The experiment was repeated three times 
(each independent experiment started from the iPSC stage). Total number of 
control cells that were examined was 4997, out of which 120 were positive for 
GFP. Therefore, transfection efficiency in the control neurons was 2.4%. Total 
number of SHANK3 cells that were examined was 5200, out of which 122 were 




2.10 Global Morphological analysis of control and SHANK3 neurons (High 
content screening) 
 
In order to measure the morphology of the whole neuronal population, high 
content screening was carried out using the Cellomics Cell Insight (Thermo 
scientific), using a program Cell Scan to analyze the cell soma area and mean 
number of neurite per neuron.  In this assay, 5 control lines from three control 
patients were compared to 4 SHANK3 lines from two SHANK3 patients. These 
were as follows: Control P1 C1, Control P1 C2, Control P2 C1, Control P2 C2 
and Control P3 were compared to SHANK3 P1 C1, SHANK3 P1 C2, SHANK3 P2 
C2 and SHANK3 P2 C3. The experiment was repeated three times (each 
independent experiment started from the iPSC stage). The total numbers of 
neurons examined for the control were 26,000 and for SHANK3 were 30,000. 
 
The scans were performed in 96 well plate format (day 22, 25, 27 and 30 of 
neuralisation).  Neurons were stained with DAP/Hoechst to stain for nuclei, this 
was then used by the cell insight to autofocus itself on the nuclei. To visualize the 
morphology of the neuron, neurons were stained with DCX (double cortin 
immature neuronal marker) and/or neuronal specific βiii tubulin (Table 2.4, and 
section 2.7).  After scanning a minimum of 10 wells of a 96 well plate (1 field per 
well), the fluorescence exposure was fixed. A mini scan was then run to take raw 
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pictures (using a 10x objective), which formed the basis of programming the 
machine to analyze the cell soma area and neurite morphology.   
 
In the following paragraph, I describe the programming protocol for the cell 
insight. Initially, the cell insight identified the nucleus. The first step is to 
smoothen the images that were taken during the mini scan. The smoothening 
reduces the sharpness of the intensity variations by redistributing their relative 
brightness over the immediate vicinity of the image.  This reduces variation noise 
from the image. The image is of neuronal nuclei stained with DAPI/Hoescht. The 
second step was to set the thresholding to Isodata. Isodata is a dynamic method 
that utilizes a threshold calculated from the histogram of pixel intensities taken 
from individual points in the image. This method worked best when there was a 
clear distinction between the background and the object.  Segmentation was 
applied to the image in order to identify individual objects. We used the intensity 
method that uses pixel intensity to separate objects. Successful segmentation 
required dominant intensity peaks for each object.  
 
Once the nuclei were identified, the next step was to detect the cell bodies using 
DCX or tuj1 staining.  Smoothing was applied to all images that were acquired 
during the mini scan after autofocus. Thresholding was set to “Fixed” so that the 
same threshold value was applied to each object in the image. The minimum cell 
body nucleus overlap was used to associate valid nuclei with cell bodies. This 
value was set to 100%, which meant that the entire nucleus must be within the 
cell body in order for it to be considered for analysis. We used the “Nuclei as 
seeds” method for segmentation between cells. This helped with segmentation 
between clusters of cells, as only cell bodies with one nucleus was considered. 
Next, “Cell Body demarcation” was selected. This process helped set up the 
boundaries that distinguish the cell soma from the neurites. The cell soma area 
was then validated using cell body nucleus count and cell soma area. The cell 
body nucleus count should give us a 1:1 ratio. For example, if there were 100 
cells in the selected field, the number of nuclei should also be 100. The cell soma 
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area was set at any value between 50-600 um2. The reason behind this is 
explained in section 2.11 below.  Once the cell bodies were validated, the plates 
were scanned to measure the cell soma area only. The settings remained 
identical for all experiments.  
 
Neurites were identified using the “Neurite identification modifier”. The neurite 
identification modifier shifts the fluorescence threshold lower than that used for 
analyzing the cell bodies, as they are dimmer in nature.  The next parameter 
selected was the “Neurite direction assay” parameter. In this, pixel number is 
used to find the direction of each segment. The last parameter used is the 
“Trace” within the cell body. This parameter assigns ownership of neurites to 
particular cell bodies. After the parameters were assigned, the plates were 
scanned for primary number of neurites, with the settings remaining identical for 
all experiments.  
 
Figure 2.3 A(I-iii). shows an example of a tracing done by the cell insight, 
including both the cell soma and neurites.  Please note that this is a 
representative picture taken from the machine while reprogramming. The cell 
insight is not capable of taking high-resolution images and does not provide any 
scale to the pictures.  
 
In all analyses, at least 12 fields were scanned for each well of a 96 well plate 
and the well was rejected if there were more than 3 sparse fields in a well.   
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Figure 2.3: Cellomics scan: A. DAPI stained control neurons nuclei at day 30.  (ii) and neurons 
(DCX). (iii) Tracing of the above two pictures where blue shows the cell soma outline, green 
shows the outline of nuclei and pink are the neurites. B. Control neurons after tracing. C. 
SHANK3 neurons after tracing. Please note that the picture depicted here is a representation of 
the machine while reprogramming. The cell insight is not capable of taking high-resolution images 





2.11 Manual counting and Error Rate  
 
 
To identify and remove any false readings generated by the Cell Insight, three 
random SHANK3 and control wells were selected and counted manually (blind to 
genotype). A histogram was generated from the manual count depicting the 
distribution of the cell soma area for both control and SHANK3 at day 30 of 
neuralisation (Figure 2.4 B). The average error rate percentage is shown in Table 
2.6. I manually counted the false positive neurons from the images taken by the 
cell insight for each cell soma area bin and divided it by the number of neurons in 
that well. 
 
As you can see, there was a 100% false error rate for any cell soma area above 
650 um2. This was due to the cell insight sometimes including an adjoining 
neurite in the cell soma measurement (Figure 2.4 A.). Therefore, in our analysis 
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we excluded all values above 600 um2. We also included this cell insight 
programming to measure cell soma area. During the programming of the cell 
insight, there is an option to set up reference values. For example, I can set up 
reference values for the cell soma area to be measured. I selected this as 50-600 
um2, so that the machine only selects for cell soma area between these values.   
The other error rate percentages (Table 2.6) were used to correct the data 
generated by the Cell Insight (presented in results chapter 3.2). Overall however, 
the manual counts confirmed the results obtained from the Cell Insight (compare 
Figure 2.4B with Figure 3.2.2).  
 
 
Figure 2.4: False reading done by the cell insight. A. DAPI stained nuclei from control neurons 
day 30. (ii) DCX positive neurons, the yellow arrow depicting the cell that has been false read. (iii) 
Yellow arrow showing the tracing of the false read neuron; it included the area next to cell soma. 
These type of cells were excluded from the data. B. Histogram showing the manual-count for 
different cell soma area bins. Please note that the picture depicted here (in A) is a representation 
of the machine while reprogramming. The cell insight is not capable of taking high-resolution 
images and does not provide any scale to the pictures.  
 
 





















2.12 Neurite Outgrowth 
 
In order to compare neurite outgrowth, time-lapse videos were taken of SHANK3 
and control neurons. These neurons were grown on glass bottom PDL laminin 
coated ibidi dishes, until they reach day 29 of neuralisation, they were then 
imaged every hour for 48 hours using a Nikon Biostation IM-Q.  Each image was 
converted into a 16bit tiff and analyzed using the neurite outgrowth application of 
metamorph offline software. In this assay, I compared 4 control lines from two 
control patients to 4 SHANK3 patient lines from two SHANK3 patients. These 
were as follows: Control P1 C1, Control P1 C2, Control P2 C1, Control P2 C2 
were compared to SHANK3 P1 C1, SHANK3 P1 C2, SHANK3 P2 C1 and 
SHANK3 P2 C2. The experiment was repeated three times (each independent 
experiment started from the iPSC stage). In this assay, in total, I compared 51 
control neurons to 59 SHANK3 neurons.  
 
Images were taken every hour from the Nikon Biostation and were individually 
evaluated. Also, each neuron in each image was tracked through the 12-hour 
period. The tracking was performed for only 12 hours due to time constraints.  
The following parameters were then measured: 
• Cell processes - total number of primary number of neurites. 
CELL	  SOMA	  AREA	  
bins	  (um2)	  
Average	  error	  rate	  %	  
100-­‐200	   2.211244982	  
200-­‐300	   1.764033915	  
300-­‐400	   2.744800639	  
400-­‐500	   4.542722668	  
500-­‐600	   3.006815262	  
600-­‐650	   0.333333333	  
>650	   	  100	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• Mean process length - the average length of neurites.  
• Cell branches - total number of secondary branches. 
• Cell body area - the area of the cell soma  
• Cell body position - the x and y coordinates of the centroid/centre of the 
cell body.  
 
These parameters were then used to calculate different aspects of neurite 
outgrowth: 
 
• Rate of primary neurite formation - we considered one neuron at a time. 
If there were 8 “Cell processes” at hour 1 and 9 at hour 2, there was a 
formation of 1 neurite. These were then averaged across 12 hours to 
gives us the rate of primary neurite formation (neurite/hour) for that 
neuron.  
• Rate of primary neurite elimination - We considered one neuron at a 
time. If there were 10 “Cell processes” at hour 1 and 8 at hour 2, there 
was an elimination of 2 neurites. These were then averaged across 12 
hours to gives us the rate of primary neurite elimination (neurite/ hour) for 
that neuron. 
• Extension rate - the neurite length extension was calculated using the 
“Mean process length” parameter. If at hour 1 the mean process length 
was 20µm and at hour 2 the mean process length was 30µm, then the 
extension was 10µm. These were then averaged across 11 hours to give 
us the extension rate (µm/hr). 
• Retraction rate - the neurite length retraction was also calculated using 
the “Mean process length” parameter. If at hour 1 the mean process 
length was 10µm and at hour 2 the mean process length was 5µm, then 
the retraction was 5µm. These were then averaged across 11 hours to 
give us the retraction rate (µm/hr). 
• Cell soma speed - we used “Cell body position x and y coordinates” to 
calculate the distance of the cell body from one point to another. This was 
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done using the Pythagoras theorem [distance =√ (x2-x1) 2+(y2-y1) 2]. Once 
we calculated the distance for each hour, it was added then divided by 12 
hours to estimate the speed per hour (µm/hr). 
• Change in cell soma area- the cell soma area was recorded for each 
hour. This was then averaged across 12 hours to calculate the change in 
the cell soma area (µm2/hr). 
• Rate of formation and elimination secondary branches - we calculated 
this in the same way as we did the rate of primary neurite formation and 
elimination. However, instead of using the cell processes we used “Cell 
branches” parameter as it counts secondary branches.  
 
 
2.13 Puromycin Assay 
 
I measured and compared the global protein translation of control and SHANK3 
neurons at day 30. We used the Puromycin/ SUnSET assay to quantify this. 
The neuronal culture was maintained for 30 days and 5mM of puromycin was 
added for 20 minutes to stop any translational activity. Puromycin is a structural 
analogue of aminoacyl tRNAs, it is incorporated into nascent polypeptide chains 
preventing their elongation (Nathan D 1969). The cells were then lysed and 
protein extracted for western blotting analysis using the puromycin antibody. I 
compared three controls and two SHANK3 lines. This experiment has been 
repeated three times. These were as follows: Control P1 C1, Control P2 C2 and 
Control P3 were compared to SHANK3 P1 C1 and SHANK3 P2 C3. After sample 
preparation, the vials were blinded analyzed separately.  
 
2.14 Preparation of Cell Lysates 
 
To prepare cell lysates, cultures was washed twice with ice cold PBS (have you 
already defined this somewhere) then with 100µl of ice cold lysis buffer (50 mM 
Tris-HCL, pH7.5, 150nM Nacl, 1mM EDTA, 1% Triton X-100, protease inhibitor 
cocktail set III (Sigma,:1000) was added and the cells were scrapped into the 
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buffer. This lysate was then incubated on ice for 10 minutes and spun at 14000 
rpm for 5 minutes.  Before storage at -80°C, Laemmli buffer (Sigma) was added 
to the sample. SDS detergent in the Laemill buffer denatures the proteins and 
subunits to give an overall negative charge so that each can be separated by 
size. The bromophenol blue dye makes it easier to load samples.  
 
When required for western blot the samples were thawed and boiled for 5 
minutes at 95°C, then spun briefly at 14000rpm. To allow equal loading of the 
samples, a BCA protein assay kit (Thermo Scientific) was used, as instructed by 
the manufacturer, to quantify the amount of protein in each sample, which was 
15µg per lane. 
 
2.15 Electrophoresis and Dry transfer of proteins 
 
Lysates, prepared as described above were run (15µg protein/lane) on pre-made 
NuPAGE Bis-Tris gel (Life technologies) for 30 minutes at 80V. The iBlot2 (Life 
technologies) was used for the protein transfer to the nitro-cellulose membrane.   
The membrane was blocked (Odyssey bloking buffer LI-COR biosciences) for an 
hour on the orbital shaker and primary antibodies were added (Table 2.4). This 
was left overnight in the cold room at 4°C.  The next day, the membrane was 
washed three times with 0.5% Tween and the secondary antibody (Table 2.5) 
was added in the blocking buffer and left for an hour. The membrane was then 
washed three times with 0.5% Tween and once with PBS. The membrane was 
imaged using the Odyssey and the resolution was set at 50µm. The channels 
used were 700nm and 800nm and the intensity was set at 3.0.  
 
2.16 Analysis of the western blot 
 
The images taken from the Odyssey were converted into 8 bit tiffs and analyzed 
using Image J software. The boxes were drawn on the band of interest and 
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fluorescence intensity peaks were reported. These were then normalized to 
fluorescent values of Alpha actin present in each sample.  
 
2.17 Synaptic Assays 
	  
For comparing the pre and post synaptic puncta staining cultures of SHANK3 
and control neurons were maintained for 65-70 days (see Figure 2.1) and then 
fixed and stained with the pre-synaptic marker Synaptophysin and post-synaptic 
marker Homer (table 2.4). In this assay, I used three control lines and two  lines, 
these were the following: Control P3, Control P2 C2, Control P1 C2 were 
compared to  P1 C2 and  P2 C1. The experiment was repeated three times (each 
independent experiment started from the iPSC stage). In this assay, in total, I 
compared 46 control neurons to 42  neurons. 
 
Images were taken from the 63x objective on a Leica TCS SP8 Confocal Laser 
Scanning Microscope coupled with LAS AF lite software. I used 386, 488 and 
594 nm lasers, along with the appropriate excitation and emission filters. These 
settings were kept consistent while taking images from all cultures. Acquired 
images were converted into 8 bit tiff files and analyzed with Image J software 
version 7.3. Using Image J, I opened the files and selected at least two portions 
of neurites, length not exceeding 50µm. This region was added to ROI (region of 
interest) manager. Following this, I thresholded the images such that the synaptic 
puncta would turn black and the background would turn white. The thresholded 
images were then analyzed through “Analyze Particles”. The thresholding was 
done because the “Analyze Particles” software does not recognize images that 
are not thresholded. The size limit at this point was set up to 0.03-3 µm2. This 
meant that only punctas with a size of 0.03 to 3 µm2 would be measured.  The 
summary from “Analyze particles” gave the total number of punctas observed in 
the region of interest. I repeated these steps until the whole neuron was 
captured. The data obtained was analyzed as the number of punctas/50µm. 
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Presynaptic and postsynaptic punctas were counted separately for control and  
neurons. Images were taken and blinded for analysis.   
 
 
2.19 Shank3 overexpression vector generation 
 
I wanted to overexpress human SHANK3 gene in SHANK3 patient lines to 
rescue the morphogenetic phenotype discovered in the earlier assays.  For this 
experiment I wanted to transduce neurons with a viral vector. Therefore, the full-
length human SHANK3 gene ORF (artificially synthesized by Genewiz) was 
cloned into pCDH-EF1-MCS (CD502-1A System Biosciences). The vector map 
for SHANK3 is shown in Figure 2.5. SHANK3 N terminal was fused with Myc tag; 
this was used to identify which of the neurons were positively transduced for 
SHANK3.  The Myc tag was used for two reasons, first it is 10 amino acid base 
tag, which is very small as the human SHANK3 ORF is 5.3 kb, which is 
stretching the limit of lentiviral capacity. Second, is that the rat Shank3 ORF has 
been previously cloned with N terminal Myc tag and does not disrupt the function 
of the gene (Nasbitt et al., 1999). Therefore, I picked the Myc tag to tag the 
SHANK3 gene at the N terminal. Two other clones were generated, SHANK3 
gene without exon18 and Myc tag only vector without the SHANK3 gene (Figure 
2.5 b,c).  
Exon 18 in the SHANK3 gene is 24 bp long. SHANK3 without exon 18 was 
generated because previous work in our laboratory indicated that the expression 
of SHANK3 with exon18 increased during the transition from neural progenitors 
to neurons (data shown in Introduction, Section 1.12).  These data also indicated 
that the SHANK3 patient lines had a reduced expression of this exon.  Since this 
expression of exon 18-containing isoforms immediately preceded the 
appearance of the morphogenetic phenotypes, we hypothesized that the failure 
to express exon 18 might be associated with these phenotypes.  If this 
hypothesis is correct then a full length SHANK3 without exon18 might fail to 
rescue the phenotype, where a construct including exon 18 would succeed. 
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Figure 2.5: The SHANK3 rescue vectors. A. Full length human SHANK3 ORF with N terminal 
Myc tag cloned into lentiviral backbone. B. Human SHANK3 without exon 18 with N terminal Myc 




	   77	  
2.20 SHANK3 lentiviral particle generation 
 
The cloned vectors of SHANK3 were transformed in lentivirus, to rescue the 
morphogenetic phenotype seen in SHANK3 patient neurons.  
Lentiviruses were generated with a three-plasmid transfection system using 
Lipofectamine LTX (Life Technologies) in HEK293FT cells as previously 
described (Kutner R et al., 2009).  Twelve hours after transfection supernatants 
were collected. Viral particles were concentrated using Lenti-X concentrator 
(Clontech) according to manufacturer’s instructions, then aliquoted (100µl), 
stored at -80°C until required. I made three viruses, first one with the full 
SHANK3 ORF (SHANK3 Plus 18), second SHANK3 without exon 18 (SHANK3 
minus 18) and third was Myc tag only without SHANK3 gene (Myc Only). The 
first virus was used to see if I could rescue the morphological phenotypes in the 
SHANK3 patient neurons. The second virus was used to test the hypothesis that 
the specific failure to express exon 18 might be associated with morphogenetic 
phenotype (Introduction section 1.12). The third virus is supposed to act as 
negative control, such that the effect of rescue in SHANK3 patient neurons would 
be due to SHANK3 and not due to the myc tag.  
 
To titer the concentration of virus to be used, I transduced a SHANK3 female 
patient line neurons (SHANK3 P2 C1) with different amounts of virus. These 
were 2, 5, 10, 20, 30 and 50µl. Approximately 80% of the cells in one well of 96 
well dish were stained positive for Myc upon addition of 5µl of virus (Table 4.0).  
 
To rescue the morphogenetic phenotypes seen in the SHANK3 cells, I 
transduced SHANK3 patient neurons (day 20/21) which were analyzed at day 30. 
At day 30 because, this is the day I see the morphogenetic phenotype 
differences between the control and SHANK3 lines.  I used high content 
screening, to see whether the overexpression of SHANK3 in SHANK3 patient 
neurons had rescued the morphological phenotype. To label neuronal cell bodies 
and processes, I stained for DCX and Myc (to identify for positively transduced 
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neurons) using the protocol described in section 2.7. The cell Insight was 
programmed to select the cells that were only positive for Myc, ensuring that it 
only selected transduced neurons. The timeline for this experiment is shown in 
Figure 2.6. We measured cell soma area and primary number of neurites per 
neuron with SHANK3 rescue (plus 18), with SHANK3 rescue (minus exon 18), 
only myc and no rescue (blank). The rescue was performed in two SHANK3 
patient lines namely SHANK3 P2 C1 and SHANK3 P1 C1.  I repeated this 
experiment three times and the total number of neurons compared from all three 
experiments were as follows: SHANK3 P2 C1 before n=1.5X103, SHANK3 P2 C1 
with rescue n=1.5X103, SHANK3 P2 C1 with rescue - exon18, SHANK3 P1 C2 
before n=1.45 X103, SHANK3 P1 C2 with rescue n=1.98 X103, SHANK3 P1 C2 
with rescue-18.	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2.21 Verification of SHANK3 overexpression constructs 
 
I used immunocytochemistry to verify that the SHANK3 overexpression virus  
(plus 18) was actually expressing SHANK3 and not something else. SHANK3 P2 
C1 neurons were fixed and stained with SHANK3 and Myc antibodies (Table 
2.4). The Myc staining overlapped with SHANK3 antibody staining [Figure 2.7 
A(I) –(iv)]. The Myc is tagged to N terminal of SHANK3 and overlapping with the 
SHANK3 antibody means it is specific for SHANK3 protein and nothing else. I 
performed a control experiment for this. I repeated the above experiment with 
only Myc virus transduced neurons (NO SHANK3). In this case, there was no 
overlap seen between the SHANK3 antibody and Myc antibody [Figure 2.7 C(I) –
(iv)].  This is exactly what we would expect. Since, the Myc only virus has no 
SHANK3 gene in it, it is expected not to overlap with SHANK3 antibody. This 



































Figure 2.7: Verification of SHANK3 overexpression virus via immunocytochemistry (Day 30 
neurons). A(I) SHANK3 P2 C1 neuron transduced with Human SHANK3 ORF plus exon 18 virus 
stained with (ii) DAPI, (iii)SHANK3 and (iv) SHANK3(plus exon18) MYC. The arrow indicates the 
overlapping of SHANK3 antibody with Myc antibody. B(I) SHANK3 P2 C1 neuron transduced with 
Human SHANK3 minus exon 18 virus stained with (ii) DAPI, (iii)SHANK3 and (iv) SHANK3(minus 
exon18) MYC. The arrow indicates the overlapping of SHANK3 antibody with Myc antibody. C(I) 
SHANK3 P2 C1 neuron transduced with only Myc virus stained with (ii) DAPI, (iii)SHANK3 and 
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2.22 Rescue cells via IGF1 and BDNF 
 
To determine whether IGF1 or BDNF could rescue the morphological phenotypes 
of SHANK3 patient neurons seen at day 30 of neuralisation (Chapter 3; Figure 
3.2.2). I performed this experiment in two SHANK3 patient lines with one clonal 
replicate of each and compared it to two control lines with one clone replicate of 
each. These were as follows: Control P1 C1, Control P1 C2, Control P2 C1 and 
Control P2 C2 were compared to SHANK3 P1 C1, SHANK3 P1 C2, SHANK3 P2 
C2 and SHANK3 P2 C3. 
 
iPSC derived neurons were grown on a 96 well plate in and IGF1 (20ng/ml) 
administered from day 23 of neuralisation to day 30 and BDNF (50ng/ml)  from 
day 26 to day 30. The neurons were then fixed at day 30 and stained using the 
protocol described in section 2.7 – with DCX, Tuj1 and DAPI. Cell soma area and 
primary number of neurites per neuron were measured as described in section 
2.10. All parameters were normalized to the cells grown without treatment. 
 
 
2.23 ES culture 
 
To further confirm that SHANK3 was the cause of the morphological phenotypes 
seen in SHANK3 patient neurons, I compared the morphology of neurons 
generated from a control male human es cell line with es cell lines where both 
copies of the SHANK3 genes had been knocked out (es shank3-/-) and where 
only one copy had been knocked out (es shank3 +/-) (Tables 2.7, 4.2). These 
lines were provided by our collaborator, Dr Ravi Jagasia at Roche (F.Hoffmann-
La Roche Ltd CNS Discovery Grenzacherstrasse CH-4070 Basel/Switzerland). 
The cell lines used are described in the table 2.7. 
 
 
	   82	  
Vials were thawed from liquid nitrogen at 37°C and revived onto wells coated 
with Geltrex (Life Technologies). Cells were grown in Dilbecco’s Modified Eagle’s 
Media F-12 (DMEM: F: 12; Sigma Aldrich) in a binder CB150 incubator at 37°C, 
5% O2, 5% CO2 and saturated humidity. For maintenance, cells were kept at 
50%-80% confluence, which typically requires passage every week. 
 
For passaging, media was removed by aspiration and cells were washed with 
pre-warmed Hank’s Balanced Salt Solution HBSS without Ca2+ and Mg2+ (HBSS; 
Life technologies). The HBSS was removed by aspiration and replaced with room 
temperature Versene (Life Technologies), which was left on for 4 minutes at 
37°C. The Versene was then aspirated off the cells detached from the plate with 
pre-warmed media and transferred into pre-coated a Geltrex coated 6 well tissue 
culture dish at a 1:6 dilution (1 well of cells into 6 wells). Growth media was then 
changed every 24 hours. See Table 2.2 for the volumes of reagents used. 
 
I differentiated these cells into hypothalamic neurons in order to study the 
morphogenetic phenotype. The same protocol was used for IPSCs (see Section 
2.2). To measure the changes in morphology of es derived neurons, we used 
high content screening on neurons at day 30 of neuralisation to analyse the cell 
soma area and primary number of neurites per neuron (see Sections 2.7 and 
2.10).  
 
Human ES cell Lines  Patient Details  
es shank3 +/+ Control male es cell line no deletion 
es shank3 -/+ es cell line heterozygous deletion of 
SHANK3 
es shank3-/- es cell line with homozygous deletion 
of SHANK3 
Table 2.7: ES cell lines 
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2.24 Data analysis and statistics 
 
All experiments were replicated at least three times using the iPS cell lines 
mentioned above. The sample size and description of the samples are reported 
in figure legends. In all cases, only the cultures that were 90% positive for Tuj1 
expression were used. For manual analysis of the images, they were blinded and 
treated. 
 
The statistical analysis used to compare the assays is reported in each figure 
legend. The normal distribution of data was checked using the Kolmogorov-
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Results 




One of the greatest obstacles in our understanding of the etiology of 
neurodevelopmental diseases is the inaccessibility of human neural cell types.  
Various rodent studies of ASD including those using Shank3 KO mice have 
successfully modeled autism-like phenotypes (Introduction section 1.6; Peca et 
al., 2012). These studies have provided some insights into the disease 
mechanisms. Nevertheless, they have not resulted in any clinical benefits for 
patients.  This could be due to the inherent genetic and anatomical variations 
between rodents and humans.  
 
Human cellular models can address these issues. One way of generating such a 
model is to reprogram somatic cells to generate induced pluripotent stem cells 
(iPSCs). iPSCs are adult cells that have been reprogrammed genetically to an 
embryonic stem cell like state. This reprogramming method was first described in 
2006 (Takahashi and Yamanaka 2006) when mouse adult fibroblasts were 
converted into the pluripotent state by the retroviral transduction of four 
transcription factors Oct3/4, Klf4, c-Myc and Sox2. Later, Takahashi et al (2007) 
generated iPSCs from human adult dermal fibroblasts. Currently, various 
protocols have been established to generate iPSCs from other adult somatic cell 
types. For example blood, urine, amniotic cells and keratinocytes, as used in this 
thesis (Methods section 2.1).   
 
In this project, the iPSCs used were generated using lenti viral reprogramming of 
keratinocytes with the Yamanaka factors (Oct4, Klf4, c-Myc and Sox2). These 
keratinocytes were derived from hair root biopsies from two autistic patients 
carrying a heterozygous deletion in the SHANK3 gene (Cocks et al., 2014). 
Similarly, three control lines were produced from healthy individuals (Methods 
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section 2.1). The lines generated were expanded and neuralised to generate 
hypothalamic neurons. The protocol is outlined in the Methods section 2.3. The 
neurons produced from this protocol were both doublecortin (DCX) and neuronal 
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The hypothalamus is a small brain structure located between the optic chiasm 
(OC) and anterior commissure (ac) and behind the organum vasculosum of the 
lamina terminalis (OVLT) (Swaab 2008).  Its main function is to link the nervous 
system to the endocrine system through the pituitary.  The hypothalamus 
releases a variety of neurohormones such as corticotropin-releasing hormone 
(CRH), gonadotropin releasing hormone (GnRH1), growth hormone-releasing 
hormone (GHRH), somatostatin (SST), thyrotropin-releasing hormone (TRH), 
oxytocin and vasopressin.  These hormones play important roles in social 
behavior, motivation, circadian rhythms, response to stress and anxiety 
(Introduction Section 1.11). 
 
There are very few biological studies that investigate the role of hypothalamus in 
autism.  Recently, an MRI study was performed on 52 ASD children with 52 
matched controls to compare the grey matter in different regions of the brain. 
Diminished grey matter was observed in the hypothalamus in ASD patients 
(Kurth et al., 2011), which is known to synthesize behaviorally relevant 
hormones.  For instance, one of the key symptoms of autism is impaired social 
interaction. CRH is known to be released from the hypothalamus, and is 
responsible for our body’s response to stress (Schulkin 2007). Elevated levels of 
CRH are associated with social withdrawal in primates (Erickson K et al., 2005).  
The current theory for autism patients is that they are thought to have higher 
levels of CRH (Schulkin 2007). Elevated levels of CRH and Neurotensin (NT) 
have been recently reported in serum of ASD children. Moreover, NT is a 
neuropeptide that has been implicated in the regulation of GnRH1 (Tsilioni et al., 
2014). GnRH1 is also synthesized by the hypothalamus. 
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Due to the potential links between hypothalamic function and symptoms found in 
individuals suffering with autism, we have generated an in-vitro model to study 
human hypothalamic neurons, with and without mutations that are known to 
cause ASD. This model will then be used to compare the morphological features 
of the neurons during development.  
 
We used ‘dual SMAD inhibition’ to direct iPSCs along a neuronal pathway.  
iPSCs were converted to neural progenitors following 8 days of growth in the 
smad inhibitor medium (Fig 3.1). By day 18, these cells formed the rosette 
structure (a radial arrangement of columnar cells that express many features of 
neuroepithelial cells that form the neural tube; Stice et al., 2008) and by day 30 
DCX positive immature neurons could be identified.   
 
In order to assess the types of neurons generated from this neuralisation 
protocol, Dr. Graham Cocks in our lab performed a microarray study with a 
control line at ten different stages of neuralisation from day 7 (early neural 
progenitors) to day 50 (synaptically active neurons).  Figure 3.1 E, shows the 
expression of hypothalamic hormones. Between day 25 and day 30, an increase 
in the expression of hormones such GnRH1, CRH (corticotropin-releasing 
hormone) and SST (somatosatin) was observed. A low expression of TBR1 (T-
box brain1), a protein specifically expressed during cortical development in layer 
VI of the human cortex. This suggested that the neuralisation protocol was not 
producing cortical neurons. 
 
As mentioned above, this assay was completed in one control line. I followed the 
same protocol for neuralising the rest of the lines.  In the first section of this 
chapter, (Section 3.1) I performed a confirmatory experiment to verify the 
neurons derived from the rest of the iPSC lines gave us a similar pattern of 
hypothalamic expression.  
 
 
	   88	  
 
 
Figure 3.1: Neuralisation A. The chart depicts the neuralisation protocol used and indicates the 
five stages of neuralisation. These are the iPSC (day 0), the neural progenitors (Day12), the 
rosette structure (Day 18), the immature neurons (day 30) and the mature neuronal stage (Day 
70). B. iPSC colony (Scale=50µm) C. Rosette structure (Scale=50µm) D. Neurons at day 26 
postive for tuj1 (Scale=50µm). E. Microarray RNA study on a control line (Control P2 C3) at ten 
different stages of neuralisation. It shows the expression of various hypothalamic hormones. 
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In the second section of this chapter, I describe the in-vitro experiments designed 
to characterize the development of SHANK3 patient hypothalamic neurons. 
Specifically, I compare the morphological changes of control and SHANK3 iPSC 
derived hypothalamic neurons.  
 
As we know, one of the main features during the development of a neuron is the 
ability to form neurites. The neurites then form into dendrites and axon, which 
forms the basis of receiving and integrating signals. Previous studies have shown 
that the deficits in dendritic morphology including retractions, formations and 
eliminations of dendrites contribute to the miscommunication between neurons, 
which is one of the major underlying causes of ASD. (Kulkarni VA et al., 2012; 
Da.Silva JS et al., 2002). Also, described in the introduction section 1.3, one of 
the hypotheses regarding the molecular mechanism behind autism is 
miscommunication between neurons due to abnormal cellular growth. 
 
Over the past decade, a number of studies have been associated with aberrant 
neuronal connectivity in psychiatric disorders such as ASD, schizophrenia and 
bipolar disorder.  Morphometric and MRI studies have observed an increase in 
white matter volume in 2 to 4 years old autistic children (Schumann.et al 2004; 
Courchesne et al., 2001) and the suggested cause for this is irregular neuronal 
growth. In addition, studies have reported changes in dendritic arborization in 
Rett’s syndrome, Fragile X syndrome and Timothy syndrome, all rare genetic 
forms of ASD (Brennand KJ et al., 2012). Dendrites represent the compartment 
of neurons that primarily collect and compute information. These structures are 
highly dynamic during development, a combination of intrinsic and extrinsic 
signals shape dendritic morphology (Gaia 2012). Thus, it is important to 
understand the impact of dendritic morphology during early development in ASD. 
 
Among the various genetic variants associated with risk for ASD, variations 
within the SHANK3 gene are known to be the most penetrant.  About 2% of 
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people who have autism and intellectual disability carry mutation in SHANK3 
(Leblond C.S et. al 2014; Bentancur.C et al., 2013; Boccuto L et al., 2013; 
Durand C.M et. al 2007).  SHANK3/Prosap2 is an integral scaffolding protein 
located in postsynaptic density (Sheng M et al., 2000; Nasbitt et al., 1999).  
Previous studies of SHANK3 have linked its role to regulating synaptic protein, 
synapse transmission and plasticity [Introduction section 1.5 (b); Jiang et al., 
2013; Shcheglovitov A et al., 2014].  
 
However, most these studies of SHANK3 focus on its role in the synapse, which 
occurs at later stages of development when the neuronal connections have been 
established. None of these studies focus on its role during early development. In 
addition to its function at the synapse, SHANK3 also binds to various actin-
binding proteins such as Abp1, SPIN90, Cortactin and many more [Introduction 
section 1.5(c); Verpelli et al., 2012]. These play a critical part in cytoskeletal 
remodeling. Therefore, the loss of SHANK3 is highly likely to play a role in the 
structural growth of neurons. Since ASD is a neurodevelopmental disorder, in the 
second section of this chapter (3.2), we focus on the role of SHANK3 in the 
structural organization of the neuron during early development.  
 
3.1: Verification of hypothalamic neurons 
 
I used a panel of antibodies against cell-type specific hypothalamic 
neurohormones - GnRH1, CRH, and SST using the microarray as reference 
point. The antibodies used are listed in detail in Table 2.4.   Both SHANK3 and 
control cultures were fixed at day 26 of neuralisation. Cultures were stained with 
each hypothalamic marker in conjunction with neuronal specific β iii tubulin (Tuj1) 
(Figure 3.1.2 A and B).  The percentages were calculated as shown below in 
table 3.1. The percentage was the total number of CRH/GnRH1 positive cells 
divided by the total number of neurons present. 
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Table 3.1: Percentage of each neuronal type:  This table describes the percentage of CRH and 
GnRH1 neurons generated from each cell line. The percentage was calculated as the total 
number of CRH/GnRH1 positive cells divided by the total number of neurons present. Details of 
each cell line can be found in Methods section 2.1. 
 
 
As shown in Figure 3.1.2, both control and SHANK3 cells were positive for 
GnRH1, and CRH with 50-60% neurons being CRH positive and 30-40% 
neurons being GnRH1 positive.  SST could not be assayed because of 
inadequate antibodies.  As mentioned previously, all staining was done with 
neuronal specific tubulin (Tuj1). Therefore, we have identified over 85% of the 
Cell	  Line	  
Name	   Percentage	  CRH	  positive±SD	  	  
Cell	  Line	  
Name	  	   Percentages	  CRH	  positive±SD	  	  
Control	  
Patient	  1	  
Clone	  1	  	   62.467±15.144	   ASD	  Patient	  1	  	   61.840±17.319	  
Control	  
Patient	  1	  
Clone	  2	   50.786±3.212	  
SHANK3	  
Patient	  1	  
Clone	  1	   44.486±17.277	  
Control	  
Patient	  2	  
Clone	  1	   40.132±10.611	  
SHANK3	  
Patient	  2	  
Clone	  1	   41.432±22.229	  
Control	  
Patient	  3	   67.921±1.277	  
SHANK3	  
Patient	  2	  
Clone	  2	   59.160±12.828	  
Control	  
Patient	  2	  
Clone	  2	  	   43.291±7.883	  
SHANK3	  
Patient	  1	  











Clone	  1	  	   33.428±11.812	   ASD	  Patient	  1	  	   30.906±7.942	  
Control	  
Patient	  1	  
Clone	  2	   43.968±4.029	  
SHANK3	  
Patient	  1	  
Clone	  1	   31.794±2.689	  
Control	  
Patient	  2	  
Clone	  1	   31.0735±10.631	  
SHANK3	  
Patient	  2	  
Clone	  1	   39.633±19.760	  
Control	  
Patient	  3	   30.441±8.526	  
SHANK3	  
Patient	  2	  
Clone	  2	   34.923±5.382	  
Control	  
Patient	  2	  
Clone	  2	  	   29.472±14.059	  
SHANK3	  
Patient	  1	  
Clone	  2	   35.271±12.994	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neurons in our culture (Figure 3.1.2), although we have not discounted the 
possibility that some cells might double stained for GnRH1 and CRH together.  
 
In addition to the SHANK3 line, we also analyzed a sporadic ASD line for 
expression of these markers (ASD P1; Figure 3.1.2 C; Table 3.1). We saw 31% 
of cells positive for GnRH1 and 62% positive for CRH. These percentages were 
quite similar to what we saw in our SHANK3 and control neurons.  
 
These results indicate that the neuralisation procedure used gives reproducible 
results, in terms of percentages and type of neurons generated, across control 
SHANK3 and ASD lines. This suggests that is this system is robust and, as such 
can be used to study the effects of autism-causing mutation on neuronal 
structure and function. 
 
Our immunocytochemical analysis of the iPSCs lines showed that the expression 
of CRH and GnRH1 is consistent with the microarray data shown in Figure 3.1. 
Nonetheless, the microarray data also showed an expression TRH (thyrotropin-
releasing hormone), SST and TH. These could account for the missing 15% of 
the unidentified cells in our culture.  
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Figure 3.1.2: Characterization of the neurons generated from iPSCs: Neurons generated 
were Hypothalamic in nature. Neurons are at day 25/26 of neuralisation. A. (i) Control line stained 
with DAPI (blue), CRH (Green) and Tuj1 (red). B (i) Control line stained with DAPI (blue) GnRH1 
(Red) and Tuj1 (green) positive. C(i) Control line stained with DAPI (blue) TH (Red) and Tuj1 
(green) positive(Scale=50µm).(i) Percentage of CRH positive cells (ii) Percentage of GnRH1 
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3.2: Morphological analysis of SHANK3 patient neurons 
 
3.2.1: Morphological analysis of single cell via eGFP 
 
In order to investigate the morphological differences between the patient and the 
control iPSC generated hypothalamic neurons. At day 30 (immature neurons) 
and day 45 (young neurons) of neuralisation, the cells were transfected with 
eGFP and visualized with fluorescence microscopy (Figure 3.2; Table 3.2). The 
following cell lines were compared: Control P1 C1, Control P1 C2, and Control 


















Table3.2: Morphological parameters assessed at different stages of neuralization. The 
table shows the median for each morphological parameter assessed at two stages of 
neuralisation, day 45 and day 30.  Since morphological parameters did not pass the KS normality 
test, we compared medians. Day 45 Control neurons n=124; SHANK3 neurons n=106, from all 3 
biological replicates. We compared 2 control lines with 2 SHANK3 lines, with one clonal replicate. 
Day 30 Control neurons n=120; SHANK3 neurons n=122, from all 3 biological replicates. We 
compared 2 control lines with 2 SHANK3 lines, with one clonal replicate 
 
 
The transfection efficiency was the same in both lines at approximately 2% 
(Methods section 2.9). The following morphological features were assessed for 
both the patient and the control lines: Primary no. of neurites per neuron, 
average neurite length (µm) and average cell soma diameter (µm).  
 
Average	  neurite	  length	  (μm)	   Control	  	  median	  	   SHANK3	  Median	  
Day	  45	  of	  Neuralisation	   387.5,	  n=124	   609.3,	  n=106	  
***p=0.0001	  
Day	  30	  of	  Neuralisation	   169.9,	  n=120	   278.2,	  n=122	  
***p=0.0002	  
Primary	  no.of	  neurites	  per	  neuron	   	   	  
Day	  45	  of	  Neuralisation	   3.44	   	  4.94	  
***p=0.0003	  
Day	  30	  of	  Neuralisation	   2.250	   3.986	  
**p=0.0012	  
Average	  cell	  soma	  diameter	  (μm)	   	   	  
Day	  45	  of	  Neuralisation	   17.68	   12.50	  
***	  p<0.001	  
Day	  30	  of	  Neuralisation	   20.92	   14.08	  
,****p<0.0001	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Figure 3.2: SHANK3 patient neurons exhibit morphogenetic deficits 
A. GFP transfected control neuron B. Tracing of the control neuron (Blue: Neurites, Pink: Cell 
body outline, Green: secondary branches) C. GFP transfected SHANK3 neuron D. Tracing of 
SHANK3 neuron.  (45 days neurons, Scale=250µm)  E. (i) Primary no. of neurites per neuron (ii) 
Average neurite length (µm). (iii) Average cell soma diameter (µm).  Significant differences were 
observed in all three parameters; data shown for day 45 neurons. Data presented as box plots 
with min and max, ***p=0.0001, ***p=0.0003, *** p<0.001 respectively. Mann-Whitney U test was 
performed. (Control neurons n=124; SHANK3 neurons n=106, from all 3 biological replicates. We 
compared 2 control lines with 2 SHANK3 lines, with one clonal replicate). 
F. (i) Primary no. of neurites per neuron (ii) Average neurite length (µm) (iii) Average cell soma 
diameter (µm). (30 days neurons). Significant differences were observed in all the three 
parameters; data shown for day 30 neurons. Data presented as box plots with min and max, 
***p=0.0002, **p=0.0012,****p<0.0001 respectively; Mann-Whitney U test was performed. 
(Control neurons n=120; SHANK3 neurons n=122, from all 3 biological replicates. We compared 
2 control lines with 2 SHANK3 lines, with one clonal replicate). 
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Morphological differences were found in the SHANK3 neurons at day 30 
(immature neurons) and day 45 (young neurons) of neuronal development. The 
cell soma diameter (µm) was smaller in the patient neurons while the neurite 
length (µm) and the mean number of neurites was higher at both stages, as 
shown via the box plots [Figure3.2.1 E (I-iii) and Figure F (I-iii)]. These data 
indicate that there are structural differences between the control and SHANK3 
neurons. These changes are consistent through different stages of neuralisation 
and occur at an earlier stage of development when the neurons are immature 
day 30. 
 
3.2.2: Tracking morphological changes through neuronal development 
 
Since GFP transfection only targeted 2% of the cell population, we wanted to test 
whether the observed morphological deficits occurred within the whole cell 
population and not just in a subset of the population.  To answer this question we 
used a high content cytometry assay to compare cell soma area and number of 
primary neurite per neuron.  This was carried out at four stages of neuralisation; 





(mean±SEM)	   SHANK3	  (mean±SEM)	  
Primary	  no.	  of	  neurite	  per	  neuron	   n=26,000	   n=30,000	  
Mean	  at	  day	  22	  of	  neuralisation	   1.265±0.2168	  	   1.204±0.244	  
Mean	  at	  day	  25	  of	  neuralisation	   1.663±0.3	   1.773±0.263	  
Mean	  at	  day	  27	  of	  neuralisation	   1.7878±0.136	   1.865±0.099	  
Mean	  at	  day	  30	  of	  neuralisation	   1.3950±0.156	  
2.698±0.212	  	  
***p=0.0002	  
Cell	  soma	  area	  µm2	  
	   	  Mean	  at	  day	  22	  of	  neuralisation	   113.2±25.809	   109.1±15.944	  
Mean	  at	  day	  25	  of	  neuralisation	   157.7±34.47	   129.6±19.187	  
Mean	  at	  day	  27	  of	  neuralisation	   155.8±20.89	   170.5±23.21	  




Table3.2.1: Morphological analysis using High content imaging. The table describes the 
mean±SEM for each morphological parameter assessed at various stages of neuralisation. We 
analyzed from 5 control lines and 4 SHANK3 lines (3 control lines with two clonal replicates and 2 
SHANK3 lines with one clonal replicate of each). We compared 5 control lines with 4 SHANK3 
lines; 3 control lines with two clonal replicates and 2 SHANK3 lines with one clonal replicate of 
each. (Control neurons n=26.0X103; shank3 neurons n=30.0X103). 
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No morphological changes were observed from day 22 to day 27. However, at 
day 30 we observe a significant decrease in cell soma area and increase in 
primary number of neurites per neuron in the SHANK3 patient lines compared to 
the control lines (Figure 3.2.2).  This not only confirmed our pervious observation 
on day 30 immature neurons (section 3.2.1) but also defined a window for 
change in the development of SHANK3 neurons (day 27 to day 30).   
 
In this assay, 5 control lines from three control patients were compared to 4 
SHANK3 lines from two SHANK3 patients. These were as follows: Control P1 
C1, Control P1 C2, Control P2 C1, Control P2 C2 and Control P3 were compared 
to SHANK3 P1 C1, SHANK3 P1 C2, SHANK3 P2 C2 and SHANK3 P2 C3 
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Figure 3.2.2: Morphological deficits found in immature SHANK3 patient neurons 
A. Control neurons cell soma B. Shank3 neurons cell soma C. Control neurons neurite D. Shank3 
neurons neurite [Scale=10µm, day 30 neurons stained with DCX (green), DAPI (grey)]. E and F. 
are cumulative frequency distribution of cell soma area at day 27 and day 30. (**** p<0.0001, the 
Kolmogorov–Smirnov test was performed, Control neurons n=26.0X103; shank3 neurons 
n=30.0X103) G and H. are primary no. of neurites per neuron day 27 and day 30. Data 
represented as mean±SD, ***p=0.0002, the student t test was performed, Control neurons 
n=26.0X103; shank3 neurons n=30.0X103). I High content screening performed to find changes in 
cell soma area µm2 from day 22 (late neural progenitors) to day 30 (immature neurons). Data 
represented as mean±sem, Mann-Whitney U test was performed for each time point, the only 
difference was seen at day 30 ***p=0.0001. J.  High content screening performed to find out the 
primary no.of neurite per neuron from day 22 (late neural progenitors) to day 30 (immature 
neurons). Data represented as mean±sem. Unpaired student t test with Welch’s correction was 
performed for each time point, the only difference was seen at day 30 ***p=0.0002. We 
performed 3 biological replicates. We compared 5 control lines with 4 SHANK3 lines; 3 control 
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3.2.3: Neurite Outgrowth 
 
Having established that SHANK3 patient neurons exhibit abnormal neurite 
morphology (Figure 3.2 and 3.2.2), I now wished to explore neurite outgrowth in 
these cells in more detail. I therefore compared the rate of neurite formation 
(neurite/hr), elimination (neurite/hr), extension (µm/hr) and retraction (µm/hr) in  
control and SHANK3 neurons at day 30 of neuralisation over a 12 hour period 
using time lapse imaging (Methods, section 2.12). 
 
I studied 4 control lines from two control patients and 4 SHANK3 patient lines 
from two SHANK3 patients. These were as follows: Control P1 C1, Control P1 
C2, Control P2 C1, Control P2 C2 were compared to SHANK3 P1 C1, SHANK3 
P1 C2, SHANK3 P2 C1 and SHANK3 P2 C2 (Figure 3.2.3).  
 
I found that the rate of formation of the primary neurite was significantly higher in 
SHANK3 neurons than in control neurons, while the rate of primary neurite 
elimination was significantly lower (Figure 3.2.3 C,G and H; Table 3.2.2). There 
was, however, no change between the patient and control lines in the rate of 
secondary branch formation and elimination (Figure 3.2.3 I and J). 
 
Similarly, when we analysed changes in the rate of extension and retraction of 
the primary neurite, the rate of extension of primary neurite length was 
significantly higher in SHANK3 neurons, whereas the rate of primary neurite 
length retraction was significantly lower (Figure 3.2.3 D, E and F; Table 3.2.2). 
 
Thus, we observed an increase in the rate of primary neurite formation and  
increase in neurite length extension in SHANK3 patient neurons. This 
corroborates our previous experiments in section 3.2.1 and 3.2.2, which showed 
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Table 3.2.2: Neurite Outgrowth: The table describes the mean±SEM for each neurite outgrowth 
parameter averaged from 4 control lines and 4 SHANK3 lines (2 control lines and 2 SHANK3 
lines with one clonal replicate of each) assessed at day 30 of neuralisation. We compared 4 
control lines with 4 SHANK3 lines; 2 control lines with two clonal replicates and 2 SHANK3 lines 



































Extension	  Rate	  	  μm/hr	   31.60	  ±	  2.787	  
70.50±2.630,	  
****p<0.0001	  
Retraction	  rate	  	  μm/hr	   58.32	  ±	  2.635	  
42.35	  ±	  
3.291,**p=0.001	  
Neurite	  formation	  rate	  neurite/hr	   0.4158	  ±	  0.02055	  
0.6555	  ±	  
0.02538,****p<0.0001,	  
Neurite	  elimination	  rate	  neurite/hr	   0.5809	  ±	  0.02885	  
0.3955	  ±	  
0.01964,****p<0.0001,	  
Second	  branch	  formation	  branch/hr	   3.018	  ±	  0.335	   3.018	  ±	  0.335	  
Second	  branch	  elimination	  branch/hr	   3.857	  ±	  0.5360	   3.005	  ±	  0.3257	  
cell	  soma	  speed	  	  μm/hr	   19.73	  ±	  0.6385	  
7.754	  ±	  0.5210,	  
****p<0.0001,	  
Avg.	  rate	  of	  change	  in	  cell	  soma	  area	  um2/hr	  
	  	  	  









Figure 3.2.3: SHANK3 patient neurons exhibit abnormal neurite outgrowth.  A (i) Phase 
contrast image of control neuron and tracing (Red: Neurite, Blue: Cell body outline, Yellow: 
secondary branches) Neuron at zero hour (ii) fourth hour (iii) eighth hour (iv) twelfth hour. B(i) 
Phase contrast image of SHANK3 neuron and tracing given below at zero hour (ii) fourth hour (iii) 
eighth hour (iv) twelfth hour (Scale = 50µm).C. Primary neurite of formation/ elimination rate were 
normalized to zero hour; above 1 represents the formation, below 1 represents elimination. Data 
presented as mean±sem.(Two way Anova performed, ****p<0.0001 b/w genotypes, ****p<0.0001 
b/w genotypes and days). D. Neurite extension/ retraction rate of primary neurite were normalized 
to zero hour; above 1 represents the extension, below 1 represents retraction. Data presented as 
mean±sem. (****p<0.0001, Two way Anova performed). E. Extension rate (µm/hr) F. Retraction 
rate (µm/hr). G. Formation rate (neurite/hour) H. Elimination rate (neurite/hour). Data represented 
as mean±SD, ****p<0.0001, **p=0.001, ****p<0.0001, ****p<0.0001 respectively. Unpaired 
student t test with Welch’s correction was performed. I. Rate of secondary branch formation 
(branch/hour). J. Rate of secondary branch elimination (branch/hour). K. Cell soma speed (µm/hr) 
L. Change in cell soma area µm2/hr.  Data represented as mean±SD. ****p<0.0001, **p=0.005 
respectively, Unpaired student t test with Welch’s correction was performed.  (Control neurons 
	   102	  
n=51; SHANK3 neurons n=59, from all 3 biological replicates). We compared 4 control lines with 
4 SHANK3 lines; 2 control lines with two clonal replicates and 2 SHANK3 lines with one clonal 
replicate of each.  
 
Figure 3.2.4: Cell soma movement: A. Depicts control neurons at day 30 at hour zero. B. 
control neuron at 4 hours C. Control neuron at 8 hour  D. Control neuron at 12 hour. Scale= 
100µm Please also see the CD attached at the back of this thesis, it contains the video of control 
and SHANK3 neurons for 24 hours, picture taken every hour. 
 
 
As described in section 3.1 of this chapter, approximately 30-35% of our cells 
were GnRH1 positive (Figure 3.1.2). During development of GnRH neurons, they 
pass through the nasal placode to several regions of the forebrain before 
reaching their final destination in the hypothalamus (Wray 2010).  Recently, it has 
been shown that the migratory mechanism of GnRH1 neurons is through the 
movement of the cell soma.  Briefly, guidance molecules cause the release of 
calcium in the cytoplasm, which reorganizes actin, microtubules and cytoskeletal 
elements. This causes contractions in the cell that linked to adhesive protein on 
the cell surface pulling the cell forward (Prakash J et al., 2012; Hutchins et al., 
2013; Hutchins et al., 2014).  
 
A similar phenomenon was observed in my experiments when carrying out time 
lapse imaging, the cell body moved from one position to another along with its 
neurites (Figure 3.2.4). In figure 3.2.4 B, the position of the control neuron is 
further down than the position it was at in figure 3.2.4 A. To analyze this, I 
calculated the speed of the cell soma movement in control and SHANK3 neurons 
and discovered that the SHANK3 neurons showed a significant decrease in cell 
soma speed (Figure 3.2.3 K). Therefore, the phenomenon I observed could be 
related to lesser migration of SHANK3 patient neurons.   
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In our previous experiments, we have shown that the cell soma area of control 
neurons is much greater than SHANK3 neurons (Figure 3.2.2). The next question 
I wanted to ask was whether the control cell soma size was inherently different 
than the SHANK3 cells or is there expansion of the cell soma size. I tried to 
correlate this with time. I calculated the average rate of change in cell soma area 
over the period of twelve hours (µm2/hr). This was found to be significantly lower 
in the SHANK3 neurons (Figure 3.2.3 L). This indicated that the control neurons 
expand the cell soma area more with time than the SHANK3 neurons. This 
suggests that there is a possible mechanism in the control neurons that causes 
them to expand with time such that its size increases. While the SHANK3 patient 
neurons, due to the loss of SHANK3, have possibly lost this function of 
expansion. Thus, their cell size remains smaller. One of the possible 
mechanisms behind this I explore in chapter 5, which could be the loss of global 
protein synthesis in the SHANK3 patient neurons.  
 
3.3: Discussion 
3.3 (a) ASD and Hypothalamus  
 
In section 3.1 of this chapter, I have characterized the neurons derived from 
control, mutant SHANK3 iPSC lines and the sporadic ASD line. The neuralisation 
protocol described gave us neurons that were positive for neuronal markers such 
as DCX and Tuj1.  We identified over 85% of the neuronal population as 
hypothalamic neurons, although we have not formally excluded the possibility 
that neurons could be expressing both CRH and GnRH1.  50-60% of the 
neuronal population was positive for CRH and 30-40% of the neuronal population 
was positive for GnRH1.   
 
There were no differences found in the neural induction of patient and control 
iPSC lines. Moreover, there was minimal variability found between the iPSCs 
lines in the percentages of the types of neurons generated. Therefore, we have 
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established a stable neuronal model to study the effects of autism in 
hypothalamic neurons.   
 
As mentioned in the introduction section 1.11, the hypothalamus produces 
hormones, which impact greatly on social behavior.  For example, increased 
levels of cortisol, testosterone and progesterone have all been reported in fetal 
development of autism (S Cohen et al., 2015). It is well known that CRH and 
GnRH hormones are precursors to cortisol and testosterone respectively 
(Quintanar J. Luis et al., 2013). Thus, it is essential we understand how 
hypothalamic neurons develop in humans with and without ASD.  
 
3.3 (b) SHANK3 haplo-insufficiency affects morphology of the neuron 
  
The shape and structure of the neuron dictates its function. Dendritic branching 
and orientation further impact on this (Meinertzhagen et al., 2009). Furthermore, 
the development of morphological features of the neuron is dependent on genetic 
factors, electrical fields and chemical cues. In this study, we specifically address 
the role of SHANK3 gene in autism during early development. I compared 
various aspects of neuron morphology in control versus SHANK3 patient 
neurons. 
 
These studies have revealed that the SHANK3 neurons were morphologically 
compromised: having smaller cell bodies, more primary neurites and longer 
primary neurites than the control neurons. Moreover, the SHANK3 neurons 
showed deficits in neurite extension and retraction. These results suggest that in 
neurons, SHANK3 plays a role in the regulation of neuronal structure. 
 
Smaller cell soma size has been consistently described in both post mortem and 
rodent models of ASD. For example, in Rett’s and Fragile X syndrome both have 
shown a reduction in cell soma size in the cerebral cortex and hippocampal 
regions of the brain (Irwin et al., 2001; Bauman et al., 1995; Chen et al., 2001; 
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Kishi and Macklis 2004: Smrt et al., 2007, Asaka et al., 2006; Moretti et al., 2006; 
Nelson et al., 2006; Noutel et al., 2011; Castern et al., 2005).  Decreased cell 
soma size has also been validated in iPSC models of the same diseases 
(Cheung et al 2011; Marchetto et al., 2010; Ananiev et al., 2011). These studies 
support our observations that SHANK3 neurons have smaller cell somas.  
 
Recently, Peca et al (2012) studied the Shank3 KO mice, they traced Golgi-
stained striatal medium spiny neurons and found increase in total dendritic 
length. Sholl analysis of the same neurons revealed neuronal hypertrophy as 
measured by increased dendritic arborization. Furthermore, they linked this back 
to significant volumetric enlargement of caudate in Shank3 KO mice. An enlarged 
caudate in autistic patients’ is associated with repetitive behavior (Hollander E et 
al., 2005; Langen et al., 2009). In our study, we saw a similar pattern of increase 
in neurite length (Figure 3.2) and increase in neurite number (Figure 3.2.2). 
Therefore, it is possible that increased brain volume seen in autistic patients 
could be due to the morphological changes we report here.  
 
In the introduction section 1.3, we described the hypothesis that abnormal 
cellular growth causes aberrant connections between neurons, which leads to 
social deficits in autistic patients (Keown C et al., 2013). Through the above 
experiments we have also shown that the SHANK3 patients have abnormal 
neuronal growth, which is increased neurite number and neurite length. This 
could lead to synaptic and electrophysiological deficits that cause 
miscommunication between neurons (preliminary results of these experiments 
have been described in Chapter 5 of this thesis). This in turn could cause the 
social deficits that are commonly reported in autistic patients. 
 
 
In this chapter, I have established a stable in-vitro system to analyze the effects 
of SHANK3 in autism. I have revealed that the loss of SHANK3 in patient 
neurons resulted in the neuronal morphology changes, which could be related 
back to autism. It is now important to confirm that these phenotypic differences 
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between cells derived from SHANK3-deletion patients and neurotypical 
individuals were genuinely due to SHANK3 haploinsufficency. In the next chapter 
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In the previous chapter, I presented data indicating that iPSC-derived neurons 
that carry a heterozygous deletion in SHANK3 show developmental defects. 
These defects are evident as early as day 30 of neuralisation when these 
SHANK3 patient neurons exhibit a decreased cell soma area, increased primary 
neurites and neurite outgrowth. 
 
It is essential to verify that these phenotypic differences between cells derived 
from SHANK3 patients and control were due to the SHANK3 haplo-insufficiency. 
I therefore undertook three further studies. In the first study, I sought to rescue 
morphogenetic phenotype in SHANK3 patient neurons by transducing into the 
cells a SHANK3 expression construct. The second I studied a genome-edited 
male human embryonic stem cell line, comparing a homozygous deletion of 
SHANK3, a heterozygous deletion of SHANK3 and a control line with no 
modifications. The third experiment used the growth factors IGF1 and BDNF as 
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4.1 Enhancing the expression of SHANK3 rescues the morphogenetic 
phenotype seen in SHANK3 patient neurons.  
 
In order to determine whether the phenotype observed in the SHANK3 patient 
neurons could be rescued by overexpressing SHANK3, I infected the SHANK3 
patient neurons with a lentivirus overexpressing the full length SHANK3 (ORF) 
where the N terminal had been fused to Myc (Figure 4.0 A; Methods section 
2.19). Non-infected SHANK3 neuronal cultures were included as controls. 
 
I used two SHANK3 patient lines to show the rescue: SHANK3 patient 2 clone 
1(SHANK3 P2 C1), and the male SHANK3 patient 1 clone 2 (SHANK3 P1 C2). 
These lines have previously revealed to have morphogenetic deficits at day 30 of 
neuralisation. They both showed a decrease in cell soma area and an increase in 
primary number of neurites (Figure 3.2.2). The neurons were infected at day 
20/21 of neuralisation and the virus was removed after twenty-four hours. After 
the removal of the virus, media was changed every other day till day 30.  
 
On day 30, neurons were fixed and stained for Myc and DCX (Doublecortin) 
using immunocytochemistry. Myc was used to identify neurons that were 
positively infected (as Myc is fused to N terminal of SHANK3 overexpression 
construct) and DCX was used to identify immature neurons. I counted the 
proportion of neurons that were positive for Myc, these were about 80% as 
described in Table 4.0. Next, I programmed the high content imaging platform 
such that it only selected the neurons that were positively infected, in other 
words, positive for Myc staining.  After the successful transduction of the 
neurons, I used high content imaging to measure the cell soma area (um2) and 
primary number of neurites per neuron.  
 
In the SHANK3 patient female line, (SHANK3 P2 C1) the overexpression of 
SHANK3 rescued both the cell soma area and the primary number of neurites 
(Table 4.1). In the SHANK3 female patient the cell soma area of 30 day neurons 
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without rescue was 153.237 ±6.52 µm2 after the enhanced expression of 
SHANK3 in the female patient neuron this increases up to 238.58±3.66 µm2 
(Figure 4.0 D).  Similarly, in the SHANK3 male patient line (SHANK3 P1 C2) the 
enhanced expression of SHANK3 increases the cell soma area from 
180.38±3.23 (without rescue) to 250.422±4.07 µm2 (Figure 4.0 E).  Therefore, 
increasing the expression of SHANK3 in SHANK3 patient neurons rescued the 
cell soma morphogenetic phenotype. 
 
We know from previous experiments that the loss SHANK3 in SHANK3 patient 
neurons results in the increased primary number of neurites (chapter 3 section 
3.2).  When we enhanced the expression of SHANK3 in the SHANK3 female 
patient line we saw a significant decrease in the primary number of neurites 
(Figure 4.0 F) that is 2.36 ± 0.04 neurites were turned into 1.20±0.03 neurites. 
However, in the male SHANK3 patient line, the enhanced expression of SHANK3 
did not cause any change in the primary number of neurites (Figure 4.0 G; Table 
4.1).  
 
Cell	  Line	   Total	  number	  
of	  neurons	  
DCX	  
Number	  of	  cells	  




SHANK3	  P2	  C1	  with	  
rescue	  
1885	   1500	   79.57%	  
SHANK3	  P2	  C1	  with	  
rescue	  -­‐18	  
2278	   1820	   79.89%	  
SHANK3	  P1	  C2	  with	  
rescue	  
2470	   1980	   80.16%	  
SHANK3	  P1	  C2	  with	  
rescue-­‐18	  
1751	   1400	   79.95%	  










Table 4.1: Enhanced expression of SHANK3 rescues morphogenetic phenotypes. The table 
above shows the mean±SEM of cell soma area (um2) before rescue, after SHANK3 rescue and 
with SHANK3 rescue without exon18 for two different SHANK3 lines. The table at the bottom 
describes the mean±SEM of primary no. of neurite before rescue, with SHANK3 rescue and with 
SHANK3 rescue without exon18 for different SHANK3 lines. Red is SHANK3 male line and Black 
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Figure 4.0: Overexpression of SHANK3 rescues the morphogenetic phenotypes: A. Day 30 
SHANK3 before rescue, (i) DCX (red) (ii) MYC (green) stained (iii) DAPI (blue), (Scale=10µm). B. 
Day30 SHANK3 neuron after rescue, (i) DCX (red) (ii) MYC (green) stained (iii) DAPI (blue), 
(Scale=10µm). C. Primary number of neurites per neuron SHANK3 Patient 2 Clone1 with and 
without rescue. D. Primary number of neurites per neuron SHANK3 Patient 1 Clone2 with and 
without rescue. Data represented as mean±SD. Data compared via unpaired student t test with 
Welch’s correction. (**p=0.0026 SHANK3 P2 C1 before vs. SHANK3 P2 C1 rescue, **p=0.0066 
SHANK3 P2 C1 before vs. SHANK3 P2 C1 rescue-18). E. Cumulative frequency distribution of 
cell soma area (µm2) of SHANK3 Patient 2 clone 1 with and without rescue.  F. Cumulative 
frequency distribution of cell soma area (µm2) of SHANK3 Patient 1 clone 2 with and without 
rescue. Data compared via Kolmogorov-Smirnov test. (****p<0.0001 SHANK3 P2 C1 before vs. 
SHANK3 P2 C1 rescue, ****p<0.0001 SHANK3 P2 C1 before vs. SHANK3 P2 C1 rescue-18, 
****p<0.0001 SHANK3 P1 C2 before vs. SHANK3 P1 C2 rescue and ****p<0.0001 SHANK3 P1 
C2 before vs. SHANK3 P1 C2 rescue-18). I repeated this experiment three times and the total 
number of neurons compared from all three experiments were as follows: SHANK3 P2 C1 before 
n=1.5X103, SHANK3 P2 C1 with rescue n=1.5X103, SHANK3 P2 C1 with rescue - exon18, 
SHANK3 P1 C2 before n=1.45 X103, SHANK3 P1 C2 with rescue n=1.98 X103, SHANK3 P1 C2 
with rescue-18. 
	   112	  
I next wanted to determine whether the enhanced expression of SHANK3 in 
SHANK3 patient neurons resulted in a completely wild-type phenotype. I 
compared the control female line to the SHANK3 female patient line with the 
rescue and the control male line to the SHANK3 male patient line with rescue 
(Figure 4.1). There was a significant shift in the cumulative frequency distribution 
in both the SHANK3 patient lines with rescue [Figure 4.1 A (I) and (ii)]. A 
significant increase in the cell soma area is shown by both SHANK3 patient lines 
with rescue as compared to SHANK3 patient lines without rescue. Moreover, if 
we glance at the cumulative frequency distribution lines for both SHANK3 patient 
lines with rescue we see that these distributions are moving towards the control 
and away from SHANK3 patient lines without the rescue [Figure 4.1 A (I) and (ii)]. 
This suggested that the enhanced expression of SHANK3 in patient lines recues 
the cell soma phenotype.  However, it does this only relatively as the cumulative 
distribution of cell soma area for the control and SHANK3 patient lines with 
rescue do not completely overlap. 	  
	  
	  
On the other hand, there was a significant decrease reported in the number of 
primary neurites per neuron in the SHANK3 female patient line with rescue 
[Figure 4.1, B (I)]. In the SHANK3 female patient line we have previously shown 
that there is an increase in the primary number of neurites as reflected in 
SHANK3 female patient without rescue. If we compare the SHANK3 female 
patient line with rescue to control we see that there is no significant difference 
between them [Figure 4.1, B (I)]. This suggests that the enhanced expression of 
SHANK3 completely rescues the primary number of neurites in the female 
patient neurons. Since, there was no rescue seen in the primary number of 











Figure 4.1: SHANK3 rescue versus control: A. I compared the cell soma area (um2) of female 
patient SHANK3 line (SHANK3 P2 C1; SHANK3 patient 2 clone 1) with rescue and without 
rescue to control female line (Control Patient 3). (ii) I compared the cell soma area (um2) of male 
patient SHANK3 line (SHANK3 P1 C2; SHANK3 patient 1 clone 2) with rescue and without 
rescue to control male line (Control patient 1 clone 2).  B (I). I compared the primary number of 
neurites per neuron of female patient SHANK3 line (SHANK3 P2 C1; SHANK3 patient 2 clone 1) 
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The SHANK3 gene produces several protein isoforms in the human brain (Jiang 
et al., 2013). The protein domain structure of each isoform has been deduced 
from mRNA expression of different human promoters. To date, no protein 
isoforms have been validated because of lack of isoform specific antibodies 
(Introduction section 1.5, Figure 1.1). 
 
Previous work in our laboratory indicates that the expression of SHANK3 with 
exon18 increases during transition from neural progenitors to neurons (data 
shown in introduction section 1.12).  These data also indicated that the SHANK3 
patient lines had a reduced expression of this exon.  Since this expression of 
exon 18-containing isoforms immediately precedes the appearance of the 
morphogenetic phenotype, we hypothesized that the specific failure to express 
exon 18 might be associated with this phenotype.  If this hypothesis were correct 
then a full length SHANK3 without exon18 might fail to rescue the phenotype 
where a construct including exon 18 would succeed.  In fact, both exon 18+ and 
exon 18- constructs rescued equally well (Figure 4.0 D to G; Table 4.1).   In the 
both male and female SHANK3 patient lines increasing the expression of 
SHANK3 rescue without exon 18 lead to increase in cell soma area, which was 
similar to SHANK3 full length rescue (Figure 4.0 D and E). Likewise, the 
overexpression of SHANK3 rescue without exon 18 resulted in the decrease of 
primary number of neurites in SHANK3 female patient line. While, no change in 
primary number of neurites was reported in the SHANK3 male patient line 
(Figure 4.0 F and G). Thus, the increase in expression of SHANK3 exon18 
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4.2 Morphogenetic deficits reported in genetically modified human 
embryonic stem cells (es) 
 
Above I have shown that increasing the expression of SHANK3 in SHANK3 
patient neurons rescued morphogenetic phenotype. To further confirm that 
SHANK3 was the cause of the morphological phenotypes seen in SHANK3 
patient neurons, I compared the morphology of neurons generated from a control 
male human es cell line with es cell lines where both copies of the SHANK3 
genes had been knocked out (es shank3-/-) and where only one copy had been 
knocked out (es shank3+/- ) (Tables 2.7, 4.2).  
 
These lines were provided by our collaborator, Dr. Ravi Jagasia at Roche 
(F.Hoffmann-La Roche Ltd CNS Discovery Grenzacherstrasse CH-4070 
Basel/Switzerland). We converted these es cell lines into hypothalamic neurons 
using the neuralisation protocol (Methods section 2.3). These were then 
analyzed at three stages of neuralisation; day 25 (early neurons), 27 and 30 
(immature neurons) using high content screening [Figure 4.2 A (I-iii)].   
 
Figure 4.2 [B (I-iii); Table 4.2] shows the cumulative frequency distribution of cell 
soma area at day 25, 27 and 30 of neuralisation. There was a significant 
difference between the cell soma area in es shank3+/- and es shank3+/+ derived 
neurons, with this area being smaller in the former. Similarly, the cell soma area 
was significantly smaller in the es shank3-/- derived neurons than in the es 
shank3 +/+ derived neurons [Figure 4.2 B (I-iii)]. These differences were not only 
evident on day 30 of neuralisation as seen in the patient lines (Chapter 3, Figure 
3.2.2), but also at day 25 and day 27.  
 
Moreover, we also saw a difference in es cell-derived neurons in the number of 
primary neurites per neuron.  Both the es shank3 +/- and es shank3-/- neurons 
showed an increase in the number of neurites present compared to the es 
shank3+/+ at all three stages analyzed [day 25, 27 and 30; Figure 4.2.1 B (I-iii),]. 
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Although this was similar to what we see in the SHANK3 patient lines, it also 
occurred at an earlier stage; from day 25 rather than day 30 (Chapter 3, section 
3.2).  However, a qualitative observation was made that the es cells neuralised 
somewhat faster than the iPSCs and this could possibly be the reason for the 
morphological phenotypes appearing earlier in es-derived neurons. 
 
Table 4.2: Morphological phenotypes of es derived neurons. The table below shows the 
mean±SEM for cell soma area (um2) and primary neurites per neuron in hES derived neurons. 
This analysis was done on days 25, 27 and 30 of neuralisation. For P values please refer figures 
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Figure 4.2: Morphogenetic deficits reported in genetically modified human embryonic 
stem cells (es). A (I-iii) day 30 es shank3+/+, es shank3+/- and es shank3/- derived neurons 
stained with DAPI, DCX and tuj1 (Scale bar=50µm). B (I) shows the cumulative frequency 
distribution of cell soma area (µm2) of day 25 neurons (ii) day27 neurons (iii) and day 30 neurons. 
Comparison were made using the Kolmogorov-Smirnov test as es shank3+/+ vs. +/- and es 
shank3+/+vs. es shank3-/- for day 25, 27 and 30. Day 25 ES+/+ vs. es shank3+/- ****p<0.0001, 
day 25 es shank3+/+ vs. es shank3-/- ****p<0.0001, day 27 es shank3+/+ vs. es shank3+/- 
****p<0.0001, day 27 es shank3+/+ vs. es shank3-/- ****p<0.0001 and day 30 es shank3+/+ vs. 
es shank3+/- ****p<0.0001, day 30 es shank3+/+ vs. es shank3-/- ****p<0.0001. C (I) shows the 
cell soma area changes through various neuralisation stages (day 25 to day 30). Data is 
represented as the Mean±sem.   Freidman’s Two-way Anova by ranks pairwise comparison 
****p<0.0001 on all three stages of neuralisation.  C (ii) shows the change in the number of 
primary neurites (day 25 to day 30). Data is presented as mean±sem, (es shank3 +/+ n= 5.1X103, 
es shank3 +/- n=5.0X103, es shank3-/- n=5.11X103 from all 3 biological replicates). Data 
represented as mean±sem.  Two way Anova with repeated measure performed at each time 
point, ***p<0.001 significant difference was found between genotypes and **p<0.005 there is an 
interaction between days and genotypes. Bonferroni's multiple comparisons test revealed 
***p<0.001 es shank3 +/+ vs. es shank3 +/-, ***p<0.001 es shank3 +/+ vs. es shank3 -/- and 
p=1.0 es shank3 +/- and es shank3 -/-. 	  
	  






Figure 4.2.1: Neurite deficits reported in genetically modified human embryonic stem cells 
(es). Day 30 of neurons A (I) es shank3 +/+, (ii) es shank3 +/-, (iii) es shank3 -/- stained with 
DAPI, DCX and Tuj1 (Scale bar=10µm).  B (I) Primary number of neurites per neuron day25, (ii) 
Primary number of neurites per neuron day27. (iii) Primary number of neurites per neuron day30. 
Data represented as mean±SD. Data compared via. Unpaired student t test with Welch’s 
correction. . Day 25 es shank3 +/+ vs. es shank3 +/- ***p<0.001, day 25 es shank3 +/+ vs. es 
shank3 -/- ***p<0.001, day 27 es shank3+/+ vs. es shank3+/- ***p<0.001, day 27 es shank3+/+ 
vs. es shank3-/- ***p<0.001 and day 30 es shank3 +/+ vs. es shank3 +/- ***p<0.001, day 30 
es+/+ vs. es-/- ***p<0.001. (es shank3 +/+ n= 5.1X103, es shank3+/-n=5.0X103, es shank3-/- 
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These experiments showed that the morphological phenotypes seen in the es 
shank3 -/- and es shank3 +/- derived neurons were similar to those observed in 
SHANK3 patient neurons. These observations suggest that the decreased cell 
soma area and increased primary number of neurites observed in these neurons 
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4.3 Growth factors are unable to rescue SHANK3 morphogenetic deficits 
 
Recently, an iPSC model was used to study Phelan Mcdermid syndrome 
(PMDS), a syndrome caused by a deletion in the 22q.13 chromosomal region 
that includes the SHANK3 gene (Shcheglovitov et al., 2013). This disorder is 
characterized by intellectual disability, seizures motor problems and autism 
(Shcheglovitov et al., 2013). The PMDS neurons generated from patient iPSCs 
revealed synaptic signaling deficits, and these were restored to normal with 
exposure to IGF1 (Shcheglovitov et al., 2013). They selected IGF1 as it 
promoted neurogenesis and synaptogenesis in hippocampal dentate gyrus 
during postnatal development of mice (O’Kusky JR et al., 2000). Recently, a 
small clinical trial is also underway to treat PMDS patients with IGF 
(clinicaltrails.gov/ct2/show/NCT01525901).  
In addition, IGF1 partially reversed cellular phenotypes associated with Rett’s 
syndrome a co-morbid disorder of ASD. It restored spine density, synaptic 
amplitude, and increased postsynaptic density protein 95 (PSD95) in mouse 
model of Rett’s syndrome (Tropea D et al., 2009).  Furthermore, a mouse model 
with Shank3 KO was given daily intraperitoneal injections of human IGF1 for over 
two weeks. This rescued LTP (Long term potentiation) and motor performance in 
these mice (Bozdagi et al., 2013).  
 
In most of the studies described above the IGF1 rescues the function at the 
synapse. In this study we report early morphogenetic deficits in SHANK3 patient 
neurons. However, a key point to remember is that the structure of the neuron 
defines its capacity to receive and integrate synaptic signals (Hausser M 2001). 
Later, in this thesis (chapter 5, section 5.3), I describe pre- and post-synaptic 
puncta deficits in SHANK3 patient neurons. This also suggests that the SHANK3 
haplo- insufficiency leads to morphological deficits in neurons which could cause 
synaptic discrepancies. Thus, in this experiment, we use IGF1 as potential drug 
to rescue the morphogenetic deficit, which might prevent the synaptic 
abnormalities from occurring. 
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During development BDNF is required for neuronal proliferation, neuronal 
migration, neuronal survival, neuronal protection, neuritogenesis, synapse 
formation, neuronal excitability and synaptic transmission, short- and long-term 
plasticity, axon guidance, axonal branching, dendritic growth, dendrite branching, 
modulation of excitatory and inhibitory synapses (Tapia-Arancibia, Lucia et al., 
2004; Lee J et al., 2013; Bath KG et al., 2012; Waterhouse et al., 2012). 
Administration of BDNF in hypothalamic rat neurons in vitro has been shown to 
stimulate neurohormone synthesis, release and increased neuronal 
differentiation (Tapia-Arancibia, Lucia et al., 2004). Moreover, BDNF stimulates 
the differentiation somatostatin (SST) and cortisol releasing hormone (CRH) 
neurons (Loudes et al., 2000). Therefore, I also investigated whether this factor 
could rescue the morphological defects of SHANK3 neurons. 
 
To determine whether IGF1 or BDNF could rescue the morphological phenotypes 
of SHANK3 patient neurons seen at day 30 of neuralisation (Chapter 3; Figure 
3.2.2). I performed this experiment in two SHANK3 patient lines with one clonal 
replicate of each and compared it to two control lines with one clone replicate of 
each. These were as follows: Control P1 C1, Control P1 C2, Control P2 C1 and 
Control P2 C2 were compared to SHANK3 P1 C1, SHANK3 P1 C2, SHANK3 P2 
C2 and SHANK3 P2 C3. 
 
IGF1 was administered at 20ng/ml for seven days starting from day 23 to day 30 
(Figure 4.3 A). The concentration of IGF1 was chosen from the iPSC study on 
Phelan McDermid syndrome (Shcheglovitov et al., 2013). BDNF was 
administered at 50ng/ml for four days starting from day 26 to day 30 of 
neuralisation. Concentration of BDNF and time period was adapted from 
McAllister et al (1997).  At day 30 cultures were fixed, stained with Tuj1 (neuronal 
specific ß-iii-tubulin) analyzed using high content imaging. Neither IGF1 nor 
BDNF had any effect on cell soma area or the mean number of primary neurites 
(Figure 4.3 B, C).   
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Figure 4.3: Effect of IGF1 and BDNF on the morphology of SHANK 3 patient neurons. A 
shows the neuralisation timeline and treatment schedule. The histograms compare the cell soma 
area (B) or Mean no. of neurites (C) of control and SHANK3 neurons with and without treatment 
with BDNF and IGF1. Data is presented as mean±SD. ****p<0.0001, one –way analysis of 
variance with Dunnet’s multiple comparisons test. All values were normalised to the mean values 
acquired from control untreated neurons. I performed this experiment in two SHANK3 patient 
lines with one clonal replicate of each and compared it to two control lines with one clone 
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4.4: Discussion 
 
In chapter 3, phenotypic analyses of SHANK3 patient neurons at the 
morphological level revealed deficits in neuronal outgrowth and cell soma size. 
Here we have used enhanced expression studies and analysis of neurons 
derived from SHANK3 KO human es cells to confirm that decrease in SHANK3 
expression is the primary cause of these deficits. This reveals that SHANK3 
plays a critical role in the formation of neurons, particularly its shape, size and 
structure.   
 
Interestingly, in the female SHANK3 patient line enhanced expression of 
SHANK3 rescued the primary number of neurites but this was not the case for 
neurons derived from the male SHANK3 patient line (Figure 4.0 F and G). Even 
though, the female SHANK3 patient line has a longer mutation, which includes 
the genes SHANK3, ACR and RABL2 (data for this is shown in supplementary 
Table 1.0 and 2.0) while the male SHANK3 patient line has a shorter deletion 
including the genes SHANK3 and ACR only. They both have the same deletion 
in the SHANK3 gene, therefore it is unlikely that the neurite morphology in the 
SHANK3 patient male line could be affected by this.  
 
The other speculation we could make that there is some protein translational 
deficits in SHANK3 patient lines. However, this also does not seem to be the 
case as firstly, the SHANK3 rescue construct managed to successfully rescue 
cell soma area phenotype for both the male and female patient line. Secondly, 
global protein translational was measured in both the SHANK3 male and female 
patient line in chapter 5 (section 5.2) of this thesis. There were no differences 
found. The other possibility could be that SHANK3 is translated or regulated 
differently in males than females.  Currently, there is no evidence in the literature 
that supports this theory.  
 
Lastly, although these patients have deletions in the SHANK3 gene, other 
mutations and potentially other deletions and or duplications for other genes on 
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other chromosomes may also exist in these patients. Indeed, our understanding 
of ASD genetics clearly indicates that no one gene can account for the disorder 
and that multiple deficits in gene function and/or expression converge to cause 
the disease. Therefore, it is entirely possible that there are unknown mutations or 
altered expression of other genes specifically in the male line that even with 
SHANK3 rescue experiment which bought SHANK3 to a “normal” expression 
level, is still not enough to compensate for this additional factor that could 
contribute towards the neurite morphology.  Hence, we currently have no 
explanations for the failure of SHANK3 to rescue the neurite morphology 
phenotype in the SHANK3 male patient line. 
 
Since, I could only rescue the cell soma area and not the primary number of 
neurites in the SHANK3 male patient line, I further verified my results using 
genetically modified male es lines. The results indicated that neurons derived 
from both homozygous and heterozygous es SHANK3 KO lines showed the 
same morphological deficits as neurons derived from the SHANK3 iPSC patient 
lines.  It was interesting to that both es SHANK3-/- and es SHANK3+/+ lines 
reacted similarly. A two way repeated measured ANOVA performed, with 
posthoc Bonferroni test revealed a significance of 1 between the two lines [Figure 
4.2 C (ii)].  This suggested like the iPSC cells the es cells even the loss of one 
copy of SHANK3 is detrimental to the neuron.   
 
One might have thought that the loss of two copies of SHANK3 would lead to 
more devastating effects that the loss one of copy of SHANK3. This however was 
not the case as they es SHANK3-/- and es SHANK3+/- lines reacted similarly. 
 
As mentioned in the discussion section of chapter 3 (section 3.3), Peca et al 
(2012) reported that neurons isolated from the striatum of Shank3 knockout mice 
showed an increase in dendritic arborization and dendritic length. These mice 
also displayed behavioral abnormalities such as excessive/repetitive grooming 
which lead to skin lesions. Therefore, this study provides a link between cellular 
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phenotype and behavioral phenotypes, which relates back to ASD patients since 
restricted repetitive behavior is one of the core symptoms of this disorder. We 
have now shown that the loss of SHANK3 in human neurons also leads to 
neurite outgrowth irregularities and by analogy with the mouse studies these 
defects could lead to the behavioral symptoms such as restricted repetitive 
behavior often observed in autism. 
 
In section 4.3, we attempted to use growth factors as drugs to restore the 
organizational deficits of the SHANK3 patient neurons. IGF1 and BDNF were not 
able to restore these deficits. Nonetheless, I have developed a stable platform 
that could be used for high content screening for a new class of drugs. These 
drugs would be capable of pharmacological amelioration of neuronal phenotypes 
for treatment or even early prevention of ASD. Also, this assay can be used as a 
forward chemical genetics approach, to find the possible mechanism behind the 
morphological deficits we see in our SHANK3 patient neurons. For example, a 
small chemical compound library could be tested with this method on the control 
lines. If we find a compound which mimics the SHANK3 patient morphogenetic 
phenotype then the chemical analysis of that compound could lead us to 
understand how SHANK3 affects neuronal structure. Currently, these 
experiments are ongoing in our lab.  
 
Therefore, experiments described in this chapter have established that loss of 
SHANK3 causes a reduction in neuronal cell soma size and increases neurite 
outgrowth. In the next chapter pilot experiments are described that investigate 
the preliminary possible mechanisms behind these phenotypes and how they 
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In the earlier chapters, we have established that SHANK3 haplo-insufficiency 
causes morphogenetic deficits in neurons. Nonetheless, we still do not 
understand how the loss of SHANK3 in patient lines causes these deficits. In this 
chapter, I describe some of the preliminary experiments that address the 
possible mechanism(s) by which these defects could arise; by altering actin 
polymerization and causing translational defects.  After this, I look at later 
developmental stage of the neuron, when synaptic markers are being expressed. 
Specifically, the change in number of pre- and post-synaptic markers. 
 
In the Introduction (section 1.5c), I discussed how SHANK3 binds to various 
actin-binding proteins such as Abp1, Abi1, Cortactin, Sharpin, SPIN90 and Alpha 
fodrin (Verpelli et al., 2011).  These actin-binding proteins play an important 
functional role in the assembly and disassembly of actin filaments and also 
modulate their organization into higher order networks (Winder et al., 2005). For 
example, Abp1 co-localizes with F actin and binds with SHANK3 to regulate 
dendritic spine morphology (Haekel et al., 2008). Further, it is known that the 
actin cytoskeleton plays an essential role in many cellular processes such as cell 
division, cell migration and neuronal polarization (Cooper GM 2000). For 
instance, actin-depolymerizing drugs were applied to rat hippocampal neurons in 
culture, resulting in multiple axon formation. The neurons produced had lost their 
polarity (Bradke et al., 1999).  
 
I therefore hypothesize that the loss of SHANK3 in patient neurons could cause 
an imbalance in one or more of the actin binding proteins that it interacts with, 
disturbing the normal polymerization of actin filaments thus leading to an 
imbalance of Filamentous (F) actin (Globular (G) actin, since G actin polymerizes 
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to form F actin (Figure 5). This imbalance could create neurite growth alterations 
as observed in patient neurons and described in chapter 3 of this thesis.  
Figure 5: Polymerisation of G actin to form F actin: Diagram showing the conversion of G 
actin to F actin. G actin (Globular actin) when bound with an ATP can polymerize to form short 
oligomers (3 to 4 subunits). These oligomers then can act as stable seeds that elongates into F 
actin (Filamentous actin). 
 
 
One of the hypotheses that has emerged from previous studies is that there 
could be enhanced translation in autism, which creates a chemical imbalance in 
the brain (Introduction section 1.3.3; Santini et al., 2012; Kelleher et al., 2008). 
For example, mutations in the genes TSC1 (Hamartin) and TSC2 (tuberin) are 
known monogenic causes of ASD. TSC1/2 inhibit the activity of mTORC1 
(rapamycin sensitive mTOR raptor complex), which is downstream of PI3 kinase 
cascade. This cascade is involved in cellular growth (Kelleher et al., 2008). The 
mTORC1 activation is dependent on protein translation. Rodent studies have 
shown that the inactivation of TSC1/2 up regulates mTORC1 activity. This leads 
to an increase in protein translation. In the same studies they reported that the 
loss of TSC1/2 impacts neuron morphology, increased cell soma size and 
dendritic spines were seen (Meike et al., 2007; Tavazoie et al., 2005; Ehninger et 
al., 2008). Thus, suggesting that the loss of TSC1/2 function enhances 
translation in neurons, which causes an increase in cell soma size.   
 
Following the reverse logic, in our SHANK3 patient neurons we report that there 
is a decrease in cell soma area, we could postulate that there might be a 
decrease in protein translation which could cause this phenotype. To test this 
possibility I have used the SUnSET (surface sensing of translation) to quantify 
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and compare global protein synthesis in SHANK3 patient and control lines 
(Section 5.2). This will indicate whether there are any protein translational deficits 
in the patient neurons that may contribute to cell size changes observed (Figure 
3.2.2).  
 
After assessing the preliminary mechanism behind the morphogenetic phenotype 
of SHANK3 patient lines, I wanted to ask whether this early morphogenetic 
phenotype affected synaptic development. In section 5.3, I therefore explore the 
changes in the synaptic puncta in control versus SHANK3. 
 
SHANK3 is among the first proteins to be expressed during the formation of the 
post-synaptic density (PSD). In the PSD, it helps anchor subcomplexes such as 
PSD95, Homer and GKAP (Grabruker et al., 2011; Boecker et. 2002; Hayashi et 
al., 2009; Carbonetto S 2013).  SHANK3 has multiple functional domains, notably 
SH3, SAM, PDZ, ankyrin repeats and the proline rich domain (Jiang et al., 2013).  
The SAM domain has been known to help in synaptic localization and assembly 
of SHANK3 into multi-molecular sheets (Carbonetto S 2013). Metabotropic 
glutamate receptors (mGluR5) bind via homer which links back to the proline-rich 
domain of SHANK3 (Verpelli et al., 2011). NMDA and AMPA receptors bind via 
PSD95 and GKAP, which in turn bind to the PDZ domain of SHANK3 (Jiang et 
al., 2013). These interactions of SHANK3 with other PSD molecules suggests 
that SHANK3 plays an important role in bringing together signaling molecules 
into scaffolds which help in downstream receptor activation. For instance, the 
knockdown of Shank3 in rat hippocampal neurons leads to the loss NMDA 
receptor hypofunction (Duffney et al., 2013). 
 
Various mouse Shank3 knockout studies have reported disruption in synaptic 
physiology and altered synaptic protein expression.  For example, decreases in 
GluA1, Homer 1b/c, GKAP, GluN2A and SHANK2 have been reported (Bozdagi 
et al., 2010; Wang et al., 2011; Peca et al., 2011; Yang et al., 2012; Schmeisser 
et al., 201). The loss of these proteins resulted in reduction of AMPAR-mediated 
transmission; decreased mEPSC amplitude and frequency were also described 
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(Bozdagi et al., 2010; Wang et al., 2011; Peca et al., 2011; Yang et al., 2012; 
Schmeisser et al., 2012).  
 
In section 5.3, I will describe experiments designed to understand how the loss of 
SHANK3 in patient neurons may have an impact on the synapse by studying 
both control and SHANK3 iPSC derived mature neurons at day 70 of 
neuralisation. We mainly focus our study on how the decrease in SHANK3 in the 
patient neurons contribute to change in presynaptic and postsynaptic puncta. 
 
Therefore, this chapter describes how the SHANK3 haplo-insufficiency in 
SHANK3 patient neurons causes changes in actin modeling, protein translation 

























5.1: Do the levels of F and G actin change in SHANK3 patient neurons?  
 
In the following experiment, I compare if the endogenous levels of G and F actin 
differ in SHANK3 patient and control neurons. These different actin forms were 
detected using the fluorescent probes DnaseI (G actin) and Phalloidin (F actin) 
and the fluorescent intensity measured using high content screening (see 
Methods, Section 2.7). The fluorescence intensity was normalized to total 
number of nuclei. The experiments were carried out at day 30 of neuralisation 
(immature neurons), as it was at this stage of development that the 
morphogenetic phenotype first (day 30, figure 3.2.2) appeared in SHANK3 
patient neurons. I compared three control lines and two shank3 lines, these were 
the following: Control P3, Control P2 C2, Control P1 C2 were compared to 
SHANK3 P1 C2 and SHANK3 P2 C1.  
 
As shown in Figure 5.1 (iii and iv), both the G actin and F actin fluorescence 
staining was significantly higher in control than in SHANK3 neurons. For 
example, the normalized fluorescence intensity for DnaseI staining [G actin; 
figure 5.1 (I) and (ii)] for control was 0.25 ± 0.039, while for SHANK3 it was 0.042 
± 0.004. Therefore, there is approximately six times higher G actin in control than 
in SHANK3 neurons.  Likewise, the normalised fluorescence intensity for 
Phalloidin staining (F actin) measured in control was 0.15 ± 0.018, while for 
SHANK3 patient neurons was 0.070 ± 0.007. Hence, there is approximately two 
times higher F actin in control than in SHANK3 neurons. 
 
Thus, this suggested that both the amount of G and F actin was lower in the 










Figure 5.1: Levels of F and G actin in control and SHANK3 neurons at day 30. (I) G actin 
staining in Control neurons, (ii) G actin staining in SHANK3 neurons, (iii) G actin fluorescence 
intensity normalized to the number of nuclei present, (iv) F actin (Phalloidin) fluorescence 
intensity normalized to the number of nuclei present. Data was collected from 13.5X103 control 
neurons and 10.1X103 SHANK3 neurons, from all 3 biological repeats for 3 control lines and 2 
SHANK3 lines and presented as mean±SD. A significant decrease in both G-actin (**p= 0.0051) 
and F actin (*p= 0.011) .Scale bar in (i) and (ii) = 150 µm. Statistical analysis was carried out 
using unpaired student t test with Welch’s correction. (Control neurons n=13.5X103 and SHANK3 
neurons n=10.1X103, from 3 biological replicates. We compared 3 control lines with 2 SHANK3 
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5.2 Does global protein synthesis vary in SHANK3 patient neurons? 
 
We hypothesized that the smaller cell soma size observed in SHANK3 neurons 
might be a protein translational deficit. To test this hypothesis, we performed a 
SUnSET assay (see Methods, Section 2.13) to compare the global protein 
synthesis in control and SHANK3 neurons.  The cell lines used in this assay were 
as follows: Control P1 C1, Control P2 C2 and Control P3 were compared to 
SHANK3 P1 C1, SHANK3 P2 C3 and ASD P1. 
  
Briefly, puromycin was added to day 30 neurons for twenty minutes, when being 
a structural analogue of aminoacyl tRNAs it is incorporated into nascent 
polypeptide chains preventing their elongation (Nathan D 1969). The cells were 
then lysed and protein extracted for western blotting using a puromycin antibody. 
The amount of puromycin detected can then be used to determine the amount of 
translation occurring in the cells (Schmidt et al., 2009).  
 
Figure 5.2 A, shows the amount of total protein synthesized from three control 
and two SHANK3 lines. Equal amount of protein was added to each lane that 
was 15µg. This was measured using the BCA Assay as described in methods 
section 2.14. This was replicated three times and total protein intensity measured 
from the western blot was normalized to the acetylated tubulin commonly found 
in neurons.  The analysis revealed that there were no differences in protein 
synthesis between the control and the SHANK3 neurons (Figure 5.2 A and B; 
actual intensity values are given in Table 5.1).  
 
Puromycin	  expression	  intensity/Alpha	  
tubulin	  expression	  intensity	   Control	  mean±SEM	   SHANK3	  mean±SEM	  
control	  vs.	  shank3	   1.517	  ±	  0.2359	   1.474	  ±	  0.1906	  
control	  vs.	  ASD	   1.517	  ±	  0.2359	   1.011	  ±	  0.2259	  
 
Table 5.1: Protein translational changes. The table describes the mean±SEM for puromycin 
expression intensity normalised to alpha tubulin expression intensity. We compared 3 control 
lines with 2 SHANK3 lines. We compared 3 control lines with 1 sporadic ASD line. 
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Figure 5.2: Protein translational changes in day 30 neurons. A. Western blot for puromycin 
and alpha tubulin carried out on lysates from control, SHANK3 neurons and from neurons 
generated from a sporadic ASD line at day 30 of neuralisation. B. Puromycin expression intensity 
normalised to acetylated tubulin expression intensity for control vs. SHANK3. C. Puromycin 
expression intensity normalised to alpha tubulin expression intensity for control vs. ASD.  
Control lines, n = 3; SHANK3 lines, n=2; sporadic ASD line, n=1. Data represented as mean±SD. 
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I also compared protein synthesis in our sporadic ASD patient neurons (Figure 
5.2 C, actual intensity values are given in Table 5.2). This was done because in 
section 5.4 of this thesis, I reported that the cell soma size of the neurons 
generated from the sporadic ASD line was smaller than those of control neurons 
(see Figure 5.4). Therefore, I also wanted to investigate whether changes in 
global protein synthesis might explain this phenotype. A decrease in protein 
synthesis was observed sporadic ASD patient neurons compared to control 
neurons, but the significance of this result could not be determined since 
statistical analysis could not be performed as we have only one sporadic ASD 
patient line.  
 
5.3:	  Are there changes in the number synaptic puncta in SHANK3 patient 
neurons?	  
	  
As a first step towards investigating whether the morphogenetic deficits observed 
in early in development in SHANK3 patient neurons affect synaptic development, 
I compared the expression synaptic markers in 70 day-old neurons for both 
control and SHANK3 patient neurons. I used three control lines and two shank3 
lines, these were the following: Control P3, Control P2 C2, Control P1 C2 were 
compared to SHANK3 P1 C2 and SHANK3 P2 C1. 
 
Synaptophysin, an integral membrane glycoprotein that occurs in presynaptic 
vesicles at excitatory synapses (Meittinen 1987) was used as a pre-synaptic 
marker (Figure 5.3A). As a post-synaptic marker, I used Homer1 which is a 
known postsynaptic density protein involved in the targeting glutamate receptors 
(Figure 5.3B). Also, SHANK3’s proline rich domain binds to Homer1, which in 
turn binds mGLuR1 and mGLuR5 (Metabotropic glutamate receptor 1 and 5; see 
Introduction section 1.5b).  To quantify expression, I used confocal imaging to 
count the number of pre- and post-synaptic puncta present per 50µm of neurite 
(Figure 5.3C).  
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There was an increase in the synaptophysin and Homer1 puncta in the control as 
compared to SHANK3 patient neurons [Figure 5.3 C (I) and (ii)]. The average 
synpatophysin puncta per 50µm of neurite for control was 208.4 ± 13.98 while for 
SHANK3 it was 94.69 ± 6.698. This suggest that there are twice the number of 
presynaptic marker for control than SHANK3. Similarly, the average Homer1 
puncta per 50µm of neurite for control was 180.3 ± 10.89 on the other hand for 
SHANK3, it was 70.61 ± 5.955. This suggests that there twice the amount 
Homer1 present in control than the SHANK3 neurons. Thus, there were 
significant differences were found in expression of both pre- and post- synaptic 
markers (Figure 5.3C). 
 
This leads us to the conclusion that SHANK3 patient neurons show deficits in 
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Figure 5.3: Changes in the number of synaptic puncta in day 70 neurons: A, Day 70 control 
neurons stained with Synaptophysin (Presynaptic marker) and Homer1 (Postsynaptic marker).  B 
(I) Day 70 SHANK3 neuron stained with Synaptophysin (Presynaptic marker) and Homer 
(Postsynaptic marker). C(I) The average number of Synpatophysin puncta per 50µm, (ii) The 
average number of Homer1 puncta per 50µm. Significant differences in expression of both 
Synaptophysin and Homer1 were found ***p<0.001 (Unpaired student t test with Welch’s 
correction).  Data is expressed as mean±SD, A, B, Scale bar=10µm. We compared 4 control lines 
with 4 SHANK3 lines; 2 control lines with two clonal replicates and 2 SHANK3 lines with one 
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5.4: Cell soma changes in sporadic ASD patients 
 
Recently, in our lab we generated one sporadic ASD patient iPSC line.  I 
therefore wanted to test this sporadic ASD generated neurons that had similar 
morphogenetic phenotypes to the SHANK3 patient neurons. This will allow help 
determine if there are any common cellular mechanisms that contribute to the 
symptoms of ASD seen in both the genetic and sporadic form.  
 
I used high content screening to assess the number of primary neurites and cell 
soma area at day 27 and 30 of neuralisation. I compared three control lines to 
two sporadic ASD lines derived from one patient.  These were the following: 
Control P1 C1, Control P2 C2, and Control P1 C2 were compared to ASD P1 and 
ASD P1 C2. This analysis showed that there were no differences in the number 
of primary neurites between the control and ASD [Figure 5.4 (iii)], yet, there was 
a decrease in the cell soma area in the ASD patient lines (Figure 5.4 i, ii).  In 
figure 5.4(I), the cumulative frequency distribution graphs show that there is no 
difference between control and ASD at day 27. At day 30, the ASD distribution 
remains the same whereas the control neuron cell soma area distribution 
expands up to 600µm2 [Figure 5.4 (ii)].   This suggests that there might be some 
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Figure 5.4: Change in cell soma area in sporadic ASD patient neurons: (I) Cumulative 
frequency distribution of cell soma area at day 27. (ii) Cumulative frequency distribution of cell 
soma area at day 30. (iii) Primary number of neurites per neuron at day30 control versus ASD. 
We performed 3 biological replicates. We compared 3 control lines with 2 ASD lines. The 2 ASD 
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5.5 Discussion 
 
In this chapter, we discovered that the SHANK3 haplo-insufficiency in SHANK3 
patient neurons causes actin changes, such as loss F and G actin. Nonetheless, 
SHANK3 deficiency in patient neurons did not induce any protein translational 
deficits. In the next assay I tried to understand how change in morphology 
impacts synaptic development. I measured the number of synaptic puncta at day 
70 of neuralisation. It was shown that the SHANK3 patient neurons have lesser 
pre and postsynaptic puncta.  
Lastly, we tested a sporadic ASD line to see if it showed any morphogenetic 
deficits as in SHANK3 patient neurons. We found a decrease in cell soma area in 
the sporadic ASD patient line. This suggested that a smaller cell body could be 
thought of as a global cellular phenotype of ASD. 
 
5.5 (a): Association of actin to SHANK3  
 
In the introduction section 1.5c of this thesis, we described that SHANK3 played 
a dynamic role in cytoskeleton modeling. It does this by either binding to actin 
directly or indirectly through various actin-binding proteins.  For instance, 
SHANK3 binds to IRSp53 (the insulin receptor substrate of 53kDa) via proline 
rich domain and PDZ domain (Kreienkamp 2008).  F actin is modulated through 
IRSp53 in the dendrites through the WAVE2 complex (Choi et al., 2005). 
Therefore, we measured the levels of actin in our SHANK3 patient neurons to 
understand how it relates to the increased number of primary neurites, as shown 
in the SHANK3 patient neurons. Both G and F actin were increased in control 
neurons as compared to SHANK3 patient neurons at day 30.  Since the amount 
of G actin is lower in SHANK3, it stands to reason that there would be less F 
actin, as G actin polymerizes to form F actin (Figure 5; Lodish Harvey et al., 
2000).  
 
A previous study by Durand et al (2012) has linked alterations in F actin levels 
with alterations in SHANK3 expression. They studied the effects of SHANK3 
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overexpression on spine morphology in rat hippocampal neurons. The study 
showed an increased spine density and, not only did the F actin co-localize with 
SHANK3 in the spines but also there was an increase in its levels. Moreover, the 
increase in SHANK3 expression caused increase in the width of spines. This 
suggested an actin dependent mechanism for spine growth and enlargement.   
 
Two de novo human SHANK3 mutations (R12C and R3000C) were modeled in 
rodent hippocampal and cerebellar neurons (Durand et al 2012; Grabrucker et 
al., 2011). Both mutations showed a decrease in spines, which were then 
associated with a decrease in F actin. Furthermore, the frequency of mEPSCs 
(spontaneous excitatory post synaptic current) was decreased in these 
mutations. A network of both long and short F actin filaments is present in the 
dendritic spine underneath the PSD. Its function is to stabilize postsynaptic 
proteins and modulate spine head in response to synaptic signaling (Hotulainen, 
Pirta et al., 2010; Honkura et al., 2008; Kuni T et al., 2006). Thus, the authors 
proposed that the loss of SHANK3 causes loss of dendritic spines due to a 
decrease in F actin. This disrupts the spine’s ability to respond to postsynaptic 
signaling, which leads to aberrant electrophysiological changes that might 
underpin the behavioral symptoms of ASD.  
 
F actin staining has also been performed on various brain regions from Shank3 
deficient mice. A significant decrease in F actin staining was observed in the 
prefrontal cortex and hippocampus (Duffney L et al., 2015). Similarly, we report 
that SHANK3 patient hypothalamic neurons at day 30 show a decrease in F and 
G actin. 
 
In addition, the Shank3 deficient mice also showed social impairment and 
excessive self-grooming, both hallmarks of ASD, along with reduced NMDAR-
EPSCs in the prefrontal cortex (Duffney L et al., 2015). Alterations in NMDAR 
function are thought to be the underlying cause of these social deficits (Won et 
al., 2012; Duffney L et al., 2013; Duffney L et al., 2015). Several studies have 
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reported that SHANK3 connects to NMDARs using actin cytoskeleton (Duffney L 
et al., 2013; Rycroft et al., 2004; Michailidis et al., 2007).  Increased actin 
depolymerization leads to the loss of F actin that causes the disruption NMDAR 
membrane delivery leading to fewer NMDAR receptors (Rosenmund et al., 1997; 
Duffney L et al., 2013). This implies that SHANK3 deficiency causes a decrease 
in F actin, which leads to hypofunction of NMDARs that in turn might triggers 
social deficits.  As it has been reported that drugs acting on various NMDAR sites 
enhance its function and lead to significant recovery of social deficits in SHANK2 
mutant mice and other ASD animal models (Won et al., 2012; Moskal et 
al.,2011). 
 
Moreover, combined biochemical and molecular studies of SHANK3 have 
described many actin-binding partners such as SPIN90, profilin1 and 2, Mena, 
βpix, αfodrin, SPAR and Sharpin (Verpelli C et al., 2012; Han Kihoon et al., 
2013). For example, Arp2/3 (Actin-related protein 2/3 complex) mediates the 
nucleation of actin filaments to form branches (Krause M et al., 2014).  SPIN90 a 
known binder of SHANK3 activates Arp2/3 without preformed F actin filaments 
(Nolen Brad 2015). SPIN90 and Arp2/3 complex together initiate lamellopodia 
formation, which is the basis of neurite outgrowth (Kim DJ et al., 2006). 
Therefore, it is highly possible that the loss of SHANK3 might interrupt SPIN90, 
which can result in the neurite outgrowth deficits that have been reported in 
previous chapters (I discuss other possible mechanisms in depth in Chapter 6, 
the general discussion part of the thesis). 
 
Taken together the rodent studies above support our culture experiments on 
SHANK3 patient hypothalamic neurons, where we also saw a significant 
decrease in F actin and G actin. Thus, we can hypothesize that the deficiency of 
SHANK3 in SHANK3 patient neurons leads to a decrease in G and F actin, which 
could result in neurite outgrowth deficits and be the foundation of synaptic 
dysfunction. 
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5.5 (b): Global protein synthesis is not altered in SHANK3 patient neurons  
 
No global protein translational deficits seen in SHANK3 patient neurons 
suggesting that, at this stage of neuronal development, SHANK3 does not play a 
role in protein translation.  Indeed, previous studies have suggested an increase 
in protein translation in autism, particularly at the synapse (Kelleher et al., 2008). 
However, it is worth noting that our analysis was carried at a stage of neuronal 
development long before neurons are synaptically active. Preliminary data for the 
sporadic ASD line does show a decrease in protein translation rather than an 




5.5 (c): Synaptic changes associated with SHANK3 patient neurons 
 
At later stages of development (day 70), the SHANK3 patient neurons show a 
reduced number of synaptic punctas. I observed a decrease in synaptophysin 
(pre-synaptic) and Homer1 (post synaptic marker) as shown in figure 5.3.  
 
A similar occurrence has been reported in patients with Phelan McDermid 
Syndrome (PMDS). PMDS is a global developmental delay disorder, commonly 
known as 22q13 deletion syndrome. This region of the chromosome includes the 
gene SHANK3 and, as might be expected, most PMDS patients have autism 
(Shcheaglovitiv et al., 2013). A study on neurons generated from PMDS iPSCs 
revealed that these cells have a decrease in number of synaptic punctas of 
Homer1 and Synapsin (Shcheaglovitiv et al., 2013). Synapsin is found in the 
presynaptic vesicles of excitatory synapses and Homer1 is found at the 
postsynaptic terminal. Hence, both pre and post-excitatory synaptic markers 
were reduced indicating that there were fewer excitatory synapses in PMDS 
neurons.  The spontaneous EPSCs were also measured in these neurons and 
both their frequency and amplitude were found to be significantly reduced relative 
to controls (Shcheaglovitiv et al., 2013). The impairment of excitatory synaptic 
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transmission in PMDS neurons is linked to lesser number of synapses. If there 
are lesser number of presynaptic punctas, there will be a lesser release of 
neurotransmitter which would result in lesser receptor binding in the plasma 
membrane of the post synaptic terminal. No secondary pathways would activate 
to initiate excitatory response. Thus, leading to an impaired synaptic 
transmission.    
 
Furthermore, this can also be connected to the “synaptic hypothesis” as the 
underlying mechanism of autism (Introduction, Section 1.3.1), which suggests 
that a decrease in synaptic number causes synaptic dysfunction, which leads to 
autistic symptoms.  
 
Many rodent studies of Shank3 KO have also reported electrophysiological 
disruptions, such as reduction in amplitude and frequency of EPSCs, paired 
pulse ratio, fiber volley and population spikes in hippocampal neurons (Jiang et 
al., 2013). However, in striatal Shank3 KO rodent neurons only EPSCs were 
affected and not the paired pulse ratio. This suggested that different regions of 
the brain may respond differently to the loss of Shank3 (Peca et al., 2012). In 
addition to the synaptic phenotype, Shank3 KO rodents also exhibit autism like 
behavior such as social reclusiveness and repetitive behavior in terms of 
excessive social grooming. The conclusion we can draw is that the loss of 
Shank3 disrupts synaptic transmission and this leads to autistic symptoms.  
 
In the introduction (1.3.2), I proposed that that the fundamental cellular 
mechanism behind autism is abnormal cellular growth, and this causes synaptic 
dysfunction, which leads to symptoms of autism. For instance, Peca et al. (2012) 
described increased dendritic length and arborization of striatal neurons in 
Shank3 KO mice. The same neurons also revealed decrease in frequency and 
amplitude of mEPSC. Moreover, these Shank3 KO mice displayed autistic 
behavior like excessive self-injurious and grooming behavior. Therefore, 
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establishing a pattern, where aberrant neuronal structure leads to changes in 
synaptic transmission, which could cause autistic behavior.  
 
Similarly, in our study, the decrease in Homer1 and Synaptophysin could indicate 
that SHANK3 patient hypothalamic neurons have significantly fewer excitatory 
synapses than controls. These could lead to electrophysiological deficits. 
Therefore, in our SHANK3 patient neurons, the hypothesis is that SHANK3 
haplo-insufficiency causes morphogenetic deficits leading to changes in both the 
number and expression of synaptic markers. These could affect synaptic 
transmission, which could produce autistic symptoms.  
 
In conclusion, published data and the data presented in this chapter suggest that 
loss of SHANK3 results in abnormal neuronal structure that causes synaptic 
dysfunction, which leads to behavioral changes. 
 
 
5.5 (d): Decrease in cell soma area a global ASD phenotype 
 
In the SHANK3 patient neurons we reported a decrease in cell soma area 
(Chapter 3, section 3.2). Similarly, we tested whether the sporadic ASD line 
showed a similar morphogenetic deficit. During our analysis we found that the 
sporadic ASD line also shows a decrease in cell soma area (Figure 5.4). 
 
Recently, a study characterized the volume of neuronal nucleus and cytoplasm of 
autistic subjects in sixteen different brain regions (Wegiel et al., 2015). Post 
mortem tissue was obtained and analyzed. In this study, they not only examined 
tissue from early childhood, but also studied tissue from autistic adolescents and 
autistic adults.  They observed the following pattern of nuclear and cytoplasmic 
changes. First, severe volume deficits were reported in both the nucleus and 
cytoplasm. These deficits were shown in thirteen out of the sixteen brain regions 
that were examined. Second, all these deficits were reported in early childhood 
from the ages of four to eight. Thus, suggesting developmental abnormalities 
begin before the age of three. Third, there was a significant increase in the 
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volumes of both the cytoplasm and nucleus during adolescence (11 to 23 ages) 
in eleven of the sixteen brain regions examined. This increase in nuclear and 
cytoplasm volume bought it closer to the level of control samples. No volumetric 
changes were observed in controls throught the various stages of development. 
In addition, no volume modifications were reported in adult autistic brains (Wegiel 
et al., 2015).   Therefore, this indicates that the ASD patient nucleus and cell 
soma takes longer to develop, as the initial volume was smaller during early 
childhood and then increased to normal levels at later stages of adolescents. 
Also, these volumetric changes in neuronal soma were correlated with changes 
in chromatin organization, which impacts neuronal development and maturation.  
 
Thus, these observations suggest that in people suffering from autism neurons 
fail to develop normally and if the neurons don’t mature properly they are bound 
to have functional deficits, which could lead to autism (Wegiel et al., 2015).   
 
Another interesting fact found in the Wegiel et al (2015) study was the size of the 
neurons. If we make the assumption that the neuron cell soma is a sphere and 
convert these cytoplasmic volumes into area, the area ranges from 112µm2 to 
600 µm2 for the control cohort (ages 4-8) and for the ASD cohort the area was 
from 87µm2 to 477µm2. Similarly, in our study of iPSC generated neurons I 
reported the following cell soma area ranges: for control cohort 105µm2 to 
600µm2, for the sporadic ASD patient 163µm2 to 492µm2 and for the SHANK3 
patient neurons 103µm2 to 476µm2.  Not only do these findings validate our data 
but also suggest a common cellular mechanism that effects the development of 
the cell body of a neuron. 
 
An additional study of human neural progenitor cells originating from the fetal 
cerebral cortex was reported. The exposure of these cells to the serum of a 3 
year old autistic donors. This increased the percentage of small sized neurons 
(Mazur-Kolecka et al., 2007). Hence, suggesting that neuronal size deficits occur 
in autistic children and begin from early development. 
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Co-morbid studies of autism like Rett’s syndrome and Fragile X syndrome have 
also reported cell soma size deficits (Brennand et al., 2012). Similarly, our study 
has shown a decrease cell soma area in both sporadic ASD and SHANK3 patient 
neurons.   
 
Taking all of these studies into account, a decrease in cell soma area could be 
thought of as a global cellular phenotype of ASD. Having said that, we still need 























	   147	  
In conclusion, I have described pilot experiments that could provide us with a 
possible mechanism on how the morphogenetic deficits occur in the SHANK3 
patient neurons. The neurite outgrowth deficits in the SHANK3 patient neurons 
could be linked to the loss of F and G actin, which involves a SHANK3-actin-
binding, mediated mechanism.  We also found out that the morphogenetic 
deficits in the SHANK3 patient neurons could contribute to synaptic development. 
As I reported a decrease in pre and postsynaptic number; this could have an 
implication in normal synaptic transmission, which could lead to autistic 
behavioral changes. Finally, the decrease in cell soma area in the sporadic ASD 
line shows a global ASD phenotype. This insinuates a common cellular 
mechanism that contributes to the symptoms of ASD, seen in both the genetic 
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Chapter 6  
General Discussion 
 
In this thesis, I described experiments showing that SHANK3 patient 
hypothalamic neurons show morphogenetic deficits early in development and 
these can be rescued by enhancing the SHANK3 expression. Later in 
development, these neurons also exhibit synaptic deficits, such as a decrease in 
pre and postsynaptic density.  This also has been reported previously in Phelan 
McDermid Syndrome iPSC generated neurons (Shcheglovitov et al., 2014) 
Neurons generated from sporadic ASD iPSCs were also observed to have a 
smaller soma size when compared with control neurons, raising the possibility 
that this soma size change could be a global ASD phenotype.  
 
Reduced expression of SHANK3 expression causes the morphogenetic changes 
as mentioned above, therefore in order to develop effective treatments, it is 
important to understand the mechanisms by which these defects arise. 
The first four sections of this chapter 6, will discuss the possible mechanisms 
behind the morphogenetic phenotypes as observed in SHANK3 patient neurons. 
The last section will discuss the possible translational research approaches.  
 
6.1: How can SHANK3 influence neurite outgrowth? 
 
Dynamic re-arrangement of cytoskeletal components is essential for the process 
of neurite outgrowth (Yuh Nung et al., 2010). As described in the introduction 
(Section 1.5), the SHANK3/PROSAP2 protein has various binding partners. 
Some of these include actin cytoskeletal proteins. Recently, gene ontology and 
pathway analysis in rodents have suggested that regulation of actin cytoskeleton 
is the principal role of the Shank3 protein (Han et al., 2013). Actin cytoskeleton is 
important for maintaining the cell’s shape and function.	  Moreover, overexpression 
of Shank3 in cultured mouse hippocampal neurons showed that Shank3 
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localized to the growth cones, suggesting that it might participate in neurite 
extension (Durand et al., 2012).   
 
Through immunoprecipitation and yeast two-hybrid screening, SHANK3 has 
been found to interact directly with two subunits of the Arp2/3 complex (Actin-
Related Proteins ARP2 and ARP3), namely ARPC2 and ARPC5L (K. Han et al., 
2013). The Arp2/3 complex consists of seven subunits that initiate nucleation and 
branching of F actin. This helps form neurites in neurons (Campellone KG et al., 
2010). 
 
It was shown in a rodent model of Shank3 duplication that ARPC2 binds with 
SHANK3, which would suggest that SHANK3 could act as a scaffold that brings 
WASF1, cortactin and ARPC2 to facilitate actin rearrangement (Figure 6.1; 
K.Han et al., 2013; Proepper C et al., 2007; Naisbitt S et al., 1999). As we know, 
actin plays a major role in many important cellular processes, including, cell 
signaling, cell motility, cell division, organelle and vesicle movement, and the 
establishment of cell junctions and cell shape (Doherty, Gary J et al., 2008). 
Therefore, one could explore the various aspects of this scaffold in order to 
understand the role of Arp2/3 complex in neurite outgrowth. In particular, does 
this SHANK3 –cortactin-WASF1-Arp2/3 complex exist in human neurons? Also, 
how does it impact actin re-arrangement in SHANK3 patient versus control 
neurons and does it contribute to the phenotype I see in our cells?  To answer 
such questions, we could assess gene and protein expression (for cortactin, 
WASF1 and Arp2/3) using real time PCR and western blots, followed by 
assessing the binding of this complex via immunoprecipitation in both control and 
SHANK3 neurons. This could point us in the direction of the mechanism behind 
the neurite changes I saw in SHANK3 patient neurons. 
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Figure 6.1: Proposed mechanism of SHANK3 in actin regulation: The Diagram above 
illustrates the various SHANK3 interactions with other proteins which help regulate F actin. 
SHANK3 binds to ßpix which binds Rac1, Pak1 and activates Limk which inhibits cofilin, cofilin 
causes disassembles actin filaments. The disassembled actin can be used by the Arp2/3 complex 
to make new branches (Duffney L et al., 2015). 
 
 
Two key players in actin dynamics are Rac1 (Ras-Related C3 Botulinum Toxin 
Substrate 1) and Cdc42 (Cell division control protein 42 homolog). They act as 
coordinators in neurite outgrowth, spine development, dendrite initiation, 
elongation and branching complexity (Duffney L et al., 2013). It has been shown 
that βPIX, the guanine nucleotide exchange factor for Rac1 coupled with PAK, 
interacts with SHANK3 at the synapse (Manser et al., 1998; Park et al., 2003).  A 
recent study indicated that Shank3-deficent mice exhibit a decrease in the levels 
of βPIX and that this, in turn, leads to a decrease in Rac1 activity. This further 
resulted in a decrease in the levels of downstream targets such as PAK1/2/3 
[(P21 Protein (Cdc42/Rac)-Activated Kinase 1)] and LIMK (LIM Domain Kinase 
1). A key downstream target of PAK1/2/3 and LIMK is cofilin, an actin-
depolymerizing factor that is inactivated when phosphorylated by LIMK at 
Serine3 (Bamburg et al., 1999; Duffney L et al., 2013;Duffney L et al., 2015. So 
when levels of LIMK decrease, more cofilin remains in the active state resulting 
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in increased depolymerisation of actin (Figure 6.1). Duffney L et al., 2015 showed 
that Shank3 deficient mice had decreased levels of F actin and behavioral 
deficits. They found that this was due to a decrease in SHANK3, which cause a 
decrease in the expression Rac1-PAK1-LIMK pathway. This all lead to an 
increase in cofilin.  So, they used an endogenous inhibitor of cofilin (Ser3-
phosphorylated cofilin to stabilize actin filaments. This stabilized F actin and 
rescued the behavioral deficits reported in Shank3 deficient mice (Duffney L et 
al., 2015). 
 
The next question that arises is: how does this link back to the increased number 
of primary neurites I see in our SHANK3 patient cell lines? To answer this 
question, we would first need to understand the mechanism behind how Arp2/3 
complex modulates actin to forms branches.  
 
In chapter 5, I discussed that G actin polymerizes into F actin (Figure 5). The F 
actin has two ends pointed and barbed.  The barbed end grows faster than the 
pointed end. Three G actin monomers are associated together in order to 
generate F actin filament. This process is called nucleation, and the actin 
filament generated is known as a primer (Krause M et al., 2014; Achard, V. et al., 
2010). The role of Arp2/3 complex in generating branches is as follows, when 
activated the Arp2/3 complex binds to preexisting actin filament (primer), and 
undergoes a conformational changes. The conformational change is such that it 
mimics the barbed end of the F actin filament, from which an actin filament 
(primer) can be elongated (Figure 6.2 A). Elongation of actin filaments (primer) is 
the addition of monomeric form of G actin at the barbed end. The new actin 
filament generated through this process is anchored via the pointed end to 
preexisting actin filament. Thus, the Arp2/3 complex can create actin branch 
networks (Krause M et al., 2014). The elongation process can be blocked by 
capping proteins. However, elongation can be enhanced with the help of 
elongation proteins such as ENA/VASP and Formin (Krause M et al., 2014).  
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As described above, the Arp2/3 complex binds to the side of pre-existing F actin 
filaments called primers. This causes it to undergo conformational changes to 
elongate actin filaments to (Polland TD 2007; Krause M et al., 2014). There are 
currently three proposed mechanisms suggested for Arp2/3 that cause the 
elongation of actin filaments (primers) into branches. These are shown in Figure 
6.2B. For the purpose of this discussion, I am mainly concentrating on the cofilin 
pathway as it links back to SHANK3. 
 
In the cofilin-mediated pathway, cofilin severs the actin filaments, which 
generates more actin filaments or primers. These uncapped filaments are 
elongated by the Arp2/3 complex. This process helps forms neurites (Ichetovkin I 
et al., 2002; Chen Q et al., 2013; Krause M et al., 2014). Indeed, in the brains of 
cofilin knock out mice, drastic cortical hypoplasia and ventricle expansion is 
observed. Morphologically, phenotypes such as reduced axonal tract formation, 
irregular neuronal migration and complete ablation of neurite processes were 
also reported (Flynn et al., 2012).  
 
I have already discussed how lack of SHANK3 results in an increase in activation 
of cofilin. Therefore, I can postulate that this causes increased severing of F actin 
filaments that could then be elongated via the Arp2/3 complex, leading to 
increase in the number of neurites I see in our patient neurons. To confirm this, 
cofilin inhibitors could be added to SHANK3 patient neurons, more cofilin would 
be inhibited leading to fewer neurites. This would be detected using  
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Figure 6.2: Priming of Arp2/3 complex leading to elongation. A. Shows the Arp2/3 
conformational change leading to elongation, creating new branches. B. The diagram above 
explains the three possible mechanisms through which Arp2/3 forms new branches .Adapted 
from	  Krause M et al., 2014. 
 
 
Another protein that links SHANK3 (Figure 6.1) to actin complex is Abp1 
(Haeckel A et al., 2008). Abp1 binds to SHANK3 and helps the Apr2/3 complex 
elongation. Both cortactin and Abp1 play a role in neurite outgrowth. It has been 
shown that the depletion of Abp1 results in increased axonal length during the 
early stages of development in rodents (Pinoyl R et al., 2007; Hering H et al., 
2003). Since SHANK3 binds to Abp1, we could consider that the decrease of 
SHANK3 in patient neurons would lead to a decrease in Abp1, which would 
increase neurite length. Again, to fully consider this as an explanation, we verify 
the interaction between SHANK3 and Abp1 in hiPSC-generated neurons via co-
immunoprecipitation.  I could then increase the expression of Abp1 using a 
genetic construct like I did for SHANK3 (Chapter4; Figure 4.0) and see whether 
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Densin -180 binds to the SH3 domain and N terminal ANK domain of SHANK3 
protein to antagonize dendritic branching. SHANK3 binds to the C terminus of 
densin-180, making the PDZ domain of densin-180 inaccessible to δcatenin. 
δcantenin binds with densin-180 and is required for the formation of new 
branches (Quitsch et al., 2005). Moreover, it has been shown that the 
overexpression of densin-180 causes excessive neuronal branching in rodent 
hippocampal neurons. These same neurons were then transfected with 
SHANK3, which lead to abrogation of dendrite formation and also lead to 
translocation of densin-180 to postsynaptic clusters (Quitsch et al., 2005). The 
hypothesis for increase in primary number of neurites as reported in SHANK3 
patient neurons would be as follows: SHANK3 deficiency leads to more densin-
180 being accessible to bind to δcatenin which causes an increase in neurite 
formation. The experiment to test this hypothesis would be to block the binding of 
densin-180 and δcatenin. This can be done by using the δcatenin inhibitor, 
namely PP2 (kinase inhibitor). It has been shown in PC12 cells that 
overexpression of δcatenin leads to neurite formation which is disrupted by 
kinase inhibition (Martinez, M. C et al., 2003). Therefore, using 
immunocytochemistry and high content screening, I can administer the PP2, to 
see if it decreases neurite formation in SHANK3 patient neurons.  
 
In conclusion, the above section discusses several possible ways in which the 
loss of SHANK3 would lead to the morphological alterations observed in our 
SHANK3 patient neurons. These potential mechanisms would need to be further 
investigated to fully understand the role of SHANK3 in the structural development 
of the neuron and to develop potential drug therapies for autism. 
 
6.2:  How is neuronal migration linked to SHANK3? 
 
My research revealed that the rate of cell soma movement is significantly lower in 
the SHANK3 patient neurons than the control neurons (Figure 3.2.3 and 3.2.4) 
and I suggested that this might reflect changes in neuronal migration. This 
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section discusses the three possible mechanisms by which immature neurons 
migrate and how it can linked to SHANK3 haplo-insufficiency. 
 
 In Chapter 3, I reported that the neuralisation protocol used in this thesis 
generates GnRH1 positive neurons (Figure 3.2.1). The first two possible 
mechanisms focus on the GnRH neuron in particular, as they are known to 
migrate from the olfactory placode to the hypothalamus (Wierman, Margaret E et 
al., 2011). 
 
The first mechanism describes that gonadotropes, endocrine cells in the anterior 
pituitary, release the hormone GnRH that phosphorylates Cortactin (cortical actin 
binding protein, Figure 6.3 A). Phosphorylation of cortactin activates the protein.   
Cortactin is a protein often found in the periphery of the cell that is activated by 
external stimuli and promotes actin polymerization (Navaratil et al., 2014). This 
protein is involved in the formation of lamellipodia and is therefore involved in the 
process cell migration (Navaratil et al., 2014). Cortactin is a known binder of 
SHANK3 [Introduction, Section 1.5(c); Verpelli et al., 2012] and links to Arp2/3 
complex to promote cell soma locomotion (Navaratil et al., 2014). Thus, a 
potential explanation for SHANK3 patient neurons showing less cell soma 
movement, could be that decrease in SHANK3 causes a decrease in cortactin. 
Hence, resulting in less of cortactin being available to form a complex with 
Arp2/3. This could result in lesser cellular locomotion, particularly in SHANK3 
patient GnRH positive neurons.  
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Figure 6.3: Possible mechanisms of GnRH neuron migration. A GnRH neuron releases 
GnRH which causes phosphorylation of cortactin to enable it to bind to the Arp2/3 complex 
increasing the formation of lamellipodia. B. FGF8 induces Sirt1 translocation from the nucleus to 
the cytoplasm where it deacetylates cortactin, to enable it to bind to the Arp2/3 complex which 
causes the GnRH neuron to migrate. From previous studies I know that cortactin binds to 
SHANK3 via its proline rich domain. (L Cramer 1997; Santé et al., 2015; Navaratil et al., 2014) 
 
The second mechanism through which GnRH neurons migrate is shown in figure 
6.3B. Here, FGF8 (fibroblast growth factor8) causes the Sirt1 (Sirtuin1) gene to 
translocate from the nucleus to cytoplasm. Sirt1 deacetylates and activates 
cortactin (Santé et al., 2015), which binds to SHANK3 to promote cell migration 
(Nasbitt et al., 1999). Since SHANK3 binds to cortactin and the SHANK3 patient 
neurons have less SHANK3, they would be expected to have less cortactin, 
which in turn could lead the lower levels of migration observed in SHANK3 
patient neurons (Chapter 3, Section 3.2.3).  
 
There is a distinct possibility that these two migration mechanisms involving the 
cortactin pathway are linked. It has been shown that FGF8 regulates the release 
of GnRH during early embryonic development (Falardeau J et al., 2008; Tsai et 
al., 2005). Therefore, the proposed mechanism would be that FGF8 increases 
the expression of GnRH hormone and induces Sirt1. They both activate cortactin 
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that binds to SHANK3. The cortactin-SHANK3 complex binds to Arp2/3 complex 





Figure 6.4: SHANK3-Abi complex triggers activation of Arp2/3 complex for cellular 
migration. Abi binds to the EVH1 domain of ENA/VASP. This activates the WAVE complex 
leading to the activation of the Arp2/3 complex (Chen X et al., 2014). 
 
 
The third mechanism (Figure 6.4) for cellular migration relating to SHANK3, 
involves the Abi protein (Abelson interactor).  The Abi proline rich domain binds 
to the EVH1 domain of ENA/ VASP proteins (Chen XJ et al., 2014) and these 
proteins are involved in cell motility through their ability to activate the WAVE 
regulatory complex (WRC) (Chen XJ et al., 2014). Therefore, Abi binds SHANK3 
(C Proepper et al., 2007) and ENA/VASP, which activates WRC, initiating the 
Arp2/3 complex resulting in actin polymerization and leading to cell migration. As 
we know, SHANK3 binds to Abi and in SHANK3 patient neurons there is less 
SHANK3, therefore there could also be reduced levels of Abi. This would result in 
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less of this protein being available to bind to ENA/VASP leading to reduced 
activation of both the WRC and Arp2/3 complexes. Altogether, this could cause 
reduced cellular migration in SHANK3 patient neurons.  
 
An interesting point to note is that, SHANK3 binds to βpix, which mediates cofilin 
through Rac1 (see Section 6.1). This was the mechanism proposed to be behind 
the neurite morphology seen in SHANK3 patient neurons. The βpix and Rac1 
pathway also activates the WRC complex, leading to activation of the Arp2/3 
complex (Figure 6.4). This suggests that these two pathways are interlinked and 
could likely contribute to both increased primary number of neurites and 
decreased cell soma movement in the SHANK3 patient neurons.  
 
6.3: Cell soma size and Autism  
 
The smaller cell soma size phenotype has been described in cortical and 
subcortical regions of the brain for both syndromic and non-syndromic autism 
(Bauman and Kemper 1995; 2005; Van Kooten et al., 2005; Casanova et al., 
2002; 2006; Wegiel et al., 2010; 2015). There are currently three main 
hypotheses that explain why the cell soma is smaller in autistic patients.  
 
The first is of “development arrest or delayed development” (Wegiel et al. 2010, 
2015) where cell soma and nuclear volume were reported to be smaller during 
the first stages of development  (4 to 8 years) but become normalized to control 
levels by the age of puberty (14 to 23 years). This suggests a development or 
growth delay in autism patients.  
 
The second hypothesis is “abiotrophy”; this simply implies that there are 
regressive changes in the cell that causes it to wither (Casanova et al., 2013). 
These regressive changes are thought to be due to oxidative stress, reduced 
protein synthesis, lack of nutrients and growth factors. In autism, abiotrophy has 
been reported mainly in the cerebellum (Basson et al., 2013). Autistic children 
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often report deficits in motor coordination, this could be because of deficits in the 
cerebellum (Becker et al., 2013). 
 
Moreover, increased oxidative stress, which causes abiotrophy has been related 
to autism (Chauhan A et al., 2006; Ghanizadeh et al., 2012).  Additionally, it was 
observed that autistic children have 20-40% lower levels of glutathione in 
plasma. Glutathione is the main antioxidant found in the brain used for 
neutralizing reactive oxygen species. Due to lower levels of glutathione in 
plasma, there are more oxygen reactive species, which leads to oxidative stress 
causing the withering of the cell (Kern et al., 2011). This could then result in a 
decrease in cell soma.  
 
The third hypothesis simply suggests that the smaller cell size is due to hyper 
connectivity of the brain (Casanova et al., 2011, 2013). In essence, the smaller 
cell soma is a compensation mechanism for the longer-range projections, which 
are metabolically expensive (Casanova et al., 2011, 2013).  This fits perfectly 
with our study, as I report that there is a decrease in cell soma area but an 
increase in neurite length and number, in our SHANK3 patient neurons.  The 
maintenance of longer neurites requires a lot more nutrients and energy resulting 
in a smaller cell soma in the SHANK3 patient neurons. Additionally, 
mitochondrial, the organelle that produces energy in the cell has been reported 
dysfunctional in autistic children (Rossignol, D A et al., 2012). 
 
In conclusion, all three hypotheses have merits and experiments would be 
designed to specifically address which of these hypotheses is the cause of the 
decrease in cell soma area. The hypothesis that relates most to the phenotype 
seen in the SHANK3 patient line, is the third one as it connects the change in cell 
soma area to neurite outgrowth.  
In the next section, I look at the mechanism related to SHANK3 that could 
influence the cell soma area phenotype.  
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6.4: Possible mechanism on how SHANK3 contributes to cell soma size 
 
The size of cell soma is determined by both intrinsic and extrinsic signals (Alison 
C Lloyd 2013). Very few studies have characterized regulatory pathways that 
control cell growth. There are two possible mechanisms through which SHANK3 
could influence this pathway such that, it disrupts cell soma morphology (see 
Figure 6.5). 
 
The first mechanism involves IGF1 (insulin growth factor1) activating the 
PI3K/AKT/mTORC1 pathway to facilitate neuronal growth (Wang, Y et al., 2014). 
Various studies have shown that IGF1 rescues the phenotypes produced by 
SHANK3 deficiency such as decrease in synaptic puncta and synaptic 
transmission deficits (Shcheglovitov et al., 2013; Bozdagi et al., 2013). Thus, 
suggesting a link between IGF1 and SHANK3, although the mechanism behind 
this link is, at present, unknown. I hypothesize that the SHANK3 haplo-
insufficiency in SHANK3 patient neurons causes a reduction in the levels of 
IGF1, leading to smaller cell size. I tested this hypothesis analyzing the change in 
cell soma area after the administration of IGF1 (Chapter 4, section 4.3).  
However, I was not able to rescue the cell soma area phenotype in the SHANK3 
patient neurons. This does not mean that the hypothesis is not valid, as there 
could be some dosage issue, which due time constraints could not be tested. For 
example, I could increase the concentration of IGF1 used and/or increase the 
dosage period to determine whether this results in rescue of the cell soma area 
phenotype.  
 
In the above section I describe abiotrophy as one of the causes of decreased cell 
soma size in autism. One of the main pathways regulated by growth factors and 
oxidative stress is the mTORC1 pathway (Alison C Lloyd 2013). Thus, another 
potential cause of the observed decrease in soma size could be an increase in 
oxidative stress in the SHANK3 patient neurons that inhibits the mTORC1 
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pathway (Sengupta et al., 2010). To determine whether this is feasible, the 
oxidative stress of the cell should be measured. This can be done by high 
content screening of neurons at the various stages of neuralisation. For instance, 
the application of a fluorogenic probe to cells that are non-fluorescent in a 
reduced oxidative state but turn bright green, orange or red upon oxidation 
(CellROX® Deep Red Reagent ThermoScientific). This intensity can then be 
measured as the readout of oxidative stress in neurons. This approach could not 
only inform us about their oxidative stress but also allow us to correlate it to the 
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Figure 6.5: Possible mechanisms linking SHANK3 to cell growth: IGF1 activates the 
PI3K/AKT pathway which in turn results in mTOR activation. This leads to activation of genes that 
promote cell growth and proliferation. Various research studies have shown that IGF1 rescues 
phenotypes associated with the loss of SHANK3, linking these two protein through an unknown 
mechanism. SHANK3 may also influence the PI3K/AKT pathway via mGluRs that are known to 
bind SHANK3 through its proline rich domain via Homer1. mGluRs cause the release of calcium 
from endoplasmic reticulum which activates the ERK pathway. This in turn leads activation of cell 
proliferation (growth too) genes through via mTORC1 and MnK (Alison C Lloyd 2013; Kelleher et 
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An alternative means by which SHANK3 could influence cell growth is via the 
interaction of its activation of metabotropic glutamate receptors (mGluRs). This 
activation of mGluRs leads to calcium release from the endoplasmic reticulum, 
which initiates ERK signaling leading to activation of the mTORC1 pathway. In 
this scenario, a decrease in SHANK3 would cause less activation of mGluR 
receptors, leading to a reduction in the activation of the mTORC1 pathway and 
hence a decrease in cell growth. For this hypothesis to be plausible, I would 
assess mGluR expression and activity throughout the various stages of neural 
development and determine whether this correlates with SHANK3 expression 
and the development of the cell soma phenotype.  This could be achieved via 
qPCR to discover when mGluR expression occurs during the neuralisation 
process, co-immunoprecipitation assay to confirm that SHANK3 binds to mGluR 
at that stage, and to check if there are any changes in the level of protein or 
mRNA levels of mGluR between the control and SHANK3 patient neurons.  If 
there is a decrease in expression levels of mGluR, then I can rescue the cell 
soma area phenotype with an mGluR agonist. There is also the possibility that 
the expression levels of mGluR are normal, but it is the activation itself that is 
affected. This can be tested by stimulating both the control and SHANK3 neurons 
with mGluR agonists and check if it increases the expression of mGluRs after 
stimulation.  
 
6.5: Possible drug targets for ASD 
 
There are only two drugs that are given to improve symptoms associated with 
ASD by the US FDA; aripiprazole (Abilify) and risperidone (Risperdal). Both of 
these act as dopamine antagonists and are given for correcting irritability and 
obsessive behavior (McPheeters et al., 2011). None of these target social and/or 
cognitive impairments in ASD. In the section below, I discuss a number of 
potential candidates’ drugs for autism specific symptoms. Most of the drug 
candidates described below relate back to mechanisms behind the 
morphogenetic phenotypes seen in SHANK3 patient neurons. 
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6.5 (a) Glutamate receptor agonists  
 
mGluR1 and mGLuR5 are metabotropic glutamate receptors that are physically 
connected to NMDARs via Homer1-SHANK3 and GKAP-PSD95 interactions 
(Verpelli et al., 2011; Naisbitt et al., 1999). Also, mGluRs are known to 
functionally potentiate NMDAR function (Won et al., 2013).  There are two 
potential theories on why agonists of this receptor could possibly work as a drug 
for SHANK3 caused Autism.  
 
First, the loss of Shank3 in mutant mice is known to reduce the expression of 
both metabotropic and ionotropic glutamate receptors mGluR5, GluA1, GluN2A, 
GluN2B, and GluA2 (Table 1.3; Verpelli et al., 2011; Wang et al., 2011; Yang et 
al., 2012; Bozdagi et al., 2010; Peca et al., 2011; Schmeisser et al., 2012). This 
loss of expression causes synaptic deficits such as decrease in frequency of 
EPSCs (Verpelli et al., 2011). Therefore, treatment with a glutamate receptor 
agonist might restore the expression levels to normal and alleviate the deficits in 
synaptic transmission. In the schizophrenia model of rat, the mGluR agonists 
increased the expression of NMDAR and enhanced its transmission (Dong et al., 
2011).  
Second, mGluR activation releases calcium from the endoplasmic reticulum, 
which leads to the activation of the ERK pathway leading to cell growth (see 
Section 6.4, Holbro et al., 2009). Also, we know that knockdown of SHANK3 in 
mice leads to a decrease in mGuR5 expression (Verpelli et al., 2011). I 
hypothesize that this may lead to a reduction in activation of mTORC1 pathway 
via the ERK pathway and cause a decrease in cell soma area (section 6.4). 
Hence, an increase in mGluR activation via treatment with mGluR agonists could 
increase the activity of the ERK pathway, leading to growth of the cell soma of 
SHANK3 patient neurons. 
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There are a large number of mGluR5 allosteric modulators available and four of 
these are known to cross the blood brain barrier (William DL et al., 2005; Gregory 
KJ et al., 2011) - CDPPB, MPPA (2-(3-mercaptopropyl) pentanedioic acid), 
ADX47273 (Acidovorax avenae subsp. avenae ATCC) and VU0092273 [(4-
Hydroxypiperidin-1-yl)(4-phenylethynyl) phenyl methanone] (Won et al., 2013).  
Treatment of wild type mice with CDPPB and ADX47273 result in an enhanced 
performance in novel object recognition, learning and memory tasks. In cells, 
these drugs facilitate LTP and LTD in the hippocampus (Ayala et al, 2009; Liu et 
al., 2008; Uslaner et al., 2009).  Treatment with CDPPB of a mouse model of 
autism and intellectual disability, due to the heterozygous deletion of TSC2 leads, 
resulted in a rescue of the cognitive impairment (Auerbach et al., 2011; Won et 
al., 2013). Also, social deficits in Shank2-/- mice were alleviated with CDPPB 
(Won et al., 2012). Thus, I could use CDPBB as a potential drug to rescue the 
morphogenetic phenotype seen in SHANK3 patient neurons.  
 
6.5 (b) Cofilin inhibitors  
 
Shank3 deficient mice exhibit autism like social deficits and repetitive behavior as 
well as significantly diminished NMDA receptor function (Duffney et al., 2013). 
These behavioral phenotypes were associated with actin filament loss and 
reduced activity of the Rac1/PAK pathway leading to an increase in cofilin activity 
(Figure 6.1; Duffney et al., 2015; 2013).  Using this information, I propose that 
reduced Rac1 activity would result in increased cofilin activity and that this could 
result in an increased number of primary neuritis, as seen in the SHANK3 patient 
neurons (section 6.1). A Cofilin inhibitor was shown to rescue both the social 
deficits and NMDA synaptic dysfunction in Shank3 deficient mice (Duffney et al., 
2015), it would be reasonable, as a next step, to ask whether cofilin inhibitors 
such as Cytochalasin-D and/or Cucurbitacin E (Shoji Ket al., 2012; Nakashima et 
al., 2010) could rescue the morphogenetic phenotype observed in our SHANK3 
patient neurons. I reason that these drugs will decrease cofilin activity and this 
will stop the excessive severing of F actin filaments, resulting in the stabilization 
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of neurites in the SHANK3 patient neurons (section 6.1). The first experiment I 
would perform, is to test if cofilin is increased in human SHANK3 deficient patient 
neurons, as SHANK3 deficiency might have a different effect on human neurons 
than Shank3 mutant rodent neurons.  This could easily be assessed via western 
blotting [Examples of good coflin antibodies -Cofilin (D3F9) XP® Rabbit mAb and 
anti-Cofilin antibody (ab42824)]. Secondly, if we can confirm that there is an 
increase in cofilin levels, we can then use these inhibitors on SHANK3 patient 
neurons to see if it rescues the neurite related morphogenetic deficits.  
 
6.5 (c) Oxytocin 
 
Oxytocin is a neuropeptide hormone released from the magnocellular cells of the 
hypothalamus (Won et al., 2013). Oxytocin is mainly associated with social 
behavior including affiliation, pair bonding, aggression and maternity (Won et al., 
2013; Liu et al., 2010; Jacob et al., 2007). Oxytocin receptor (OXTRs) knockout 
mice display autistic behavior and also several mutations in OTXRs are 
associated with ASD. Nasal administration of oxytocin improved social interaction 
and communication and reduced self-injurious repetitive behavior in ASD 
individuals (Kosaka et al., 2012; Andari et al., 2010). Though, the molecular 
pathway of this is not fully understood, we can still apply this drug to the SHANK3 
patient neurons to see if this rescues the observed morphogenetic deficit and 
study the cellular mechanism through which it acts. This will lead to a better 
understanding of the action of oxytocin in neurons and could also be used as a 
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In conclusion, this thesis presents the novel idea that SHANK3 haplo-
insufficiency causes early structural deficits in neurons. This project has not only 
defined a critical period during development when cellular deficits occur in ASD 
but has also determined a period for successful rescue of these. I have provided 
some evidence that these early morphogenetic deficits can later produce 
changes in the number of synapses, which is commonly reported in autism 
(Jiang et al., 2013). Moreover, I have successfully modeled autism using iPSCs 
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Supplementary figures  
 




Table 2.0: Taqman Assay values: Table below describes the values obtained for each probe for 
control gDNA, SHANK3 patient 1 and 2. The probe value between 1.5 to 2 is considered as both 
copies of SHANK3 are being expressed, while values less than 1.5 is considered as deletion as 
only one copy of SHANK3 is being expressed. For both patients, it is evident that after probe 
exon 5, there is only one copy of SHANK3 being expressed the other is deleted.  
 
Taqman Probe  Average CNV 
value for control 
Average CNV 
value for SHANK 
patient 1 
Average CNV value 
for SHANK3 patient 
2 
Probe intron 2 1.91 1.74 1.6 
Probe intron 3 2.04 2.12 2.38 
Probe exon5 2.05 1.02 0.9 
Probe intron 13 1.98 1.31 0.495 
Probe ACR 2.05 1.41 0.9775 
 
The RABL2 gene could not be assessed via TaqMan assay as this region is 
highly GC rich (about 80%). For this I used, qPCR RABL2 primer, which gave the 
mean CNV value of 2.08 for SHANK3 patient 1 and 1.44 for SHANK3 patient 2. 
This suggested that SHANK3 patient 1 has a heterozygous deletion in SHANK3 
from exon 4 onwards to ACR while SHANK3 patient 2 has a heterozygous 
deletion in SHANK3 that stretches from exon4 to RABL2. RABL2 forward primer 











'()*& +,"-**./0001*20& **304-44$& 52& 676767+87676777+676767++8+8&
9"#$%&
'()4& +,"-**./000/554&& **304-44$& 00:& 77++6677+8+68677+6777+878&
9"#$%&%;/& +,"-**./000<*/=& **304-44$& 0:*& 7+68887767+67887886776776&
9"#$%&
'()04& +,"-**./004<=*/& **304-44$& 0:/& 67878888787+766666++88876&
9"#$%&
8+>& +,"**./00<1**4& **304-44$& 20& 8+87+86788788776+878+8887&&
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Human SHANK3 ORF sequence that was sent Genewiz for synthesis. 
 
Please note: The green highlighted bit is the Myc sequence 
 





























































Human SHANK3 ORF without exon 18 highlighted in blue, that was sent 
Genewiz for synthesis. 
	  
Please take out the highlighted blue region (24 bp) 




























































Figure 1.0:  SHANK3 rescue compared to Myc only: A. In this I compared the cell soma area 
after the overexpression of the SHANK3 (SHANK3 P2 C1 rescue and SHANK3 P2 C1 rescue-18) 
to SHANK3 P2 C1 myc only. Dunn’s Multiple comparison test revealed SHANK3 P2 C1 myc only 
vs. SHANK3 P2 C1 rescue ****p<0.0001, similarly Dunn’s Multiple comparison test revealed  
SHANK3 P2 C1 myc only vs. SHANK3 P2 C1 rescue-18 ****p<0.0001.  
B. In this I compared the cell soma area after the overexpression of the SHANK3 (SHANK3 P1 
C2 rescue and SHANK3 P1 C2 rescue-18) to SHANK3 P1 C2 myc only. Dunn’s Multiple 
comparison test revealed SHANK3 P1 C2 myc only vs. SHANK3 P1 C2 rescue ****p<0.0001, 
similarly Dunn’s Multiple comparison test revealed SHANK3 P1 C2 myc only vs. SHANK3 P1 C2 
rescue-18 ****p<0.0001. The purpose of this experiment was to show that it is the SHANK3 gene 
that causes the rescue of morphogenetic phenotype and the only myc tag did not influence 
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